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Résumé 
La moxonidine, un médicament antihypertenseur sympatholytique de type imidazolinique, agit 
au niveau de la médulla du tronc cérébral pour diminuer la pression artérielle, suite à 
l’activation sélective du récepteur aux imidazolines I1 (récepteur I1, aussi nommé nischarine). 
Traitement avec de la moxonidine prévient le développement de l’hypertrophie du ventricule 
gauche chez des rats hypertendus (SHR), associé à une diminution de la synthèse et une 
élévation transitoire de la fragmentation d’ADN, des effets antiprolifératifs et apoptotiques. 
Ces effets se présentent probablement chez les fibroblastes, car l’apoptose des cardiomyocytes 
pourrait détériorer la fonction cardiaque. Ces effets apparaissent aussi avec des doses non 
hypotensives de moxonidine, suggérant l’existence d’effets cardiaques directes. Le récepteur 
I1 se trouvé aussi dans les tissus cardiaques; son activation ex vivo par la moxonidine stimule 
la libération de l’ANP, ce qui montre que les récepteurs I1 cardiaques sont fonctionnels malgré 
l’absence de stimulation centrale.  
Sur la base de ces informations, en plus du i) rôle des peptides natriurétiques comme 
inhibiteurs de l’apoptose cardiaque et ii) des études qui lient le récepteur I1 avec la 
maintenance de la matrix extracellulaire, on propose que, à part les effets sympatholytiques 
centrales, les récepteurs I1 cardiaques peuvent contrôler la croissance-mort cellulaire. 
L’activation du récepteur I1 peut retarder la progression des cardiopathies vers la 
défaillance cardiaque, en inhibant des signaux mal adaptatifs de prolifération et 
apoptose.   
Des études ont été effectuées pour : 
1. Explorer les effets in vivo sur la structure et la fonction cardiaque suite au traitement 
avec moxonidine chez le SHR et le hamster cardiomyopathique. 
2. Définir les voies de signalisation impliquées dans les changements secondaires au 
traitement avec moxonidine, spécifiquement sur les marqueurs inflammatoires et les 
voies de signalisation régulant la croissance et la survie cellulaire (MAPK et Akt).  
3. Explorer les effets in vitro de la surexpression et l’activation du récepteur I1 sur la 
survie cellulaire dans des cellules HEK293. 
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4. Rechercher la localisation, régulation et implication dans la croissance-mort cellulaire 
du récepteur I1 in vitro (cardiomyocytes et fibroblastes), en réponse aux stimuli 
associés au remodelage cardiaque : norépinephrine, cytokines (IL-1β, TNF-α) et 
oxydants (H2O2).  
Nos études démontrent que la moxonidine, en doses hypotensives et non-hypotensives, 
améliore la structure et la performance cardiaque chez le SHR par des mécanismes impliquant 
l’inhibition des cytokines et des voies de signalisation p38 MAPK et Akt. Chez le hamster 
cardiomyopathique, la moxonidine améliore la fonction cardiaque,  module la réponse 
inflammatoire/anti-inflammatoire et atténue la mort cellulaire et la fibrose cardiaque. Les 
cellules HEK293 surexprimant la nischarine survivent et prolifèrent plus en réponse à la 
moxonidine; cet effet est associé à l’inhibition des voies ERK, JNK et p38 MAPK. La 
surexpression de la nischarine protège aussi de la mort cellulaire induite par le TNF-α, l’IL-1β 
et le H2O2.  
En outre, le récepteur I1 s’exprime dans les cardiomyocytes et fibroblastes, son activation 
inhibe la mort des cardiomyocytes et la prolifération des fibroblastes induite par la 
norépinephrine, par des effets différentiels sur les MAPK et l’Akt. 
Dans des conditions inflammatoires, la moxonidine/récepteur aux imidazolines I1 protège les 
cardiomyocytes et facilite l’élimination des myofibroblastes  par des effets contraires sur JNK, 
p38 MAPK et iNOS. 
Ces études démontrent le potentiel du récepteur I1/nischarine comme cible anti-hypertrophique 
et anti-fibrose à niveau cardiaque. L’identification des mécanismes cardioprotecteurs de la 
nischarine peut amener au développement des traitements basés sur la surexpression de la 
nischarine chez des patients avec hypertrophie ventriculaire. Finalement, même si l’effet 
antihypertenseur des agonistes du récepteur I1 centraux est salutaire, le développement de 
nouveaux agonistes cardiosélectifs du récepteur I1 pourrait donner des bénéfices additionnels 
chez des patients non hypertendus.       
Mots-clés : Récepteur aux imidazolines I1, moxonidine, hypertension, hypertrophie du 
ventricule gauche, défaillance cardiaque, cardiomyocyte, fibroblaste, HEK293, 
norépinephrine, cytokines. 
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Abstract  
Moxonidine, an antihypertensive sympatholytic imidazoline compound, reduces blood 
pressure by selective activation of non-adrenergic imidazoline I1-receptors (also known as 
nischarin) in brainstem medulla. Moxonidine prevents left ventricular hypertrophy 
development in hypertensive rats, associated with reduced cardiac DNA synthesis and early 
transient increase in DNA fragmentation. It is likely that the anti-proliferative and apoptotic 
effects occur in fibroblasts, as cardiomyocyte apoptosis may deteriorate cardiac function. The 
effects also occurred to sub-hypotensive doses, suggesting a blood-pressure-independent 
mechanism and pointing to a local cardiac action.  Imidazoline I1-receptors have been 
identified in cardiac tissues, and their ex vivo activation by moxonidine stimulates ANP 
release, demonstrating that cardiac imidazoline I1-receptors are functional without the 
contribution of the central nervous system.   
Based on the above studies and on i) the role of natriuretic peptides in inhibition of myocardial 
cell apoptosis and ii) studies linking imidazoline I1-receptors to the maintenance of the 
extracellular matrix and PC12 cell survival, we propose that apart from centrally-mediated 
sympatholytic function, imidazoline I1-receptors in the heart may control cell growth and 
death. Activation of imidazoline receptors may delay the progression of cardiac pathologies 
into heart failure by inhibition of maladaptive proliferative signalling and downstream 
apoptotic pathways.   
In order to test this hypothesis studies were performed to: 
1. Explore the in vivo effects of moxonidine on cardiac structure and function in 
SHR and cardiomyopathic hamsters.  
2. Define the pathways involved in the observed changes following moxonidine 
treatment, specifically, on inflammatory markers and pathways involved in 
LVH and cardiac cell survival/death (MAPK and Akt). 
3. Explore in vitro the effect of imidazoline I1-receptor activation by moxonidine, 
on cell survival by over-expressing nischarin in HEK293 cells, to circumvent 
the lack of specific imidazoline I1-receptor agonists and antagonists. 
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4. Investigate in vitro, imidazoline I1-receptor localization (cardiomyocytes and 
fibroblasts), regulation and implication in cell growth/death in response to 
cardiac remodelling-associated stimuli: norepinephrine, cytokines (IL-1 , TNF-
), and oxidants (H2O2). 
The studies reveal that hypotensive and sub-hypotensive concentrations of moxonidine 
improve cardiac structure and performance in SHR by mechanisms that involve inhibition of 
cytokines, p38MAPK, and Akt signalling pathways. In cardiomyopathic hamsters 
moxonidine improves cardiac performance, in association with differential inflammatory/anti-
inflammatory responses that culminate in attenuated cardiomyocyte death and fibrosis and 
altered collagen type expression. HEK293 cells, transfected with nischarin cDNA, show 
increased viability/proliferation in response to moxonidine. The overall survival response is 
associated with moxonidine’s inhibition of ERK, JNK, and p38MAPK. Nischarin also opposes 
the reduced cell viability in response to oxidative stimuli (TNF-α, IL-1β and H2O2), with 
differential responses to moxonidine.  Furthermore, the imidazoline I1-receptor is expressed in 
cardiac fibroblasts and myocytes and its activation inhibits norepinephrine-induced 
cardiomyocyte death and fibroblast proliferation, through differential effects on MAPKs and 
Akt. Moxonidine/imidazoline I1-receptor protects cardiomyocytes and facilitates elimination 
of myofibroblasts in inflammatory conditions, through opposite effects on JNK, p38MAPK 
and iNOS activity.  
These studies emphasize the potential importance of imidazoline I1-receptor/nischarin as an 
anti-hypertrophic and anti-fibrotic target. Identification of the cardio-protective mechanisms of 
cardiac nischarin could result in specifically-tailored cell/gene-driven nischarin treatments, 
which could be important for patients with heart disease. Also, while the antihypertensive 
action of centrally acting compounds is appreciated, new cardiac-selective I1-receptor agonists 
may confer additional benefit.  
Keywords: Imidazoline I1-receptor, moxonidine, hypertension, left ventricular hypertrophy, 
heart failure, cardiomyocyte, fibroblast, HEK293, norepinephrine, cytokines. 
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Chapter 1. Introduction 
Cardiovascular pathologies, including hypertension, coronary artery disease, and heart failure, 
are the most common cause of death in the western world today (World Health Organization, 
2014). According to the World Health Organization (WHO), more people die of 
cardiovascular diseases (CVD) yearly than any other cause or pathological condition, with 
approximately 17.3 million deaths due to CVDs in 2008, a number which is predicted to rise 
to 23.6 million by the year 2030 (Mathers & Loncar, 2006).  In Canada, over 28.6% of total 
deaths per year are due to major cardiovascular diseases (Statistics Canada, 2012); in fact at 
every 7 minutes someone is suffering from acute myocardial infarct in Canada. The cost of 
cardiovascular diseases in Canada is of around $20.9 billion per year (Heart and Stroke 
Fundation of Canada, 2013), and this burden and cost will most likely increase with the aging 
of the population.  
 
1.1 The burden of cardiovascular disease. Focus on hypertension 
and heart failure 
High blood pressure is the leading risk factor for cardiovascular disease mortality, causing 
more than 7 million deaths every year worldwide (World Health Organization, 2014). 
Hypertension is also a growing problem. In Canada alone, the prevalence of hypertension has 
grown from 12.5% in 1988/1989 to 19.6% for the year 2007/2008; in the same year, in the age 
group of 75 to 79 years, 69.5% had hypertension (Robitaille et al., 2012). This increasing trend 
most likely will accelerate in time, due to the ageing of the population (Employment and 
Social Development Canada, 2014). In spite of all the efficacious antihypertensive treatments, 
one third of Canadian adults with hypertension have uncontrolled blood pressure (Campbell, 
McAlister, & Quan, 2013; Danaei et al., 2011).  
Uncontrolled hypertensive patients develop left ventricular hypertrophy (LVH) (Ferrara, 
Vaccaro, Cardoni, Mancini, & Zanchetti, 2004). Using echocardiography, a sensitive method 
for LVH detection, a survey in Italy revealed that around 30 to 50% of hypertensive patients 
had LVH (Cuspidi et al., 2011). In hypertension, the degree of hypertrophy is directly 
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correlated to the severity of blood pressure elevation, being present in all patients with severe 
hypertension (Belenkov, Vikhert, Belichenko, & Arabidze, 1992). LVH is an independent 
cardiovascular risk factor (Chobanian et al., 2003) and lowering it using antihypertensive 
treatments lowers both cardiovascular and total mortality (Devereux et al., 2004).  
A second major complication of hypertension is heart failure (Chobanian et al., 2003). The 
Framingham study showed that 75% of heart failure patients detected in the cohort had 
hypertension (defined as a blood pressure above 160 mmHg systolic or 95 mmHg diastolic). 
Additionally, heart failure risk is 10 times higher in hypertensive patients with LVH, linking 
these two complications (Kannel, Castelli, McNamara, McKee, & Feinleib, 1972). Heart 
failure has a very high mortality rate, with roughly 50% of patients dying during the first 5 
years of diagnosis, even with modern treatments (Levy et al., 2002; Roger et al., 2004). 
Noteworthy, effective treatments of hypertension, which reduce LVH, also reduce the 
incidence of heart failure (Larstorp et al., 2012), pointing towards the importance of treatment 
of LVH as a preventive measure for heart failure.  
Hypertension treatment usually involves the use of 2 or more medications from different 
pharmacological groups. Antihypertensive medications include thiazide diuretics, calcium 
channel antagonists, blockers of the renin-angiotensin-aldosterone system and peripheral or 
centrally acting antagonists of the sympathetic nervous system (Chobanian et al., 2003; 
Hackam et al., 2013) (see section 1.5 Current pharmacological treatment options for 
hypertension and heart failure for details). Despite this plethora of options, around 15% of 
treated patients will not have blood pressure within normal limits following the use of 3 or 
more different medication classes, thus being classified as having resistant hypertension 
(Daugherty et al., 2012; Khan et al., 2014).  
Better understanding of possible interactions of systems that control blood pressure and/or 
cardiac function may lead to innovative ways of treatment to prevent cardiac pathologies 
progression, avoiding the pathophysiological consequences of heart failure.  
A common feature in cardiovascular diseases, including hypertension and heart failure, is 
over-activity of the sympathetic nervous system (SNS) (Meredith et al., 1993; Schlaich et al., 
2003).  The SNS is implicated in the regulation of blood pressure and cardiac function. 
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However SNS over-activity contributes to the pathogenesis and consequences of 
cardiovascular diseases, by activating signaling events intimately linked to vascular and 
cardiac cell growth and death (Dorn, 2002; Osadchii, 2007). Imidazoline I1-receptors in the 
brainstem are involved in the control of SNS activity, and consequently its deleterious effects 
on the heart, through mechanisms that inhibit the release of the neurotransmitter, 
norepinephrine (Bousquet, Feldman, & Schwartz, 1984; Raasch, Jungbluth, Schafer, Hauser, 
& Dominiak, 2003). Imidazoline I1-receptors are also found in the heart (El-Ayoubi, 
Gutkowska, Regunathan, & Mukaddam-Daher, 2002; El-Ayoubi, Menaouar, Gutkowska, & 
Mukaddam-Daher, 2003, 2004) and are involved in atrial natriuretic peptide (ANP) release 
(Mukaddam-Daher, Lambert, & Gutkowska, 1997; Mukaddam-Daher, Menaouar, & 
Gutkowska, 2006), yet their cellular localization and function are not fully elucidated.  
Investigation of heart imidazoline I1-receptor interaction with hypertension- and heart failure-
associated control mechanisms may lead to new treatments of cardiovascular disease. We have 
enough evidence to propose that cardiac imidazoline I1-receptors are involved in cardiac cell 
growth and death, thus may be a new therapeutic target.  
 
1.2 The heart  
For the ancient Egyptians, the heart was one of the main organs of the body, being the center 
of emotions and intelligence as well as responsible for transport of blood (Ziskind & Halioua, 
2004). This spiritual point of view has evolved towards the present view of the heart as a 
structure with multiple and tightly controlled functions on the cardiovascular system. The 
heart is involved in the maintenance of blood pressure and blood flow towards the different 
organs (Silverthorn, 2013; West, 1990). It acts as a pump that propels blood towards the 
vasculature, and as an endocrine organ that produces natriuretic hormones involved in blood 
pressure and volume control (de Bold, Borenstein, Veress, & Sonnenberg, 1981).  
Furthermore, both pump and endocrine activities are under homeostatic control of the 
sympathetic nervous system, as well as circulating and locally produced neurohormones and 
cytokines (Silverthorn, 2013; West, 1990). Abnormalities in the control mechanisms lead to 
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altered heart structure and function and consequently impair cardiac function (Cacciapuoti, 
2011; Chaggar, Malkin, Shaw, Williams, & Channer, 2009).  
 
1.2.1 The heart as a pump  
The heart contracts and relaxes in a cyclical way (Iaizzo, 2009; West, 1990). During 
contraction, the phase known as systole, the heart contracts, pumping into the aorta a quantity 
of blood. This pumping function works against a resistance, generating pressure, an effect that 
maintains blood flow. Blood pressure is the product of flow (or cardiac output) and the 
resistance to flow, also known as arterial resistance (Fukuta & Little, 2008; Iaizzo, 2009).  
Cardiac output is an indicator of total blood flow, because all the blood that leaves the heart 
flows through the tissues. Since the needs of the body are variable, blood flow (cardiac output) 
adapts to accommodate different situations. Cardiac output, a common measure of cardiac 
function, directly varies with the ejected volume per contraction (stroke volume, SV) and by 
the number of cardiac cycles (or beats per minute, heart rate, HR) in a relationship shown in 
the formula: CO = SV x HR (reviewed by West, 1990) (West, 1990).  This relationship that 
appears simple is extremely complex, as many factors are involved in the regulation of each 
parameter. 
Heart rate is under the control of the autonomic nervous system, decreasing by active 
parasympathetic nervous system and increasing by active SNS and epinephrine (Bonow, 
Mann, Zipes, Libby, & Branwald, 2012). Increased heart rate may be maladaptive under 
pathological circumstances (Bonow et al., 2012; Brunton, Chabner, & Knollmann, 2011), and 
thus could be a target for treatment with sympatholytics. 
On the other hand, stroke volume varies with the amount of blood that returns from the tissues 
to the heart. This amount of blood (venous return) is controlled by muscle pump, respiratory 
pump as well as by sympathetic innervation of veins, which constricts the veins, squeezing 
more blood out of them and into the heart (Levy, Koeppen, & Stanton, 2006; Silverthorn, 
2013). With a larger ventricular volume at the beginning of the next contraction (end diastolic 
volume, EDV), the muscle fibers stretch, and then contract more forcefully, ejecting more 
 20 
blood. The degree of myocardial stretch before contraction begins is called the preload on the 
heart, because this stretch represents the load placed on cardiac muscles before they contract. 
Changes in preload change contractility in the same sense, so, an increase of the preload will 
increase contractility and stroke volume, a phenomenon known as Frank-Starling mechanism 
(Bombardini, 2005; Shiels & White, 2008). The Frank-Starling mechanism fails in heart 
failure, when the heart is unable to respond to preload changes, thus elevating the pressure in 
the venous system, and increasing the symptoms of congestion (Kemp & Conte, 2012). This is 
the rationale for the use of medications that reduce preload, like diuretics and some venous 
dilators, in the current in treatment of heart failure (Hunt et al., 2009).  
Stroke volume is also influenced by afterload, which is the combined load of EDV and arterial 
resistance created by blood filling the arterial system during ventricular contraction. For all 
practical purposes, unless there is an obstruction to blood flow, afterload is directly related to 
the systolic pressure (Fukuta & Little, 2008; Silverthorn, 2013) and clinically, arterial blood 
pressure is often used as an indirect indicator of afterload. As blood pressure is inversely 
related to the vessel radius, a small decrease in vessel radius will induce marked increase in 
blood pressure that increases afterload and might affect cardiac output (Levy et al., 2006; 
West, 1990).   
Vessel radius (and thus afterload) is mainly controlled by the sympathetic nervous system 
(SNS) and the renin-angiotensin-aldosterone system (RAAS). Through corresponding release 
of neurohormones and hormones, these vasoconstrictive, anti-natriuretic, anti-diuretic and 
growth promoting systems influence vessel radius and tone and consequently cardiac function 
(Kemp & Conte, 2012; Silverthorn, 2013; West, 1990).  In cardiovascular pathologies, such as 
hypertension or heart failure, afterload is usually elevated, increasing cardiac wall stress and 
work (Kemp & Conte, 2012; Lam et al., 2013). This is the rationale for treatment with 
medications that act through blocking the activities of the RAAS and the SNS (Hackam et al., 
2013; Hunt et al., 2009).  
Ventricular contraction occurs due to the entry from the extracellular space of small amounts 
of calcium, which in turn induce the release of large amounts of calcium from the endoplasmic 
reticulum of cardiomyocytes, permitting the cross-link between actin and myosin 
(Bombardini, 2005). Calcium concentration and myofilament sensitivity to calcium can be 
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modified by mechanical (preload) or endocrine/paracrine factors, including catecholamines, 
which increase the available calcium, thus increase contractility. Medications that modify 
sympathetic tone also modify contractility (Bombardini, 2005; Brunton et al., 2011; Shiels & 
White, 2008; Silverthorn, 2013).  
The second component of cardiac function, relaxation (called lusitropism), depends on the 
active extrusion of calcium (including its rate). Once the cytoplasmic calcium concentration 
decreases, the cross-link between actin and myosin disappears and the tension decreases, 
starting the diastole (Bombardini, 2005; Levy et al., 2006; West, 1990). Relaxation also 
depends on the static properties of the myocardium, specifically the amount of collagen in the 
tissue. In pathological conditions, the lack of relaxation can disturb ventricular function by 
impeding the filling of the heart (Bonow et al., 2012; Diez et al., 2002).  
From the above description, it is clear that the in vivo determinants of cardiac function act in 
concert to maintain cardiac output following a wide range of changes, and that the SNS plays 
an important role in the neurohormonal control of each of these determinants (Figure 1). 
 22 
 
Figure 1: Schema showing the central role of the sympathetic nervous system in the control of cardiac output 
(Silverthorn, 2013). 
 
1.2.2 The endocrine heart 
The heart itself is in a privileged position to sense the hemodynamic conditions present in the 
circulatory system. This sensory system responds to volume changes by secreting diverse 
substances, including cardiac natriuretic hormones and other paracrine/autocrine factors like 
adrenomedullin and endothelin-1 (Ogawa & de Bold, 2014). 
Adrenomedullin is mostly produced in the adrenal medulla, but it’s also detectable in the 
heart, both in atria and ventricles (Ichiki et al., 1994). Adrenomedullin can act locally to 
decrease angiotensin II-induced cardiomyocyte protein synthesis, a marker of hypertrophy, 
thus cardiac production of adrenomedullin may counter-regulate cardiac hypertrophy (Ogawa 
& de Bold, 2014; Tsuruda et al., 1998). 
Endothelin-1, the most potent vasoconstrictor known, is mostly produced in vascular 
endothelial cells, but also detected in other tissues, including the heart, in cardiomyocytes, 
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fibroblasts and endothelial cells (Sakurai et al., 1991; van Wamel, Ruwhof, van der Valk-
Kokshoom, Schrier, & van der Laarse, 2001; Yanagisawa et al., 1988). Endothelin-1 induces 
cardiomyocyte hypertrophy and fibrosis (Drawnel, Archer, & Roderick, 2013), thus it is 
involved in the development of LVH. On the other hand, endothelin-1 induces cardiac 
secretion of natriuretic peptides (Horio, Kohno, & Takeda, 1993), a counter-regulatory 
protective effect. 
The natriuretic peptide family, atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP), and C-type natriuretic peptide (CNP), are structurally and functionally related peptide 
hormones that are involved in blood pressure regulation and body fluid homeostasis under 
normal and pathological conditions, such as heart failure and hypertension (Ogawa & de Bold, 
2014). They are primarily of cardiac origin, but also produced by several extracardiac tissues, 
including the gastrointestinal tract and the brain (Gower et al., 1994; Teran, Rodriguez-Iturbe, 
Parra, & Gutkowska, 1991). In the heart, ANP is synthesized and stored in granules in cardiac 
atrial cardiomyocytes (de Bold et al., 1981). ANP release into the circulation is continuous, 
increasing in response to stimuli that result in atrial distension (Dietz, 2005; McGrath & de 
Bold, 2005; Thibault, Amiri, & Garcia, 1999). ANP secretion is stimulated by increasing 
venous return or increasing aortic pressure, as well as by vasoactive factors, neurotransmitters, 
and pro-inflammatory cytokines (Interleukin (IL)-1β, IL-6, tumor necrosis factor-α) (Ambler 
& Leite, 1994; Dietz, 2005; Mukaddam-Daher, 2006; Schiebinger & Greening, 1992). Nitric 
oxide, calcitonin gene-related peptide, and histamine inhibit ANP release (Dietz, 2005; Li et 
al., 2003; Piao, Cao, Han, Kim, & Kim, 2004). 
BNP is co-stored with ANP in some atrial and ventricular  granules (Nakamura et al., 1991); it 
is believed that BNP is secreted predominantly from cardiac ventricles (myocytes and 
fibroblasts), yet most of regulated BNP secretion, in response to increased ventricular stretch 
and endothelin, happens in the atria (Ogawa & de Bold, 2014; Ogawa, Vatta, Bruneau, & de 
Bold, 1999). BNP levels are increased in cardiovascular diseases, including ischemia, 
arrhythmias, fibrosis, cardiac hypertrophy, coronary endothelial dysfunction and heart failure 
(Mukaddam-Daher, 2006; Ogawa & de Bold, 2014). CNP is synthesized and secreted by the 
coronary endothelium and by cardiac myocytes and fibroblasts (Del Ry et al., 2011). 
Endothelial production of CNP is enhanced in response to shear stress, pro-inflammatory 
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cytokines and lipopolysaccharide, and inhibited by insulin and VEGF. Myocardial production 
of CNP is increased in chronic heart failure. Plasma CNP, which is normally very low or 
undetectable, is significantly increased in patients with chronic heart failure, cirrhosis, and 
sepsis (reviewed by Mukaddam-Daher, 2006)(Mukaddam-Daher, 2006). 
The natriuretic peptides elicit a number of vascular, renal and endocrine effects that help 
maintain blood pressure and extracellular fluid volume, and are involved in neuronal cardiac 
regulation, influencing contractility and beating rate (Antunes-Rodrigues, de Castro, Elias, 
Valenca, & McCann, 2004; Mukaddam-Daher, 2006). Circulating ANP and BNP can produce  
hypotensive effects, particularly in elderly patients (Hausdorff, Clark, Shannon, Elahi, & Wei, 
1995), due to their diuretic, natriuretic, and vasodilatory properties (Koda, Sakamoto, & 
Ogawa, 2005; Melo, Steinhelper, Pang, Tse, & Ackermann, 2000). These effects are attained 
by direct inhibition of renal tubular sodium reabsorption, particularly in the distal tubule 
(Zhao, Pandey, & Navar, 2010), by inhibition and counteracting the effects of the sympathetic 
nervous system and the renin-angiotensin-aldosterone system, as shown in KO mouse models 
and in patients (Kasama et al., 2007; Melo et al., 2000), and by action on brain regulatory sites 
to suppress thirst, and inhibit vasopressin and ACTH release and sympathetic outflow 
(Antunes-Rodrigues et al., 2004). Natriuretic peptides inhibit the production of endothelin and 
secretion of renin and aldosterone. CNP is considered as a neuropeptide and an endothelium-
derived autocrine/paracrine regulator exerting a hypotensive effect, positive inotropic action, 
but no significant diuretic or natriuretic actions; however, it inhibits aldosterone synthesis in a 
similar manner to ANP & BNP (reviewed by Mukaddam-Daher, 2006)(Mukaddam-Daher, 
2006).  
The important role of ANP in chronic blood pressure regulation has been shown in transgenic 
mouse model overexpressing ANP, where elevated plasma ANP was associated with a 25-30 
mmHg blood pressure reduction, an opposite effect is observed in ANP KO, where blood 
pressure is around 30 mmHg higher when compared to wild type animals (Melo et al., 2000). 
Knockout mice with a homozygous disruption of the pro-ANP gene (-/-) are incapable of 
producing ANP and are hypertensive relative to their wild-type siblings, developing salt-
sensitive hypertension after prolonged feeding of a high salt diet, in part due to a synergistic 
interaction between angiotensin II and sympathetic nerve activity, and their inability to reduce 
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plasma renin activity (Melo et al., 1999). The mechanism mediating the chronic relaxant effect 
of ANP is indirect, since the resistance vasculature is relatively insensitive to direct cGMP-
mediated relaxation by ANP. Melo et al., have shown in ANP knockout mouse that the 
chronic hypotensive effect of ANP is mediated by attenuation of tonic cardiovascular 
sympathetic tone (Melo et al., 1999). 
The actions of natriuretic peptides ANP and BNP are mediated by a common transmembrane 
cell surface guanylyl cyclase receptor (NPR-A), and CNP through NPR-B, which act through 
generation of cGMP and subsequent activation of cGMP-dependent protein kinase G (PKG) 
(Ogawa & de Bold, 2014). All 3 peptides bind to a more abundantly expressed receptor (NPR-
C), which lacks the cytoplasmic guanylyl cyclase domain. NPR-C promotes the peptide 
clearance from the circulation and mediates inhibition of endothelin release and antagonism of 
the renin-angiotensin-aldosterone via Gi  and inhibition of adenylyl cyclase/cyclic adenosine 
monophosphate (cAMP) (El Andalousi, Li, & Anand-Srivastava, 2013; Li, Sarkar, Brochu, & 
Anand-Srivastava, 2014). Natriuretic peptide receptors are ubiquitous, present in kidneys, 
vasculature, lungs, brain, thymus, macrophages etc., and recently demonstrated in the heart, 
where local actions of natriuretic peptides may occur (Lin, Hanze, Heese, Sodmann, & Lang, 
1995). In the heart, the mRNAs for all three NPRs are found in fibroblasts with 80% of the 
NPR-C subtype. NPR-A is abundant in ventricular myocytes, whereas NPR-B is abundant in 
fibroblasts and endothelial cells (Lin et al., 1995). 
Based on the previously described findings, it is clear that the heart protects itself through its 
endocrine functions, both systemically, by regulating blood pressure, and locally, by counter-
regulating hypertrophic and fibrotic stimuli. 
 
1.3 The continuum hypertension-LVH-heart failure 
During exercise, the heart is required to pump facing increases in preload (for example in 
swimming), afterload (weightlifting), or both (rowing) (Ekblom & Hermansen, 1968; 
Pelliccia, Maron, Spataro, Proschan, & Spirito, 1991; Weeks & McMullen, 2011). The 
ventricle increases its force of contraction to maintain adequate stroke volume, increasing the 
muscle’s need for oxygen and ATP production. Also, neurohormonal compensatory 
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mechanism are activated, causing cardiovascular stress (reviewed by Weeks and McMullen, 
2011) (Weeks & McMullen, 2011). However, normal, short term cardiovascular stresses, such 
as bursts of exercise, have beneficial effects on the cardiovascular system and are an integral 
part of preventive and treatment strategies in hypertension and heart failure (Chobanian et al., 
2003; Hackam et al., 2013; Hunt et al., 2009). In contrast, chronic cardiovascular stress (such 
as chronically increased afterload as occurs in hypertension) cause myocardial cells to 
hypertrophy, resulting in increased thickness of the ventricular wall, leading to maladaptive 
changes such LVH (Weeks & McMullen, 2011). In hypertension, the degree of hypertrophy is 
directly correlated to the severity of blood pressure elevation, being present in all patients with 
severe hypertension (Belenkov et al., 1992).  
The hypertrophic response of the heart is a dynamic process that involves progressive changes 
in gene expression that creates structural, hemodynamic, and cellular alterations (Carreno, 
Apablaza, Ocaranza, & Jalil, 2006; Weeks & McMullen, 2011). LVH involves cardiomyocyte 
hypertrophy, cardiac fibroblast proliferation, increased synthesis and deposition of collagen, and 
progression of interstitial and perivascular fibrosis (Cacciapuoti, 2011). Initially, these alterations 
contribute to lowering of the ventricular wall stress and preservation of contractile function; a 
stage known as adaptive or compensatory. Eventually, the remodeling process leads to 
ventricular stiffness, secondary to a decrease in the active extrusion of calcium after the 
contraction of the myocardium (i.e. reduced relaxation), and alterations of the static properties 
of the myocardium, secondary to the increased amount of collagen in the tissue. Cardiac 
stiffness can impede the filling of the heart, hence, results in reduced force of contraction 
(Frank-Starling mechanism) and subsequent reduction in ejection fraction, stroke volume, and 
cardiac output (Bonow et al., 2012; Kemp & Conte, 2012).  
The kidneys respond to reduced cardiac output and subsequently reduced renal perfusion by 
altering their hemodynamic milieu through a number of physical and neurohumoral mechanisms, 
including activated renin-angiotensin-aldosterone system (RAAS) and vasopressin, as well as 
stimulated catecholamines and renal nerve activity. These vasoconstrictive and sodium and water 
retaining mechanisms lead to volume expansion and to further deterioration in cardiac 
performance (Bonow et al., 2012; Kemp & Conte, 2012). The result is a failing heart that cannot 
pump out sufficient blood to supply the needs of the body and progressive volume retention, 
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which results in systemic and pulmonary edema, as well as progressive apoptosis and fibrosis 
(Kemp & Conte, 2012; Ward, Crossman, & Cannell, 2011). Exaggerated apoptosis, a mode of 
cell death in which the cell participates in its own demise, may account for the loss of 
contractile cardiomyocytes in the hypertensive left ventricle, which may further progress 
towards heart failure (Diez, Fortuno, & Ravassa, 1998; Ikeda, Hamada, & Hiwada, 1999; Li, 
Bing, Long, Robinson, & Lakatta, 1997).  
In fact, LVH is linked to unfavorable prognoses and various deleterious sequelae of 
cardiovascular diseases, with conditions, such as coronary heart disease, stroke, congestive 
heart failure and sudden death, being aggravated by LVH (Devereux et al., 2004; Larstorp et 
al., 2012). Importantly, LVH can often be reversible. It is not surprising, therefore, that 
numerous therapeutic approaches have been pursued with the aim of regressing/preventing 
LVH and, hence, reducing both cardiovascular and total mortality (Devereux et al., 2004). 
 
1.4 Factors involved in the development of LVH and heart failure 
Similar to all cells in the body, cardiomyocytes and fibroblasts sense and respond to their 
mechanical and neurohormonal environment (Bernardo, Weeks, Pretorius, & McMullen, 
2010; Haggart, Ames, Lee, & Holmes, 2014). The mechanical environment includes 
mechanical stretch as well as the composition and stiffness of the extracellular matrix (ECM), 
a network of cellular and extracellular constituents that comprises the left ventricular 
myocardium (Jane-Lise, Corda, Chassagne, & Rappaport, 2000). In vivo cardiac remodelling, 
including cytoskeleton reorganization, results from a combination of the effects of mechanical and 
biochemical factors in close interaction with extracellular matrix (ECM) proteins, integrins, and 
proteins secreted locally, such as metalloproteinases (Bernardo et al., 2010).  
 
1.4.1 Mechanical Factors 
Pressure overload in hypertension or volume overload, for example, in mitral valve 
insufficiency, result in mechanical stretch, which influences many basic cellular processes 
such as growth, remodeling, apoptosis, and gene expression (Liu et al., 1992; Sadoshima, 
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Jahn, Takahashi, Kulik, & Izumo, 1992; Wilson, Mai, Sudhir, Weiss, & Ives, 1993), as well as 
differentiation (Reusch, Wagdy, Reusch, Wilson, & Ives, 1996), rearranged cytoskeleton or 
focal contacts (Carver, Nagpal, Nachtigal, Borg, & Terracio, 1991; Davies, Robotewskyj, & 
Griem, 1994; Girard & Nerem, 1995; Moore et al., 1994), or altered composition of the 
extracellular matrix (Jane-Lise et al., 2000).   
Mechanical stretch induces protein synthesis and hypertrophy, both in isolated cardiomyocytes 
and in papillary muscle preparations (Haggart et al., 2014; Lammerding, Kamm, & Lee, 2004; 
Wang, Wu, Cheng, & Shyu, 2013), induces secretion or synthesis of bioactive molecules from 
cardiomyocytes (Shyu, 2009), and increases production of extracellular matrix proteins by 
fibroblasts, the principal cell type responsible for extracellular matrix synthesis during growth 
and pathophysiological conditions (Jugdutt & Amy, 1986; Kuwahara et al., 2003; Weber, 
Brilla, & Campbell, 1992).  
Mechanical stretch is detected by cardiac cells through multiple mechanisms, including 
mechanosensitive ion channels, which are stretch activated channels that permit the handling 
of sodium and calcium (Bonow et al., 2012; Lammerding et al., 2004) as well as by cell 
surface adhesion receptors, termed integrins (Lammerding et al., 2004).  
Integrins form the primary link between extracellular matrix ligands and cytoskeletal 
structures, which is important for maintaining the architecture of tissues (Hynes, 1992; 
Lammerding et al., 2004; Ruoslahti, 1991). In myocardial tissue, integrins play a role in 
transmitting and distributing the mechanical force generated by the contraction of each 
myocyte to the extracellular matrix, and preventing myocytes from overstretching by elevated 
tension (Borg, Johnson, & Lill, 1983; Winegrad & Robinson, 1978). 
Integrins are a family of transmembrane glycoproteins that function as mechanotransducers, 
converting mechanical forces to biochemical signals. The integrin large extracellular domain 
binds directly to ECM proteins, like collagen or fibronectin, among others (Evans & 
Calderwood, 2007; Lammerding et al., 2004), playing a crucial role in ECM organization. The 
integrin cytoplasmic tail does not have an intrinsic enzymatic activity (Lammerding et al., 
2004), but binds to cytoskeletal proteins, such as F-actin, through the interaction of integrin 
tails with talin (Ross, 2002; Ross et al., 2013), as well as to signalling proteins, including 
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integrin linked kinase (ILK), focal adhesion kinase (FAK), the small guanosine triphosphate 
(GTP) binding proteins Rho and Rac1, with downstream activation of mitogen activated 
protein kinases (MAPK), p21-activated kinase (PAK), nuclear factor-κB (NF-κB) and 
Akt/protein kinase B (PKB), pathways that have been linked to hypertrophy, proliferation,  
and apoptosis in different cell types, including cardiomyocytes and fibroblasts (Figure 2) 
(Aikawa et al., 2002; Bettink et al., 2010; Krishnamurthy, Subramanian, Singh, & Singh, 
2007; Lammerding et al., 2004; Ross, 2002).   
 
 
Figure 2: Mechanisms involved in integrin-mediated mechanotransduction in cardiomyocytes. Of note the link 
with cytoskeletal proteins and signalling pathways inducing hypertrophy. For details see text (Ross, 2002). 
 
Rac1 is a small guanosine triphosphatase catalytic subunit of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (Hordijk, 2006). Rac1 activation increases 
intracellular reactive oxygen species (ROS), such as superoxide (∙O2−) and H2O2, into which 
∙O2 is rapidly converted. ROS are important mediators of cellular signal transduction cascades 
such as proliferation, migration, and apoptosis (Maack et al., 2003). Excess ROS production 
damages DNA, protein and lipids, causing cardiac cell death. Activation of Rac1 and its 
effector protein NADPH oxidase can also regulate proliferative signals through mechanisms 
that include NF-κB stimulation (Hordijk, 2006), mediated by increasing intracellular ROS or 
through phosphatidylinositol-3 kinase (PI3-K)/Akt. The Rac1–ROS signaling pathway is a 
crucial mediator of cardiovascular disease (Hordijk, 2006). Inhibition of Rac1 by statins 
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decreases NADPH oxidase-related production of ROS in cardiomyocytes and reduces cardiac 
hypertrophy (Maack et al., 2003), demonstrating the importance of Rac1 activity in cardiac 
pathologies. The direct involvement of Rac1 in cardiovascular disorders has been confirmed 
by both cardiac-specific transgenic and knockout mice. Mice overexpressing the constitutively 
active form of Rac1 clearly evidence a dramatic cardiomyopathy phenotype (Sussman et al., 
2000). In contrast, in cardiac-specific Rac1 knockout mice, infusion of angiotensin II increases 
systolic blood pressure but does not induce cardiac hypertrophy in association with the 
inhibition of NADPH oxidase-dependent generation of O2
-
 and NF-κB transcriptional activity 
(Satoh et al., 2006). 
Mammalian integrins comprise 18α and 8β subunits (Ross & Borg, 2001). Cardiac myocytes 
predominantly express β1 integrin, the main integrin subtype that mediates adhesion to the 
extracellular matrix (Ross & Borg, 2001). β1 integrin heterodimers signiﬁcantly contribute to 
cardiomyocyte adhesion to the ECM, and inhibition of β1 integrin-mediated adhesion leads to 
ventricular dilatation of the normal heart, and plays a significant role in the progression of 
adverse myocardial remodeling that leads to heart failure (Stewart, Gardner, Brower, & 
Janicki, 2014). In addition, β1 integrin signaling protects cardiomyocytes against β-adrenergic 
receptor-stimulated apoptosis in vitro and left ventricular remodeling and myocyte apoptosis 
in vivo (Krishnamurthy et al., 2007). In vivo infusion with β-adrenergic receptor agonist 
isoproterenol increases cardiomyocyte apoptosis in mice with partial knock-out of β1 integrin 
subunit, in association with reduced ventricular function and overactivation of c-Jun N-
terminal kinase (JNK), when compared to wild type animals subjected to the same treatment 
(Krishnamurthy et al., 2007). Over-expression of β1 integrins, in neonatal rat ventricular 
myocytes, enhances the hypertrophic effects of α1-adrenergic stimulation, and inhibition of β1 
integrin function and signaling reduces the hypertrophic response (Ross et al., 1998).  
The α5 integrins,  on the other hand, modulate cardiac neural crest proliferation and survival, 
and are required for cardiac morphogenesis and, in particular, for the formation of the cardiac 
outflow tract (Mittal, Pulina, Hou, & Astrof, 2010, 2013). The expression of α1, α3 and 
α5 integrins is low in normal cardiomyocytes, but is upregulated by myocardial infarction in 
rats (Nawata et al., 1999). Integrin α5 subunit is also over-expressed in LVH (Ross, 2002). 
The expression of integrin α5 subunit is regulated by cardiovascular disease-activated growth 
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factors and cytokines (Nawata et al., 1999). Platelet derived growth factor (PDGF) upregulates 
the expression of the α5 integrin subunit in cardiomyocytes. Transforming growth factor-β 
(TGF-β) and inflammatory cytokines, such as interleukin 1β (IL-1β), tumor necrosis factor α 
(TNF-α) or interferon γ (IFN-γ) enhance the expression of both α1 and α5 integrin subunits 
(Gailit, Xu, Bueller, & Clark, 1996; Nawata et al., 1999). In fibroblasts, the expression of α5 
integrin is relatively higher in cells obtained from exercised rat hearts and lower in those from 
hypertensive hearts when compared to control, and these cells migrate on fibronectin at higher 
and lower rates respectively, demonstrating a direct correlation between the expression of α5 
integrin and fibroblast migration (Burgess, Terracio, Hirozane, & Borg, 2002). 
The β1 integrin forms dimers with multiple α subunits. Each specific dimer serves as a 
receptor for a specific extracellular matrix protein. For example α1β1 and α2β1 integrin 
complexes can bind to collagen and laminin, α4β1 and α5β1 to fibronectin, while α3β1 binds 
collagen, laminin, and fibronectin (Ross & Borg, 2001).  
The α5β1 integrin (fibronectin receptor) is present in cardiomyocytes, but predominantly in 
fibroblasts (Clark et al., 2005). It supports migration in several cell types (Alahari, Lee, & 
Juliano, 2000) and its mutation or knock-out results in reduction or abolition of migration 
(Huttenlocher, Sandborg, & Horwitz, 1995). Increased expression of α1β1 and α5β1 
heterodimers are found in association with increased adhesion during the compensatory 
hypertrophy secondary to renovascular hypertension (Terracio et al., 1991). 
 
Over-expression of α5β1 integrin protects cell lines against apoptotic stimuli, in part by 
modulating the expression of the anti-apoptotic protein Bcl2, by activating the PI3-K/Akt 
pathway (Figure 3) (Lee & Ruoslahti, 2005; Lee & Juliano, 2000).  
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Figure 3: Signalling pathways stimulated by α5β1 integrin leading to an increase in Bcl-2 expression. Grb2: 
Growth factor receptor-bound protein 2; Ras: Rat sarcoma protein; PI3-K: Phosphatidylinositol-3 kinase; CREB: 
cAMP response element-binding protein; FKHR: Forkhead in rhabdomyosarcoma protein; FAK: Focal adhesion 
kinase; CaMK IV: Calcium calmoduline dependant kinase IV (Lee & Ruoslahti, 2005).   
 
Furthermore, modulation of the α5β1 receptor ligand, fibronectin, is implicated in cardiac 
remodeling.  Loss of fibronectin leads to further deterioration of cardiac function in a mouse 
model of myocardial infarction, due to impaired wound healing and reduced progenitor cell 
recruitment (Konstandin, Toko, et al., 2013).  In contrast, genetic conditional ablation of the 
fibronectin gene in adult mice blunts cardiomyocyte hypertrophy upon pressure overload 
induced by transverse aortic constriction, and delays development of heart failure and 
improves survival (Konstandin, Volkers, et al., 2013). Noteworthy, induction of fibronectin 
expression upon myocardial infarction is very quick, while in the pressure overload model, 
fibronectin continuously increases over time at a lower level of expression (Konstandin, Toko, 
et al., 2013; Konstandin, Volkers, et al., 2013). Accordingly, it appears that the duration and 
intensity might impact the ultimate outcome of fibronectin expression.  
Taken together, these studies show that mechanical overload leads to hypertrophic 
remodeling, mediated by mechanotransducing integrins, including α5β1 fibronectin receptor 
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and activation of Rac1 and subsequent ROS production. Of interest to our studies, imidazoline 
I1-receptor/nischarin associates with the α5 subunit of the α5β1 integrin and reduces cell 
proliferation and migration through inhibition of Rac1 (Alahari et al., 2000). The association 
with integrins puts imidazoline I1-receptors/nischarin at the heart of ECM control and cardiac 
remodelling, a function that may go beyond its established central and peripheral sympatholytic 
effect. 
 
1.4.2 Biochemical Factors 
The hypertensive heart undergoes significant structural changes that occur in response to 
biochemical stress, induced by activated sympathetic nervous system (SNS), the renin-
angiotensin-aldosterone system (RAAS), growth factors, and pro-inflammatory cytokines. In 
addition to their hemodynamic activity, these factors initiate and maintain left ventricular 
hypertrophy through a complex array of signaling events, with cross-talk and positive and/or 
negative interaction, and contribute to regression to a fetal program of gene expression 
(reviewed by Cacciapuoti, 2001; Sugden and Clerk, 1998)(Cacciapuoti, 2011; Sugden & 
Clerk, 1998). On the other hand, the heart produces natriuretic peptides (ANP and BNP), 
vasodilatory, diuretic and natriuretic hormones, and more importantly, with anti-hypertrophic, 
anti-proliferative, anti-inflammatory, and sympatholytic actions (reviewed by Ogawa and de 
Bold, 2014) (Ogawa & de Bold, 2014).  
 
1.4.2.1 The sympathetic nervous system  
The sympathetic nervous system (SNS) plays an important role in the regulation of blood pressure 
and cardiac function (Grassi, Seravalle, & Quarti-Trevano, 2010). It is involved in minute-to-
minute control of blood pressure because it responds to pressure alterations within seconds 
(Silverthorn, 2013; West, 1990). SNS also influences long term pressure control through 
activation of the renin-angiotensin-aldosterone system (RAAS). Renal nerves stimulate renin 
release and positively enhance angiotensin II, which directly stimulates muscle sympathetic 
nerve activity and facilitates adrenergic sympathetic transmission (Brunton et al., 2011; 
Silverthorn, 2013). 
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Sympathetic nervous activity is regulated in centers in the brainstem and transmitted to organs and 
blood vessels that are innervated by sympathetic nerve endings (Brunton et al., 2011). 
Overactivation of the sympathetic outflow to the heart, kidneys and skeletal muscle vasculature is 
commonly present in young patients with essential hypertension, where it leads to the 
development of cardiac risk factors, such as development of left ventricular hypertrophy, 
predisposing to ventricular arrhythmias, increasing insulin resistance and accelerating 
atherogenesis (Grassi et al., 2010). The level of sympathetic drive to the heart is a major 
determinant of prognosis in patients with hypertension and heart failure, and a decrease in heart 
rate and nerve activity by treatments that directly block or oppose the sympathetic nervous 
system has been shown to be beneficial for long-term prognosis in these patients (Frohlich, 
Gonzalez, & Diez, 2011).  
The effects of the SNS are mediated by the neurotransmitter norepinephrine, a catecholamine 
synthesized in the neurons from tyrosine. The rate-limiting step for this synthesis is in the 
transformation of tyrosine to L-dopa, by the enzyme tyrosine hydroxylase (Figure 4) (Becker, 
2012; Brunton et al., 2011).  Norepinephrine is then stored at nerve endings until released by 
exocytosis upon stimulation. At the adrenal medulla, which is considered as a sympathetic 
ganglion, norepinephrine undergoes methylation producing epinephrine, which has similar 
actions to norepinephrine, but binds with similar affinity to all adrenergic receptor subtypes, 
while norepinephrine binds with higher affinity to β1- than β2- adrenergic receptors (Brunton 
et al., 2011).  
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Figure 4: Steps involved in catecholamine synthesis. Of note, different catecholamines are produced in different 
sites depending on the local availability of enzymes (Becker, 2012). 
 
Norepinephrine signals via its interaction with α- and β-adrenergic receptors, a family of G 
protein-coupled receptors (Becker, 2012; Brunton et al., 2011). Norepinephrine controls its 
own release by acting on α2-adrenergic receptors present on the pre-synaptic membrane, 
inhibiting further release (Brunton et al., 2011; Kalant, Grant, & Mitchell, 2007). 
Norepinephrine release is also inhibited by activation of imidazoline I1-receptors, non-
adrenergic receptors expressed in brainstem medulla and pre-synaptic membranes (Chan, 
Burke, Zhu, Piletz, & Head, 2005; Molderings & Gothert, 1998). The effects of 
norepinephrine are terminated through two mechanisms: reuptake by the norepinephrine 
transporter, and diffusion followed by degradation by extracellular enzymes (Brunton et al., 
2011; Kalant et al., 2007).  
The released norepinephrine causes vasoconstriction through binding to vascular α1-
adrenergic receptors (Hosoda et al., 2005; Zacharia, Hillier, & MacDonald, 2004). In the 
kidney, stimulated SNS activity/norepinephrine constricts afferent arterioles and reduces 
glomerular filtration rate by decreasing blood flow into glomerular capillaries (DiBona, 2002).  
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On the heart, norepinephrine acutely increases heart rate and contractility by activating β1-
adrenergic receptors, the main adrenergic receptor subtype (80%) present in the heart, 
specifically in cardiomyocytes (Brunton et al., 2011; Singh, Xiao, Remondino, Sawyer, & 
Colucci, 2001). Short term (10 minutes) activation of the β1-adrenergic receptor increases 
cardiomyocyte contractility by inducing an increase in calcium transients, which are 
dependent on the activation of protein kinase A (PKA) (Wang et al., 2004). Longer  exposure 
(24 h) to β1-adrenergic stimulation of isolated adult rat cardiomyocytes switches the increase 
in contractility and calcium transients from PKA dependency towards dependency on the 
activity of the calcium/calmodulin-dependent protein kinase II (CaMKII), an enzyme that has 
also been linked to adrenergic-induced apoptosis (Wang et al., 2004; Zhu et al., 2003).  
In heart failure, the expression of β1-adrenergic receptor in cardiomyocytes is down-regulated 
and uncoupled, leading to a decrease in contractility (Bristow et al., 1986; Lamba & Abraham, 
2000; Osadchii, 2007; Parati & Esler, 2012). The down regulation of β1-adrenergic receptors 
gives importance to the activity of β2- and α1-adrenergic receptors (Lamba & Abraham, 2000; 
Osadchii, 2007). During β1-adrenergic receptor down regulation, α1-adrenergic receptors 
sustain adrenergic function (Lamba & Abraham, 2000).  
In vivo and in vitro studies demonstrate that prolonged exposure to norepinephrine causes 
ventricular hypertrophy, with cardiomyocyte hypertrophy and death, fibroblast proliferation, 
and an increase in collagen accumulation (Bhambi & Eghbali, 1991; Lamba & Abraham, 
2000; Singh et al., 2001), increasing the risk of cardiac failure. In genetically engineered mice, 
deletion of α2A- and α2C-adrenergic receptors leads to cardiac hypertrophy and failure due to 
chronically enhanced catecholamine release (Hein, Altman, & Kobilka, 1999) and 
sympathectomy prevents cardiac fibrosis in hypertensive rats independent of blood pressure 
(Perlini et al., 2006). Also, mice that are unable to synthesize norepinephrine exhibit less 
cardiac hypertrophy and preserved ventricular function after aortic banding (Esposito et al., 
2002). Overexpression of β1-adrenergic receptors in the heart produces a cardiomyopathic 
phenotype (Seeland et al., 2007). Prolonged in vitro exposure to norepinephrine or 
isoproterenol increase the number of apoptotic myocytes via stimulation of the β1-adrenergic 
receptor pathway (Communal, Singh, Pimentel, & Colucci, 1998; Iwai-Kanai et al., 1999), and 
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β1-adrenergic receptor selective antagonists completely prevent norepinephrine-stimulated 
apoptosis (Morisco, Zebrowski, Vatner, Vatner, & Sadoshima, 2001; Osadchii, 2007).  
The β1-adrenergic receptor, coupled to Gs, exerts a pro-apoptotic action via a cAMP/PKA-
dependent mechanism, which appears to involve mitochondria and ROS, and is associated 
with the activation of glycogen synthase kinase-3β /JNK and p38 MAPK. Pro-apoptotic action 
of β1-adrenergic receptor may also involve activation of calcium/calmodulin-dependent 
protein kinase II (CaMKII). (Lamba & Abraham, 2000; Singh et al., 2001; Zaugg & Schaub, 
2004). Amin et al. (2011) have shown that chronic β-adrenergic stimulation causes 
cardiomyocyte apoptosis and myocardial remodeling, and that the involvement of β1 integrin 
has protective effects via the FAK and PI3-kinase/Akt pathways (Figure 5) (Amin, Singh, & 
Singh, 2011). 
 
 
Figure 5: Schema illustrating the interaction between the β-adrenergic receptor and the β1 integrin signalling in 
cardiomyocytes. β-AR: Beta adrenergic receptor; ECM: extracellular matrix; MMP-2: Matrix metalloproteinase 
2; EUB: Extracellular ubiquitin; PI3-K: phosphatidylinositol-3 kinase; FAK: Focal adhesion kinase; GSK: 
glycogen synthase kinase (Amin et al., 2011). 
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The β2-adrenergic receptor couples to Gs, Gi, or Gq depending on its functional status (Zaugg 
& Schaub, 2004). Similarly to β1-adrenergic receptor, β2-adrenergic receptor coupling to Gs 
exerts a pro-apoptotic action via cAMP pathways. Alternatively, β2-adrenergic coupling to Gi 
exerts an anti-apoptotic action which is mediated by PI3-kinase/Akt. Thus, in some cases, β2-
adrenergic receptor activity in cardiomyocytes may oppose some of the deleterious effects of 
long-term β1-adrenergic receptor stimulation (Singh et al., 2001; Zaugg & Schaub, 2004). 
The α1-adrenergic receptor signals through Gq/G11-Phospholypase C pathway, leading to an 
increase in intracellular calcium and an increase in contractility (Lamba & Abraham, 2000; 
Shannon & Chaudhry, 2006; Woodcock, 2007; Zaugg & Schaub, 2004). Overexpression or 
activation of α1-adrenergic receptors also results in cardiomyocyte hypertrophy and reduced 
apoptosis, through extracellular signal-regulated kinases (ERK) activation (Singh et al., 2001; 
Woodcock, 2007). So, depending on the balance between the activities of α1-, β2- and β1-
adrenergic receptors, adrenergic activation can be pro- or anti-apoptotic for the cardiomyocyte 
(Figure 6).  
 
 
Figure 6: Signalling pathways involved in adrenergic receptor-mediated regulation of cardiomyocyte apoptosis. 
AR: adrenergic receptors; JNKs: c-Jun-N-terminal kinase; GSK-3β: glycogen synthase kinase-3β; ROS: reactive 
oxygen species; PKA: protein kinase A; AC: adenylyl cyclase; Gs: stimulatory G protein; Gi: inhibitory G 
protein; Gq: phospholipase C activating G protein; ATP: adenosine triphosphate; cAMP: cyclic adenosine 
monophosphate; CaMKIIδ: calcium calmodulin kinase IIδ; PI-3K: phosphatidylinositol 3-kinase. Modified from 
Amin et al. (2011) and Sing et al. (2001) (Amin et al., 2011; Singh et al., 2001).   
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Chronic adrenergic stimulation of 1-week-old rat heart fibroblasts induces proliferation and 
stimulates collagen production (Bhambi & Eghbali, 1991; Lai, Sanderson, & Yu, 2009), 
through β1- and α1-adrenergic receptors, respectively (Lai et al., 2009). On the other hand, 
exposure of adult rat fibroblasts to norepinephrine causes cell proliferation, by a β2- but not 
β1- or α1-adrenergic receptor action (Leicht, Greipel, & Zimmer, 2000). This proliferative 
effect is mediated through ERK activation and production of interleukin (IL)-6, being 
decreased by blocking any one of these two mechanisms (Leicht, Briest, & Zimmer, 2003; 
Leicht et al., 2000). Intriguingly, β2-adrenergic receptor activation in adult rat fibroblasts 
results in reduced collagen I deposition, secondary to an increase in degradation. The 
importance of this effect in vivo remains to be demonstrated, but it is tempting to view this 
effect as a possible counterbalancing mechanism mediated by β2-adrenergic receptors 
(Aranguiz-Urroz et al., 2011). 
In general, fibroblasts respond to noxious stimuli by morphologically and functionally 
changing to myofibroblasts, which are characterized by the expression of α-smooth muscle 
actin (Baum & Duffy, 2011; Rohr, 2011). These cells are metabolically active and contractile, 
have the ability to migrate, and locally produce inflammatory factors, including IL-1β, TNF-α 
and nitric oxide (NO) (Baum & Duffy, 2011; Turner et al., 2009). Noteworthy, fibroblasts in 
culture show markers of myofibroblast differentiation as early as the first passage (Rohr, 2011; 
Santiago et al., 2010), indicating that, in the literature, most of the in vitro studies on cardiac 
fibroblasts essentially refer to myofibroblasts (Baum & Duffy, 2011; Rohr, 2011).  
Taken together, these studies demonstrate that excess catecholamines accelerate left 
ventricular remodelling and worsen myocardial function. The effects are mediated through 
direct activation of adrenergic receptors present in the heart. Furthermore, left ventricular 
remodelling and regulation of cardiac function may also be mediated indirectly, through 
catecholamine activation of the renin-angiotensin-aldosterone system, inflammatory 
cytokines, and oxidative stress. 
 
 40 
1.4.2.2 The renin-angiotensin-aldosterone system  
The renin-angiotensin-aldosterone system (RAAS) is considered a key factor in the long term 
regulation of blood pressure. The system is composed of a series of enzymatic cleaves that 
lead to the production of angiotensin II and aldosterone (reviewed by Carey, 2013 and Nguyen 
Dinh Cat and Touyz, 2011) (Carey, 2013; Nguyen Dinh Cat & Touyz, 2011). The classical 
RAAS is composed of the following cascade: renin, an enzyme that metabolizes plasma 
angiotensinogen into angiotensin I; then the angiotensin converting enzyme cleaves 
angiotensin I to produce the active vasoconstricting peptide, angiotensin II. The activity of 
angiotensin II in the suprarenal gland induces the production of aldosterone (Figure 7) (Carey, 
2013; Kurtz, 2012; Nguyen Dinh Cat & Touyz, 2011). 
 
 
Figure 7: Current view of the renin-angiotensin-aldosterone system. ACE, angiotensin converting enzyme; 
(P)RR, (pro)renin receptor; AT-1 and AT-2, angiotensin receptor 1 and 2; Mas, Mas receptor; MR, 
mineralocorticoid receptor. Reviewed by Fournier et al., 2012 (Fournier, Luft, Bader, Ganten, & Andrade-
Navarro, 2012). 
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Renin is produced in the kidney from cells located in the afferent arteriole, a zone known as 
the macula densa (De La Pena & De Castro, 1960). This anatomic localization allows for an 
easy  detection of low blood pressure, one of the factors that control renin production (Blaine 
& Davis, 1971). Other mechanisms that stimulate renin release include reduced renal 
perfusion and high salt content in the distal tubules (Khayat, Gonda, Sen, & Smeby, 1981; 
Nguyen Dinh Cat & Touyz, 2011) as well as catecholamine activation of the β1-adrenergic 
receptor localized in the macula densa (Holmer et al., 1997; Weber, Brodde, Anlauf, & Bock, 
1983). On the other hand, a negative feedback has been observed in the RAAS, since 
angiotensin II decreases renin secretion (Khayat et al., 1981). 
The angiotensin II effects are mediated by angiotensin receptor 1 and 2 (AT1 and AT2 
receptors). The AT1 receptor is considered the main effector of the RAAS, generating 
vasoconstriction, increasing renal sodium reabsorption, and inducing cardiomyocyte 
hypertrophy (Gray, Long, Kalinyak, Li, & Karliner, 1998) and apoptosis (Goldenberg, 
Grossman, Jacobson, Shneyvays, & Shainberg, 2001), with associated cardiac fibrosis (Lijnen, 
Petrov, & Fagard, 2000), and induces aldosterone production and secretion (Tanabe et al., 
1998). Furthermore, elevated angiotensin II levels in the central nervous system induce 
sympathetic activity (Gao et al., 2005), creating a positive feedback loop in cardiovascular 
diseases (reviewed by Zucker et al. 2014) (Zucker, Xiao, & Haack, 2014).  
In contrast, the AT2 receptor has vasodilatory (Siragy & Carey, 1997), natriuretic (Lo, Liu, 
Lantelme, & Sassard, 1995) and anti-fibrotic effects (Kurisu et al., 2003), without a direct 
effect on aldosterone secretion (Aguilera, 1992; Tanabe et al., 1998). The effect of AT2 
receptor activity on cardiomyocyte hypertrophy is controversial, as studies have shown  no 
change, decrease, or increase in hypertrophy following AT2 receptor activity (reviewed by 
Carey and Siragy 2003 and Carey 2013) (Carey, 2013; Carey & Siragy, 2003).  
 The final step in the classical RAAS system is the secretion of aldosterone from the adrenal 
medulla, following AT1 receptor activation (Aguilera, 1992; Shapiro et al., 2010). The main 
regulators of aldosterone secretion are changes in the extracellular potassium and the activity 
of angiotensin II (reviewed by Beuschlein 2013) (Beuschlein, 2013). Aldosterone increases 
renal sodium reabsorption (Fine, Meiselas, & Auerbach, 1958), increases blood pressure in 
nephrectomized animals (Friedman, Friedman, & Nakashima, 1958), with vasoconstriction, 
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endothelial dysfunction and later vascular remodelling (reviewed by Tomaschitz et al. 2010) 
(Tomaschitz, Pilz, Ritz, Obermayer-Pietsch, & Pieber, 2010), by action on the 
mineralocorticoid receptor (Pruthi et al., 2014). Additionally, aldosterone has been linked to 
cardiomyocyte hypertrophy (Rossier, Python, & Maturana, 2010), oxidative stress (Nolly et 
al., 2014), and cardiac fibrosis (Lin et al., 2012). Accordingly, the main effectors of the 
classical RAAS system increase blood pressure and have a deleterious cardiac effect, inducing 
hypertrophy and ventricular fibrosis. 
In parallel, angiotensin1-7 is produced from Angiotensin I through 2 step-cleavage by ACE2 
and ACE (Schiavone, Santos, Brosnihan, Khosla, & Ferrario, 1988), causing vasodilatation, 
inhibition of renal sodium reabsorption, and anti-fibrosis (Pinheiro et al., 2009; Santos, 2014), 
thus acting as a functional antagonist of the classical RAAS. Angiotensin1-7 vasodilatory 
actions are mediated by the MAS receptor (Peiro et al., 2013), a G-protein coupled receptor 
mediating all cellular effects of angiotensin1-7 (Santos et al., 2003).  
 
1.4.2.3 Inflammation and its effects on the development of LVH 
Another mechanism involved in the changes following chronic cardiac overload is 
inflammation. Chronic, low level inflammation is part of the physiopathology of cardiac 
changes of both hypertension and heart failure (Ahn & Kim, 2012; Schiffrin, 2013; Wrigley, 
Lip, & Shantsila, 2011). Inflammation can induce cardiomyocyte apoptosis and fibrosis, on 
the other hand, it might also exert protective effects under some circumstances, for example in 
ischemia-reperfusion conditions (Ahn & Kim, 2012; Hedayat, Mahmoudi, Rose, & Rezaei, 
2010).  
The main inflammatory mediators are cytokines, paracrine factors that regulate immune 
responses (Gullestad et al., 2012). Cytokines are divided into interleukins, such as IL-1β, IL-6, 
and tumor necrosis factor alpha (TNF-α) and chemokines (Wrigley et al., 2011). TNF-α is 
mainly produced by cells of the immune system, especially from the monocyte/macrophage 
line (Kleinbongard, Heusch, & Schulz, 2010; Wrigley et al., 2011). In the heart, TNF-α is 
released by immune cells and also by both cardiomyocytes and fibroblasts in response to 
stress, such as that induced by catecholamines and oxidative stress (Hedayat et al., 2010; 
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Kleinbongard et al., 2010; Wrigley et al., 2011). Chronic norepinephrine stimulation of 
neonatal rat cardiomyocytes increases oxidative stress, which induces TNF-α synthesis and 
release (Fu et al., 2004). 
IL-1β is produced by non-myocytes, primarily from macrophages that migrate to the 
myocardium following different inflammatory insults, and endothelial cells (Long, 2001). In 
fact, studies in vivo have shown a direct correlation between myocardial expression of IL-1β 
and myocardial invasion with monocytes, following experimental myocardial infarction or 
hypertension (Shioi et al., 1997; Yue, Massie, Simpson, & Long, 1998). In the same studies, 
no evidence of IL-1β secretion from cardiomyocytes was detected. Interestingly, in cultured 
cells, only fibroblast respond by secreting IL-1β in response to ischemic stress (Long, 2001; 
Porter & Turner, 2009), yet in pressure overload mice, IL-1β is produced in both 
cardiomyocyte and fibroblasts following stretch (Honsho et al., 2009). These results show the 
complexity of cardiac IL-1β regulation, but support the view that most of cardiac IL-1β 
secretion comes from non-myocyte sources. 
Circulating and cardiac expression of TNF-α and IL-1β are increased in hypertension and 
heart failure, and have been implicated in LVH and remodeling (Aukrust et al., 1999; 
Duerrschmid et al., 2013; Gullestad et al., 2012; Timonen et al., 2008).  Cytokines and other 
cytokine-related inflammatory factors contribute to cardiac remodeling by initiating or 
stimulating the cytokine cascade, inducing apoptosis/anti-apoptosis and regulating collagen 
(Hedayat et al., 2010; Kleinbongard et al., 2010; Siwik, Chang, & Colucci, 2000). Cytokines 
lead to cardiomyocyte hypertrophy and apoptosis in vivo and in vitro (Haudek, Taffet, 
Schneider, & Mann, 2007; Hiraoka et al., 2001; Hu et al., 2009), and stimulation of cardiac 
fibroblast proliferation and differentiation into activated myofibroblasts, which produce large 
amounts of collagens (Petrov, Fagard, & Lijnen, 2002). Cardiac over-expression of TNF-α 
results in cardiac fibrosis (Kubota et al., 2001; Zhang et al., 2011). Exposure to TNF-α reduces 
myocardial contractility, and, at long term, increases cardiomyocyte apoptosis and heart 
fibrosis (Hedayat et al., 2010). These long-term effects impede cardiac contractility and 
compromise cardiac performance (Haudek et al., 2007; Hiraoka et al., 2001; Sugden & Clerk, 
1998). In fact, cytokines exert negative inotropic effects (Figure 8), thus aggravate already 
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impaired left ventricular function (Hedayat et al., 2010; Kubota et al., 2001; Yokoyama et al., 
1993). 
 
 
Figure 8: Opposing effects of TNFR1 and TNFR2 over cardiac contractility. Of note, the predominant effect in 
most of the cases is the TNFR1-mediated negative inotropic effect. TNFR: TNF-α receptor; MSK1: Mitogen‐ and 
stress‐activated protein kinase‐1; cPLA2: Cytoplasmic phospholipase A2; PKCζ: Protein kinase C ζ; CaMKII: 
Calcium calmodulin dependant protein kinase II; T17-PLB: Phospholipase B phosphorylated at threonine 17; 
ROS: Reactive oxygen species (Defer, Azroyan, Pecker, & Pavoine, 2007). 
 
In the heart, the effects of IL-1β are controversial. IL-1β has been linked to the induction of 
apoptosis, ventricular remodelling, and cardiac dysfunction following acute non re-perfused 
infarct in mice (Toldo et al., 2013). In contrast, another study has shown that IL-1β knockout 
mice have increased ventricular apoptosis and fibrosis when subjected to aortic constriction, 
thus suggesting that IL-1β has a protective effect against pathological remodelling in this 
experimental model (Honsho et al., 2009). In pressure overload induced by aortic banding in 
mice, IL-1β is produced in both cardiomyocytes and fibroblasts, and results in ventricular 
hypertrophy, but maintains cardiac function, and modulates fibrosis (Honsho et al., 2009). The 
protective effect of IL-1β in overloaded ventricles includes the expression of insulin growth 
factor 1 (IGF-1), with downstream activation of ERK and Akt (Honsho et al., 2009). In 
contrast, the use of Anakinra, a recombinant form of the IL-1 receptor antagonist, in humans 
post-infraction reveals a tendency towards a decrease in development of heart failure (Abbate 
et al., 2013).   
 45 
In addition, IL-1β reduces fibroblast proliferation, matrix activity, cell motility and α-smooth 
muscle actin expression, which are all hallmarks of myofibroblast differentiation (Bronnum, 
Eskildsen, Andersen, Schneider, & Sheikh, 2013). These findings suggest that IL-1β, besides 
its acknowledged adverse role in the inflammatory response, can also exert beneficial effects 
in cardiac fibrosis by actively suppressing differentiation of cardiac fibroblasts into fibrogenic 
myofibroblasts (Bronnum et al., 2013). 
In vitro, cytokines have been shown to increase, decrease, or not change cardiomyocyte 
survival (Higuchi et al., 2002; Ing, Zang, Dzau, Webster, & Bishopric, 1999; Krown et al., 
1996). These heterogeneous results depend on the experimental conditions as well as on the 
complex intracellular mechanisms which mediate cytokine actions. TNF-α and IL-1β 
primarily bind to respective receptors to modulate the activities of common intracellular 
signalling pathways involved in cell apoptosis or anti-apoptosis. These pathways include 
cytokine activation of MAPKs: ERK1/2, p38, and JNK (Bogoyevitch et al., 1996; Dhingra, 
Sharma, Singla, & Singal, 2007; Sugden & Clerk, 1998; Yndestad et al., 2010). The ERK1/2 
cascade mediates cell growth and survival signals, while p38 and JNK are generally pro-
apoptotic (Mizote et al., 2010; Yeh et al., 2010). The effects are achieved through regulation 
of gene and protein expressions, either through direct phosphorylation of transcription and 
translation factors, or via intermediate kinases (Mizote et al., 2010). Cytokines activate the 
transcription factor nuclear factor-κB (NF-κB), which in turn, is apoptotic and anti-apoptotic. 
NF-κB induces inducible nitric oxide synthase (iNOS) expression and NO production, which 
can contribute to cell death or block the apoptosis signalling cascade (Haudek et al., 2007; 
Hiraoka et al., 2001; Hu et al., 2009; Lu et al., 2008).  In addition, TNF-α and IL-1β increase 
the intracellular production of second messenger sphingolipid metabolites: ceramide, 
sphingosine, and the phosphorylated derivative of sphingosine, sphingosine 1 phosphate (S1P) 
(Krown et al., 1996). Ceramide and sphingosine induce growth arrest and apoptosis, through 
protein kinase C (PKC) inhibition and downregulation of Akt phosphorylation and Bcl-2 
(Hannun & Obeid, 2008). Conversely, S1P inhibits apoptosis and promotes proliferation 
through upregulation of Akt (Spiegel & Milstien, 2003). Thus, a dynamic balance between 
pro-apoptotic and anti-apoptotic pathways determines the fate of the cells whether to die or 
survive. 
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In fibroblasts, both proliferation, mediated by ERK and NF-κB (He et al., 2011) or apoptosis, 
mediated by NO and peroxynitrite (Tian, Liu, Bitterman, & Bache, 2002), have been described 
in vitro, again raising the possibility of a dual effect of IL-1β in cardiac cells. 
In summary, pro-inflammatory cytokines IL-1β and TNF-  activate multiple signal 
transduction pathways inducing or suppressing a wide variety of genes, including those 
encoding for other cytokines and iNOS. It is important to note that the effects of cytokines, 
including left ventricular dysfunction may be completely reversed once cytokine production is 
either blocked or attenuated (Mann & Young, 1994; Remick et al., 2001).  However, recent 
clinical trials of anti-TNF-  therapy in heart failure patients have been disappointing (Chung, 
Packer, Lo, Fasanmade, & Willerson, 2003; Mann et al., 2004). The failure of these treatments 
has been explained by the protective effect of TNF-α on cardiomyocytes under some 
physiological circumstances as well as lack of effect of these therapies on other pro-
inflammatory cytokines (Gullestad et al., 2012).  
 
1.4.2.4 Natriuretic peptides as part of the cardiac response to stress 
Natriuretic peptides are elevated in pathological states, specifically in hypertension associated 
with left ventricular hypertrophy (Irzmanski et al., 2007). In the adult mammalian heart, ANP 
is mainly produced by the cardiac atria, whereas ventricular synthesis of ANP and BNP is very 
low. However, ventricular peptide synthesis is re-induced when hypertrophy develops, so that 
ANP expression in the ventricles is frequently used as a marker for myocyte hypertrophy 
(Kaganovsky et al., 2001; Takemura et al., 1989). 
It is important to note however, that elevated ANP and BNP in the heart may act as counter-
regulatory mechanisms against further hypertrophy, heart failure, and its consequences 
(Mukaddam-Daher, 2006; Ogawa & de Bold, 2014). This is based on multiple studies showing 
that, independent of their role in blood pressure control, natriuretic peptides have direct anti-
hypertrophic and anti-fibrotic actions on the heart.  Deletion of a single copy of the pro-atrial 
natriuretic peptide gene (Nppa
+/-
) results in exaggerated cardiac hypertrophy and remodeling 
after pressure overload stress (Franco et al., 2004). Mice lacking the natriuretic peptide receptor 
A (NPR-A) are hypertensive and display a marked cardiac (atrial and ventricular) hypertrophy, 
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with extensive fibrosis and chamber dilatation by 3 months of age, as well as high mortality rate 
due to sudden death (Lopez et al., 1995).  Although BNP and ANP signal through the same 
NPR-A receptor, mice with disrupted BNP exhibit a different phenotype than ANP-deficient 
mice. BNP knockout mice are not hypertensive and do not develop ventricular hypertrophy, 
but develop multifocal fibrotic lesions in their ventricles (Tamura et al., 2000). Also,
 
ANP and 
BNP suppress hypoxia-induced collagen synthesis in fibroblasts (Tamamori, Ito, Hiroe, Marumo, & 
Hata, 1997). 
The anti-growth actions of natriuretic peptides are mediated by different mechanisms. 
Natriuretic peptides inhibit MAPK via the inhibition of upstream kinase(s), including MEK, 
uniquely resulting from ligand binding to NPR-C clearance receptor (Prins et al., 1996). Also, 
ANP/NPR-A system negatively regulates MAPK/ERK2 activity and proliferation of 
mesangial cells in a PKG-dependent manner (Pandey, Nguyen, Li, & Boyle, 2000).  
Kato et al. (2005) reported that high concentrations (10
-6
 M) of ANP stimulate apoptosis, 
evidenced by increased caspase 3, but at lower concentrations, ANP was anti-apoptotic, protecting 
cardiomyocytes from staurosporine challenge, by mechanisms that include cGMP-dependent 
nuclear accumulation of Akt (Kato et al., 2005). The anti-apoptotic effect of natriuretic 
peptides was also shown in serum-deprived PC12 cells, where prolonged cGMP elevations 
caused by ANP or BNP inhibited apoptotic DNA fragmentation and prolonged cell 
survival (Fiscus, Tu, & Chew, 2001). The protective effect may involve suppression of 
cytokine production, as ANP attenuates TNF-  production by macrophages, by suppressing p38 
MAPK and NF- B activation (Tsukagoshi et al., 2001) and protects from ischemia-reperfusion liver 
injury by reducing TNF-  mRNA expression and NF- B activation via cGMP (Kiemer, Vollmar, 
Bilzer, Gerwig, & Gerbes, 2000).  
Furthermore, the natriuretic peptide interaction with nitric oxide (NO) places ANP in a unique 
position of being able to maintain the essential or protective actions of NO while inhibiting 
potentially cytotoxic or detrimental effects (Drexler, 1999). ANP stimulates endothelial nitric 
oxide synthase (eNOS) (Murthy, Teng, Jin, & Makhlouf, 1998), but inhibits pro-inflammatory 
cytokine-induced nitric oxide (iNOS) production in human proximal tubular cells in culture 
exposed to a combination of IL-1 , TNF- , and IFN-  (Chatterjee, Hawksworth, & McLay, 
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1999). In contrast, IL-1 -stimulated iNOS mRNA and nitric oxide production from ventricular 
cardiomyocytes (Harding, Carretero, & LaPointe, 1995) and cultured rat vascular smooth 
muscle cells (Iimura et al., 1998) is augmented in the presence of ANP and BNP (Yamamoto, 
Ikeda, & Shimada, 1997). These studies imply cell and stimulus-dependency. 
 
 
Figure 9 : Protective effects of natriuretic peptides in cardiac pathology (reviewed by Mukaddam-Daher, 2006) 
(Mukaddam-Daher, 2006). 
 
In summary, natriuretic peptides serve as acute and chronic control mechanisms against 
cardiac overload, serving as a counterbalancing mechanism, reducing cardiac remodelling. 
Through sympatholytic and anti-inflammatory actions, natriuretic peptides are anti-
hypertrophic, anti-proliferative and anti-fibrotic (Ogawa & de Bold, 2014). Based on their 
multiple protective effects (Figure 9) pharmacological therapy has been approved and includes 
inhibition of endogenous natriuretic peptide degradation or by potentiating natriuretic peptide 
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levels by intravenous infusion of recombinant ANP or pro-ANP (reviewed by: Mukaddam-
Daher, 2006; George et al., 2014) (George, Rajaram, Shanmugam, & Vijayakumar, 2014; 
Mukaddam-Daher, 2006). Other pharmacological compounds that potentiate endogenous 
natriuretic peptides include β-blockers (atenolol, carvedilol, propranolol, bisoprolol, tertatolol) 
and centrally-acting sympatholytic drugs, like clonidine and, recently, moxonidine (El-
Ayoubi, Menaouar, Gutkowska, & Mukaddam-Daher, 2005; Mukaddam-Daher & Gutkowska, 
1999, 2000). Clinically, moxonidine has been shown to be a very efficacious antihypertensive 
agent with cardioprotective effects that, at least in part (as presented below, section 1.6.1 
Moxonidine in hypertension), may be mediated by potentiated natriuretic peptide levels.   
 
1.5 Current pharmacological treatment options for hypertension 
and heart failure 
Current heart failure treatment guidelines emphasizes treatment of predisposing factors as a 
first step of treatment , and thus overlap with treatment guidelines for other cardiovascular 
pathologies, especially hypertension, which is a major risk factor for heart failure (Hunt et al., 
2009; Kannel et al., 1972).  
Hypertension treatment recommendations include changing lifestyle, such as weight loss, 
exercise, and reduction of sodium intake and stress levels. These treatment venues can be 
moderately effective (for example reducing salt intake can decrease mean blood pressure 
around 4 mmHg) (Chobanian et al., 2003; Mancia et al., 2007), yet most hypertensive patients 
need pharmacological treatment, and in most cases 2 or more drugs are required (Chobanian et 
al., 2003; Hackam et al., 2013; James et al., 2014).  
Several classes of antihypertensive medications are currently available, including vasodilators, 
thiazide diuretics, RAAS blockers, including angiotensin converting enzyme (ACE) inhibitors 
and angiotensin receptor blockers (ARB), long acting calcium channel antagonists, and 
sympatholytics, including β-adrenergic blockers and centrally acting α2-adrenergic and 
imidazoline I1-receptor agonists (Brunton et al., 2011; Hackam et al., 2013; Mancia et al., 
2007; Poirier & Lacourciere, 2012). The choice of therapy depends on the presence of other 
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risk factors, such as LVH, diabetes, obesity, and others. It is important that in addition to 
lowering blood pressure, pharmacological antihypertensive therapy takes into consideration 
these risk factors, thus should aim at regressing LVH, improving cardiac function, as well as 
improving, or at least not worsening, insulin sensitivity and lipid metabolism (Hackam et al., 
2013; James et al., 2014).  
In this respect, some medications, while excellent vasodilators, reducing blood pressure, are 
not part of the current treatment of hypertension due to their lack of effect on complications, 
like LVH, or even an increase in the risk of cardiovascular events due to their ability to 
activate the sympathetic nervous system (Brunton et al., 2011). Hydralazine is a potent arterial 
vasodilator, yet it increases sympathetic activity and does not regress LVH (El-Ayoubi et al., 
2004; Leenen, Burns, Myers, & Frankel, 1990; Tsoporis & Leenen, 1988). Thiazide diuretics 
also induce dyslipoproteinemia and stimulate the sympathetic nervous system (Pischon & 
Sharma, 2002). Calcium channel blockers are considered metabolically neutral and are 
successfully used to treat patients with hypertension and stable angina pectoris, however they may 
have unfavorable effects in patients with impaired left ventricular function, due in part to 
baroreceptor-mediated activation of the SNS (Toal, Meredith, & Elliott, 2012), an effect which 
could decrease their benefit (Fisher & Fadel, 2010; Toal et al., 2012).  
On the other hand, inhibitors of the RAAS are very effective antihypertensive treatments, 
improving cardiac function and having a favorable metabolic profile, producing increases in 
insulin sensitivity (Manrique, Lastra, Gardner, & Sowers, 2009). In addition to 
opposing/inhibiting the deleterious effects of RAAS, the important clinical benefits of ACE 
inhibitors and
 
angiotensin II receptor blockers (ARBs) could also be explained by their 
blunting or inhibiting the SNS effects
 
in patients with cardiovascular disease (De Tommasi et 
al., 2003);
 
reviewed by Nap et al. 2003 (Nap, Balt, Mathy, & Van Zwieten, 2003).  
Therefore, it appears imperative that selection of vasoactive drugs for the treatment of 
cardiovascular diseases take into consideration their effects on the sympathetic nervous system, 
where, ideally, treatment should also blunt sympathetic activity, or at least avoid activating it.  
It is evident that sympathetic nervous system dysfunction, manifested as persistent and adverse 
activation of sympathetic outflows to the heart and kidneys, is crucial in the development of 
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heart failure and hypertension (Grassi, 2013; Grassi et al., 2010). Current strategies that 
directly target the activity of the sympathetic nervous system include β-adrenergic receptor 
blockers and centrally acting medications. Both groups attenuate sympathetic effect on target 
organs (Brunton et al., 2011; Fisher & Fadel, 2010). In fact, these medications, although 
routinely used in treatment of hypertension (Hackam et al., 2013; Mancia et al., 2007), remain 
underutilized. The use of some β-blockers is waning because of their metabolic effects, 
including weight gain and predisposition to diabetes development (Brunton et al., 2011). 
However, in patients with reduced ejection fraction, or symptomatic heart failure, modulation 
of the activity of the sympathetic nervous system with the use of β-blockers is an integral part 
of treatment (Hunt et al., 2009). In heart failure patients, β-blockers increase ejection fraction 
(Gilbert et al., 1996), increase exercise capacity (Dekleva et al., 2012), and reduce heart failure 
symptoms and mortality (DiNicolantonio, Lavie, Fares, Menezes, & O'Keefe, 2013; Hunt et 
al., 2009). It is worth noting that during β-blockade, adverse effects of norepinephrine may be 
observed following unopposed α1-adrenergic stimulation. In this respect, the combined β- and 
α1-adrenergic blocker carvedilol is favored as it improves cardiac output and mortality in 
patients with heart failure (Brodde & Michel, 1999; Packer et al., 1996). These results stress 
the importance of correctly modulating sympathetic nervous system activity in heart failure 
and favor inhibition of norepinephrine release rather than actions. Centrally acting drugs, such 
as clonidine and -methyldopa, reduce central sympathetic drive and norepinephrine release.  
These drugs, consequently, maintain cardiac output, arterial tone, and body fluid volume 
(Azevedo, Newton, & Parker, 1999; Brunton et al., 2011; Sanjuliani, Francischetti, Genelhu 
de Abreu, & Ueleres Braga, 2004). Despite their clinical efficacy, the use of these “first 
generation centrally acting drugs” was often limited by their side effects, which include dry mouth, 
sedation, and mental depression (Brunton et al., 2011; Webster & Koch, 1996). Also, rebound 
over-activity of the sympathetic nervous system has been described following sudden 
discontinuation of clonidine (Brunton et al., 2011; Webster & Koch, 1996). However, the 
discovery of imidazoline I1-receptors and development of selective compounds, moxonidine and 
rilmenidine, which show an improved side-effect profile (in comparison to clonidine), revived 
interest in centrally acting drugs (Edwards, Brown-Bryan, McLean, & Ernsberger, 2012). The 
improved side-effect profile is based on the higher affinity of moxonidine and rilmenidine to 
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imidazoline I1-receptors and lower affinity to α2-adrenergic receptors (Ernsberger, Giuliano, 
Willette, Granata, & Reis, 1988). 
 
1.6 Moxonidine  
Moxonidine (4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-
pyrimidinamine), the prototype of the “second generation centrally acting drugs”, is a 
chemical derivate of clonidine that retains the 5-membered imidazoline ring, but has different 
substitutions in other parts of the molecule (Figure 10) (Ernsberger, 2000). Moxonidine shows 
70 times higher affinity to imidazoline I1-receptors compared to α2-adrenergic receptors, as 
observed in binding assays performed in bovine rostro-ventro lateral medulla (RVLM) 
(Ernsberger, Damon, Graff, Schafer, & Christen, 1993). Thus, moxonidine is an effective 
antihypertensive compound, with far less side effects, and no rebound effect upon 
discontinuation (Planitz, 1987), most likely due to its low affinity for the α2-adrenergic 
receptor (Ernsberger, 2000; Ernsberger et al., 1993).   
 
 
Figure 10 : Structure of imidazoline agonists clonidine and moxonidine. 
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1.6.1 Moxonidine in hypertension 
Moxonidine is an antihypertensive medication with an oral half-life of 2.1 hours (Trenk, 
Wagner, Jahnchen, & Planitz, 1987), but approved to be used once a day, due to its lasting 
actions on blood pressure (Edwards et al., 2012). In humans, moxonidine reduces blood 
pressure, with good tolerability (Prichard et al., 2002). Its blood pressure-lowering effect 
equals that of thiazides, calcium antagonists, ACE inhibitors, α- and β-adrenergic receptor 
blockers, and the first generation centrally-acting antihypertensives, such as α-methyldopa and 
clonidine (Fenton, Keating, & Lyseng-Williamson, 2006; Kuppers et al., 1997; Ollivier & 
Christen, 1994).  
In addition to blood pressure reduction, moxonidine improves glycemic control in patients 
with diabetes mellitus or metabolic syndrome (Chazova & Schlaich, 2013; Derosa et al., 2007; 
Kemme et al., 2003) and reduces bodyweight in hypertensive obese patients (Sharma, Wagner, 
& Marsalek, 2004). Also, moxonidine reduces plasma TNF-α level in hypertensive and 
overweight postmenopausal women (Poyhonen-Alho et al., 2008). Taken together, these 
studies support the use of moxonidine in patients with hypertension complicated with 
metabolic syndrome. 
Moxonidine results in a clinically relevant reduction in blood pressure in patients with renal 
disease and resistant hypertension; and may be an “add-on” treatment in elderly patients whose 
hypertension is poorly controlled despite treatment with two or more antihypertensive agents 
(Hausberg, Tokmak, Pavenstadt, Kramer, & Rump, 2010; Martin, Hill, & O'Mahony, 2005; 
Neumann, Ligtenberg, Oey, Koomans, & Blankestijn, 2004). Furthermore, moxonidine has 
anxiolytic and anti-depressant effects, which may be especially important in cardiovascular 
diseases (Konstam, Moser, & De Jong, 2005).  
Moxonidine treatment also regresses LVH in hypertensive patients and animals (Haczynski, 
Flasinski, Przewlocka-Kosmala, & Spring, 2001; Mall et al., 1991; Paquette et al., 2008). The 
anti-hypertrophic effect of moxonidine may include induction of natriuretic peptides, as 
suggested by studies performed in our laboratory on normotensive and hypertensive rats. 
Acute (1-4 h) (Mukaddam-Daher & Gutkowska, 1999, 2000) and chronic (1week) in vivo 
moxonidine treatment increase circulating ANP levels (Menaouar, El-Ayoubi, Jankowski, 
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Gutkowska, & Mukaddam-Daher, 2002). Furthermore, moxonidine stimulates ANP release 
from isolated rat hearts ex vivo, an effect mediated, in part, by cardiac imidazoline I1-receptors 
(Mukaddam-Daher et al., 2006). 
Previous observations from this laboratory have also shown that chronic treatment of 
spontaneously hypertensive rats (SHR) with non-hypotensive and hypotensive doses of 
moxonidine results in reduced left ventricular hypertrophy, by mechanisms that include a 
sustained decrease in DNA synthesis as well as by a transient increase in ventricular apoptosis 
(detected as an increase in DNA laddering and caspase 3 expression), appearing after 1 week 
and subsiding by 1 month of treatment (Paquette et al., 2008). However, based on the link 
between cardiomyocyte apoptosis and heart failure (Kemp & Conte, 2012), the effect of the 
transient apoptotic action of moxonidine in hypertension on cardiac function warrants further 
investigation. 
 
1.6.2 Moxonidine in heart failure 
Despite the overwhelming evidence that moxonidine is a safe and effective antihypertensive 
drug, its use in heart failure is controversial.  Dickstein et al. (1999) reported that acute use of 
moxonidine in patients with heart failure markedly decreased plasma norepinephrine, 
implying a decrease in sympathetic output (Dickstein et al., 1999).  This effect was later 
confirmed in a small 12-week trial, in which heart failure patients received moxonidine with 
good tolerability (Swedberg, Bergh, Dickstein, McNay, & Steinberg, 2000). In 2002, a study 
using different doses of moxonidine (extended release preparation) revealed that high doses of 
moxonidine were associated with a decrease in plasma norepinephrine, but an increase in 
adverse effects was also observed (Swedberg et al., 2002). In 2003, a phase III trial, the 
Moxonidine Congestive Heart Failure (MOXCON) trial was conducted on patients with 
NYHA class II-IV heart failure and LVEF ≤ 35%. This trial reported more deaths in the 
moxonidine-treated group (54 vs. 32 patients), which led to its abrupt termination without 
further investigation of the underlying mechanisms (Cohn et al., 2003). Several reasons may 
underlie the findings of the failed study, including very high doses (5 times higher than the 
recommended antihypertensive doses) leading to strong suppression of much needed residual 
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sympathetic activity to the heart, lack of patient compliance leading to rebound effect of the drug, 
increased myocardial metabolism, or interference with other heart failure medications (Coats, 
1999; Floras, 2002; Mobini et al., 2006).  
On the other hand, in post-infarction rats, a model of acute heart failure, moxonidine treatment 
reduced LVH and increased ventricular capillary density, implying an increase in myocardial 
oxygen supply to the cardiomyocytes (Van Kerckhoven, van Veghel, Saxena, & Schoemaker, 
2004), a beneficial effect in post-infarcted hearts. 
These studies clearly demonstrate that the mechanism of action of moxonidine may have 
alternative drug targets (adrenergic, non-adrenergic) or different target distribution (organ- or 
cell-specific), regulation, cell-specific signaling pathways, and interaction with other 
mechanisms stimulated in hypertension or heart failure.  
 
1.7 The imidazoline I1-receptor 
Blood pressure reduction by the centrally acting compound moxonidine is mediated by 2 
functionally and genetically distinct receptors: α2-adrenergic receptors and non-adrenergic 
imidazoline I1-receptors, with higher affinity at imidazoline I1-receptors (Ernsberger et al., 
1993; Ernsberger et al., 1988). 
 
1.7.1 Characterization of the imidazoline I1-receptor 
The existence of imidazoline receptors was first suggested by Bosquet and co-workers in 
1984, following an experiment in which microinjections of the imidazoline compounds, 
cirazoline and ST-587 (both α1 adrenergic agonists), in cat’s nucleus reticularis lateralis had 
hypotensive and bradicardic effects similar to clonidine, an imidazoline compound described 
at that time as a central α2-adrenergic agonist (Bousquet et al., 1984). On the other hand, 
injection of the catecholamine α-methylnorephinephrine, a putative α2-adrenergic agonist, 
injected in the same zone did not change heart rate or blood pressure (Bousquet et al., 1984). 
The investigators observed that only substances with an imidazoline 5-membered ring 
structure were hypotensive, which led them to suggest the existence of a site that binds 
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imidazoline compounds, but not catecholamines. Later, the existence of central “imidazoline 
preferring, non-α adrenergic membrane receptors” was confirmed by binding assays (Bricca et 
al., 1989).  
Imidazoline receptors are a non-adrenergic heterogeneous group of proteins, broadly divided 
into I1, I2, and I3, based on physiological function, location, and pharmacological tools 
available to differentiate them (Hamilton, 1995). Imidazoline I2-receptors, mainly found in the 
brain, are involved in mood disorders (Garcia-Sevilla et al., 1995; Halaris & Piletz, 2003), 
while imidazoline I3-receptors in the pancreas control insulin secretion (Morgan & Chan, 
2001). On the other hand, imidazoline I1-receptors (the focus of our studies) occur mainly in 
the brainstem medulla, adrenal chromaffin cells, and, to a lower extent, in the kidneys. 
(Vauquelin, De Backer, Ladure, & Flamez, 1999).  
Our laboratory was the first to identify functional imidazoline I1-receptors in the heart 
(Mukaddam-Daher et al., 1997). Using binding assays, Western blots, and 
immunohistochemical techniques, imidazoline I1-receptors were localized to heart atria and 
ventricles of several species, including rats, hamsters, and humans (El-Ayoubi et al., 2002). 
Furthermore, imidazoline I1-receptors were shown to be up-regulated in atria of SHR with 
already developed  LVH, and in ventricles of hamsters with advanced cardiomyopathy, and in 
human ventricles with heart failure (El-Ayoubi et al., 2002).  Heart imidazoline I1-receptors, but 
not 2-adrenergic receptors, were altered by chronic in vivo treatment of hypertensive rats with 
moxonidine (El-Ayoubi et al., 2003, 2004). These studies indicated that heart imidazoline I1-
receptors are responsive to chronic exposure to agonist as well as to changes in the cardiovascular 
environment. 
The nature of imidazoline I1-receptor was not identified until in 1998, when the group of Piletz 
and Ernsberger characterized an 85 kilodalton (kDa) protein as a candidate for the imidazoline 
I1-receptor in rat brain and in rat neuronal pheochromocytoma PC12 cells (Ivanov, Zhu, et al., 
1998). The characterization of the receptor took a great leap forward once this group found 
that the imidazoline I1-receptor was coded by the “imidazoline receptor antisera selected” 
(IRAS) cDNA, isolated from a library of human hippocampus cDNA, which was expressed in 
E. coli and tested for immunoreactivity with 2 specific anti-imidazoline binding protein 
antisera. The positive clones were sequenced and found to code for a single cDNA (Ivanov, 
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Jones, Dontenwill, Bousquet, & Piletz, 1998; Piletz, Jones, Zhu, Bishara, & Ernsberger, 1999). 
Transfection of IRAS full cDNA into Chinese hamster ovary cells (CHO) developed high-
affinity imidazoline I1-binding sites (Piletz et al., 2000).  
Independently, Alahari and co-workers (Alahari et al., 2000), using a yeast two-hybrid system 
with the α5 integrin cytoplasmic tail as bait, and an embryonic mouse cDNA library coding 
for the prey proteins, discovered a ~190 kDa protein that binds to the integrin α5 tail of the 
α5β1 fibronectin receptor. Transfection of 3T3 embryonic fibroblast cell line or Chinese 
hamster ovary cells with cDNA coding for this protein slowed cell migration. Accordingly, 
Alahari called it Nischarin, a Sanskrit word that denotes slow motion (Alahari et al., 2000). 
Nischarin was further described as a cytosolic protein whose mRNA is expressed in several 
mouse tissues, including brain, kidney, lung, and heart. Sequencing of nischarin revealed 80% 
homology with human IRAS (Alahari et al., 2000), thus nischarin is the murine homologue of 
human IRAS. In PC12 cells, the use of IRAS/nischarin antisense lowers the density of 
imidazoline I1-sites in the cells, providing evidence that nischarin expression is related to the 
imidazoline I1-receptor (Sun, Chang, & Ernsberger, 2007). In addition, IRAS/nischarin 
antisense inhibited ERK activation induced by the selective imidazoline I1-receptor agonists, 
rilmenidine (Zhang & Abdel-Rahman, 2006) or moxonidine (Sun et al., 2007), confirming the 
relation between nischarin expression and the imidazoline I1-receptor.  
Nischarin is located both in cell membrane and cytosol. In nischarin-transfected COS-7 
fibroblast-like cells and non-transfected neuro 2A neuroblast cells, using sub-cellular 
fractionation by ultra-centrifugation, followed by Western blot, Alahari found that nischarin 
was mostly a cytosolic protein, with a small pool near the membrane that binds to the 
fibronectin receptor (Alahari et al., 2000). On the other hand, using immunofluorescence, 
Zhang and Abdel-Rahman (2006) found that PC12 pheochromocytoma cells express nischarin 
mainly in the cellular membrane (Zhang & Abdel-Rahman, 2006). Accordingly, nischarin 
localization may vary depending on the cell type studied.  
In 2008, the group of Bousquet proposed that the imidazoline I1-receptor functionally interacts 
with the G-protein inwardly rectifying potassium channel (GIRK). This hypothesis was based 
on intracisternal injections studies in rabbits, showing that opening the GIRK pore increased 
the hypotensive effects of the selective imidazoline I1-receptor ligands LNP509 and LNP640, 
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and closing the pore diminished their actions (Yoro Sy et al., 2008). Also, binding studies 
performed on PC12 cells, showed that the binding of the selective imidazoline I1-receptor 
ligand LNP911 was modified by substances that open or close the GIRK pore, without 
changing the affinity, suggesting that the imidazoline binding site could be located inside 
GIRK (Yoro Sy et al., 2008). 
Finally, the group of Molderings, also using PC12 cells, and siRNA for the lysophospholipid 
receptors of S1P (S1P1-3) and lysophosphatidic acid receptor families, have shown that binding 
of clonidine was markedly reduced by the inhibition of S1P1 and S1P3 expression, suggesting 
that the imidazoline I1-receptor in PC12 cells is part of the lysophosholipid S1P receptor 
family (S1P1 and S1P3) (Molderings et al., 2007), and that it requires nischarin expression for 
its trafficking towards the membrane, thus nischarin is part of its signalling pathway 
(Molderings et al., 2007; Zhang & Abdel-Rahman, 2006).  
Based on the above described studies, the imidazoline I1-receptor/nischarin might interact with 
several membrane components. The importance of these interactions is not completely 
understood, but, it is clear that imidazoline I1-receptor/nischarin expression is a key factor in 
the regulation and function of imidazolines. 
 
1.7.2 Structure of imidazoline I1-receptor/nischarin 
Mouse nischarin is described as a 1593 amino acid (aa) protein (accession no NP_073147) 
(Lim & Hong, 2004), with multiple functional domains.  
 
Figure 11 : Domain map of nischarin. For details see text (Sun et al., 2007). 
 59 
 
Figure 11 shows the described domains of nischarin as compiled by Sun et al. (2007) (Sun et 
al., 2007). The PX domain describes a sequence that is common to a group of proteins called 
sorting nexins; this domain is necessary for nischarin targeting towards the cell membrane and 
trafficking towards endosomes (Lim & Hong, 2004). In addition, trafficking needs the 
presence of the coiled coil region, which allows nischarin to homo-oligomerize (Lim & Hong, 
2004); the coiled coil region also binds ruthenium red, and has been proposed as the 
imidazoline binding site (Piletz et al., 2000; Sun et al., 2007).  Leucine-rich repeats (LRR in 
Figure 11) have been described as sites for protein to protein interaction, with activities such 
as receptor regulation, cytoskeletal configuration and apoptosis regulation (reviewed by Kobe 
and Kajava, 2001) (Kobe & Kajava, 2001). The interaction partners for the 5 observed 
leucine-rich repeats sequences present in nischarin are currently unknown. Recently, the group 
of Alahari has described an interaction between nischarin and the tumor suppressor protein 
liver kinase B1 (LKB1), enhancing the kinase activity of this protein. This interaction 
enhances the tumor suppressor abilities of both nischarin and LKB1. The interaction site was 
mapped near the N-terminal site, between amino acids 416 and 624 (Jain et al., 2013).   
Finally, there is the α5 integrin subunit binding site (part of the fibronectin receptor), 
described by Alahari and coworkers in the original publication describing nischarin (Alahari et 
al., 2000). Interestingly, overexpression of IRAS can redistribute surface α5 integrin to 
intracellular endosomal structures, and this could be linked to the observed alterations in 
migration following nischarin expression (Lim & Hong, 2004).  
 
1.7.3 Signalling through the imidazoline I1-receptor/nischarin 
Due to the lack of specific imidazoline I1-receptor agonists devoid of activity at the α2-
adrenergic receptors, most of the imidazoline I1-receptor signalling studies have been 
performed on neuronal rat pheochromocytoma cell line (PC12). These cells express 
imidazoline I1-receptor but not α2-adrenergic receptor or I2-receptors, as confirmed by RT-
PCR and membrane binding studies (Molderings, Bonisch, Hammermann, Gothert, & Bruss, 
2002). 
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In PC12 cells, activation of imidazoline I1-receptors by moxonidine (Figure 12) activates 
phosphatidylcholine-selective phospholipase C (PC-PLC) and induces the accumulation of 
diacylglycerol (DAG)  (Ernsberger, 1999; Separovic, Kester, & Ernsberger, 1996; Separovic, 
Kester, Haxhiu, & Ernsberger, 1997), and downstream activation of 2 isoforms of protein 
kinase C (PKC), specifically the cPKCβII and aPKCζ isoforms (Edwards et al., 2001). The 
activity of PKC induces the activation of ERK and JNK, but in the presence of nerve growth 
factor (NGF), a potent activator of neuronal PC12 cell differentiation, moxonidine almost 
completely reverses NGF-induced ERK activation (Edwards et al., 2001).
 
Therefore, 
depending on the stimulus, imidazoline I1-receptors can either activate or inactivate ERK. 
Imidazoline I1-receptor activation induces the production of arachidonic acid, which in turn 
produces prostaglandin E2 (PGE2), by mechanisms that include activation of PC-PLC and are 
independent of calcium or phospholipase A2 (Ernsberger, 1998) (Figure 12). Interestingly, in 
the H9C2 cardiomyoblast cell line, blocking PGE2 production by the use of the 
cyclooxygenase 2 blocker celecoxif induces cell death (Sakane et al., 2014). These studies 
suggest a protective effect of locally produced PGE2 following imidazoline I1-receptor 
activation.  
 
 
Figure 12 : Imidazoline I1-receptor mediated production of PGE2 in PC12 cells (Ernsberger, 1998). 
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In vivo studies have shown that injecting the PC-PLC inhibitor D609 in the rostro-ventro-
lateral medulla (RVLM) blocks the antihypertensive effect of moxonidine in hypertensive rats, 
and thus this mechanism is important in the physiological effects of the imidazoline I1-
receptor (Separovic et al., 1997). Furthermore, central blocking (using intracisternal 
cannulation) of ERK phosphorylation in the RVLM in Sprague-Dawley (SD) rats blocks the 
hypotensive effects of the imidazoline I1-receptor agonist rilmenidine (Zhang & Abdel-
Rahman, 2005). Additionally, the effect of rilmenidine on blood pressure reduction and ERK 
activation depends on the expression of nischarin, since blocking its expression in vivo by 
nischarin antisense reduces hypotension and ERK activation (Zhang & Abdel-Rahman, 2008), 
linking the ERK activation by imidazoline I1-receptor agonists to the expression of nischarin. 
Finally, blocking either ERK or p38 MAPK activity in the central nervous system of rats with 
acute renal failure blocks the hypotensive effects of moxonidine, suggesting that, in vivo, the 
hypotensive effects of imidazoline I1-receptor activation are mediated by both ERK and p38 
MAPK (El-Mas, El-Gowelli, Ghazal, Harraz, & Mohy El-Din, 2009). These results imply that 
the imidazoline I1-receptor/PC-PLC/ERK/p38 MAPK pathway mediates the central 
hypotensive effects of the imidazoline I1-receptor agonist moxonidine. 
IRAS/nischarin co-immunoprecipitates with the insulin receptor substrate 4 (IRS-4) in human 
embryonic kidney (HEK293) cells (Sano, Liu, Lane, Piletz, & Lienhard, 2002). It also 
precipitates with IRS 1, 2 and 3 in Cos7L cells, but with lower affinity (Sano et al., 2002). The 
binding of the imidazoline I1-receptor to the IRS1-4, especially to IRS-4, opens the possibility 
of activation of Akt via the canonical PI3-K/Akt pathway. In fact, moxonidine activates Akt in 
HEK293 cells transfected with IRAS (Edwards et al., 2012). Therefore, imidazoline I1-
receptor agonists also signal through an imidazoline I1-receptor/nischarin/IRS/PI3-K/Akt 
pathway (Edwards et al., 2012)(Figure 13).  
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Figure 13 : Signalling through the imidazoline I1-receptor. For details see text (Edwards et al., 2012). PC-PLC: 
Phosphatidylcholine-selective phospholipase C; AA: Arachidonic acid; DAG: diacylglycerol 
 
Activation of the imidazoline I1-receptor/nischarin/IRS/PI3-K/Akt pathway is consistent with 
the observation that moxonidine improves the metabolic profile of the obese SHR (SHROB), a 
strain with reduced insulin sensitivity (Ernsberger et al., 1999).  
The current view of imidazoline I1-receptor signalling is summarized in Figure 13. 
In addition to the PC-PLC- and IRS-mediated pathways described so far, other cellular 
pathways and actions for the imidazoline I1-receptor have been described in cells over-
expressing nischarin. Nischarin overexpression in NIH 3T3 fibroblast cell line reduces cell 
migration in association with a reduction in the activation of Rac (Alahari et al., 2000), a GTP-
binding protein that is part of the Rho/Rac family (Bustelo, Sauzeau, & Berenjeno, 2007). This 
effect has been confirmed in human breast carcinoma and colon adenocarcinoma cells, 
showing that migration of these cells is inhibited by nischarin through inhibition of Rac-PAK 
pathway (Alahari, 2003). Nischarin also interacts with LIMK1, a downstream enzyme of 
PAK, and this interaction inhibits LIMK1 activity and reduces cell invasion in a breast cancer 
cell line (Ding, Milosavljevic, & Alahari, 2008).  
Overexpression of hIRAS in PC12 cells markedly reduces cell apoptosis induced by 
starvation, by mechanisms that include protection of mitochondrial function, and signal 
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through PI3-K/Akt pathway (Dontenwill, Piletz, et al., 2003). In contrast, the expression of 
nischarin is decreased in invasive human breast cancer and  nischarin over-expression reduces 
proliferation of breast cancer cells in vitro and in vivo, and reduces metastasis in an animal 
model (Baranwal et al., 2011). These studies implicate imidazoline I1-receptor/nischarin in cell 
growth/proliferation and show that the specific effect (induction or reduction of 
proliferation/cell survival) would depend on the cell type and model used. 
Collectively, these studies in different cell lines reveal that imidazoline I1-receptor/nischarin 
signalling involves enhanced MAPK phosphorylation via the PC–PLC–PKC pathway, 
enhances Akt phosphorylation via IRS-PI3-K pathway, and might be involved in apoptotic 
and anti-apoptotic processes, depending on the cell type and stimulus. In addition, imidazoline 
I1-receptor/nischarin signals through inhibition of Rac1 and alters the distribution of α5-
integrin, thus it is involved in maintenance of the ECM.  
Further studies are required to investigate whether similar mechanisms mediate imidazoline I1-
receptor/nischarin signalling in primary cardiac cells. Furthermore, it is important to localize 
and identify the cellular actions of imidazoline I1-receptor signalling in different cardiac cell 
types and in response to different growth/death inducing stimuli, such as those present in 
cardiac pathologies, as inhibition of fibroblast proliferation/action protects the heart from 
fibrosis, while inhibition of myocyte apoptosis stops/delays progression of heart disease in the 
hypertensive heart. Identification of these mechanisms may lead to tailoring specific cell-
driven imidazoline I1-receptor agonists for treatment of patients with heart disease. 
 
  
 
Chapter 2. Hypothesis and aims 
Moxonidine, an antihypertensive sympatholytic imidazoline compound, reduces blood 
pressure by selective activation of non-adrenergic imidazoline I1-receptors (also known as 
nischarin) in brainstem medulla (Edwards et al., 2012). Previous studies from our group have 
shown that moxonidine treatment prevents the development of LVH in SHR, associated with 
reduced cardiac DNA synthesis and early (after 1 week) transient increase in DNA 
fragmentation (Paquette et al., 2008). It is likely that the anti-proliferative and apoptotic 
effects have occurred in fibroblasts, as DNA fragmentation in cardiomyocytes may deteriorate 
cardiac function (Abbate et al., 2006). Furthermore, moxonidine exerts anti-inflammatory 
effects in SHR ventricles and result in normalization of left ventricular natriuretic peptide 
synthesis, an index of treatment efficacy (El-Ayoubi et al., 2003). Noteworthy, the effects of 
moxonidine have occurred in response to hypotensive as well as sub-hypotensive doses, 
implying a blood-pressure-independent mechanism and pointing to a local cardiac action 
(Paquette et al., 2008).  In fact, imidazoline I1-receptors have been identified in cardiac atria 
and ventricles (El-Ayoubi et al., 2002; El-Ayoubi et al., 2004). Cardiac imidazoline I1-
receptors are regulated in cardiovascular diseases and by chronic in vivo exposure to 
moxonidine (El-Ayoubi et al., 2002; El-Ayoubi et al., 2003). Also, activation of cardiac 
imidazoline I1-receptors by moxonidine stimulates ANP release from isolated rat hearts ex 
vivo (Mukaddam-Daher et al., 2006). These studies demonstrate that cardiac imidazoline I1-
receptors are functional without the contribution of the central nervous system.   
Therefore, based on the above studies and on i) those showing a direct anti-arrhythmic effect of 
moxonidine in an isolated working rabbit heart model of ischemia-reperfusion, in the absence 
of systemic effects, arguing in favor of local action (Wolk, Kane, Cobbe, & Hicks, 1999); ii) 
the role of natriuretic peptides in inhibition of myocardial cell apoptosis in hypertension and 
heart failure, through directly blocking apoptosis signaling pathways and/or by modulating 
neurohormonal factors involved in their regulation (reviewed by Mukaddam-Daher, 2006) 
(Mukaddam-Daher, 2006); iii) studies linking imidazoline I1-receptors to the  maintenance of 
the extracellular matrix (Amann et al., 1992) and PC12 cell survival (Dontenwill, Pascal, et 
al., 2003; Dupuy et al., 2004), we propose cardiac imidazoline I1-receptors as a therapeutic 
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target. Our working hypothesis is that apart from centrally-mediated sympatholytic 
function, imidazoline I1-receptors in the heart may control cell growth and death. 
Activation of imidazoline receptors may delay the progression of cardiac pathologies into 
heart failure by inhibition of maladaptive proliferative signalling and downstream apoptotic 
pathways.   
 
Specifically studies have been performed to: 
1. Explore in vivo the effects of low (sub-hypotensive) and high (hypotensive) 
doses of moxonidine on cardiac structure and function in two models of cardiac 
pathology characterized by high sympathetic output but opposite changes in 
cardiac structure and function, specifically in primary hypertension (SHR) and 
non-ischemic heart failure (cardiomyopathic hamsters).  
2. Define in SHR and cardiomyopathic hamsters, the effect of in vivo moxonidine 
treatment on inflammatory markers and pathways involved in LVH and cardiac 
cell survival/death (MAPK and Akt). 
3. Explore in vitro the influence of imidazoline I1-receptor and its activation by 
moxonidine, on cell survival in inflammatory conditions. To circumvent the 
lack of specific imidazoline receptor agonists and antagonists, studies are 
performed in HEK293 cells overexpressing nischarin (murine imidazoline I1- 
receptor).  
4. Investigate in vitro, in the absence of central and hemodynamic effects, 
imidazoline I1-receptor cellular localization (cardiomyocytes and fibroblasts) 
and regulation as well as implication in cell growth and death in response to 
hypertension- and heart failure-associated stimuli : norepinephrine, cytokines 
(IL-1 , TNF- ), and oxidants (H2O2). 
 
 
  
 
Chapter 3. Results 
3.1 Contributions of co-authors 
The results of my work as a PhD student are presented in the following 4 papers. I have 
performed most of the experimental work and data analyses. I have also participated in the 
writing and review of all these papers. My research directors, Dr Suhayla Mukaddam-Daher 
(advisor) and Dr Nicolas Noiseux (co-advisor) supervised all stages of research and 
manuscript writing.  
Other participants in the experiments and writing of the articles are: 
 
For article 1: “Moxonidine improves cardiac structure and performance in SHR through 
inhibition of cytokines, p38 MAPK, and Akt”  
Br J Pharmacol. 2011 Oct;164(3):946-57. doi: 10.1111/j.1476-5381.2011.01355.x.  
Angelita Stabile: Participated in the general care and follow-up of animals used in the study 
and in Western blot analysis.  
Georges Farah: Contributed to cardiomyocyte and fibroblast culture and Western blot 
analyses. 
 
For article 2: “Functional and molecular effects of imidazoline receptor activation in 
heart failure” 
Life Sci. 2011 Mar 14;88(11-12):493-503. doi: 10.1016/j.lfs.2011.01.008.  
Angelita Stabile: Participated in the general care and follow-up of the animals used in the 
study, the biochemical measurements in tissues and in manuscript writing. 
Kim Stockmeyer: Performed measurements of collagen in ventricular tissues.  
Dr Abdel A. Abdel Rahman: Kindly provided nischarin antibody and performed the 
immunohystochemical analysis in ventricular tissues and review of the manuscript. 
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For article 3: “Nischarin over-expression opposes cell-death induced by oxidative stress” 
Proceedings of the 6
th
 European Congress of Pharmacology. 2012: 35-41. ISBN: 978-88-
7587-670-8 
Luis Cobos Puc: Participated in the HEK293 cell culture, Western blots and FACS. 
Georges Farah: Participated in the HEK293 cell culture, preparation of cDNA, and 
overexpression of nischarin. 
 
For article 4: “Moxonidine modulates cytokine signalling and effects on cardiac cell 
viability” 
Eur J Pharmacol. 2014 Jul 15;740C:168-182. doi: 10.1016/j.ejphar.2014.06.047 
Georges Farah:  Participated in cardiomyocyte and fibroblast culture and Western blots. 
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3.2 Article 1. Moxonidine improves cardiac structure and 
performance in SHR through inhibition of cytokines, p38 MAPK, 
and Akt 
Br J Pharmacol. 2011 Oct;164(3):946-57. doi: 10.1111/j.1476-5381.2011.01355.x.  
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Abstract 
BACKGROUND AND PURPOSE 
Regression of left ventricular hypertrophy by moxonidine, a centrally acting sympatholytic 
imidazoline compound, results from a sustained reduction of DNA synthesis and transient 
stimulation of DNA fragmentation. Because apoptosis of cardiomyocyte may lead to contractile 
dysfunction, we investigated in spontaneously hypertensive rats (SHR), time- and dose-
dependent effects of in vivo moxonidine treatment on cardiac structure and function as well as 
on the inflammatory process and signalling proteins involved in cardiac cell survival/death. 
EXPERIMENTAL APPROACH 
12 week old SHR received moxonidine at 0, 100, and 400 µg.kg
-1
.h
-1
, s.c., for 1 and 4 weeks. 
Cardiac function was evaluated by echocardiography; plasma cytokines were measured by 
ELISA and hearts were collected for histological assessment of fibrosis and measurement of 
cardiac proteins by western blotting. Direct effects of moxonidine on cardiac cell death and 
underlying mechanisms were investigated in vitro by flow cytometry and Western blotting. 
KEY RESULTS 
After 4 weeks, the sub-hypotensive dose of moxonidine (100 µg) reduced heart rate and 
improved global cardiac performance, reduced collagen deposition, regressed left ventricular 
hypertrophy, inhibited Akt and p38 MAPK phosphorylation, and attenuated circulating and 
cardiac cytokines. The 400 µg dose resulted in similar effects but of a greater magnitude, 
associated with blood pressure reduction. In vitro, moxonidine inhibited norepinephrine-
induced neonatal cardiomyocyte mortality but increased fibroblast mortality, through I1-
receptor activation and differential effects on downstream Akt and p38 MAPK. 
CONCLUSIONS AND IMPLICATIONS 
While the antihypertensive action of centrally acting imidazoline compounds is appreciated, 
new cardiac-selective I1-receptor agonists may confer additional benefit. 
Index words: Left ventricular hypertrophy, echocardiography, apoptosis, flow cytometry, 
cardiomyocytes. 
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Abbreviations: α-SMA, α smooth muscle actin; AGN192403 (2-endo-amino-3-exo-
isopropylbicyclo[2.2.1]heptane); AW, anterior wall; EDD, end diastolic diameter; EDV, end 
diastolic volume; ESD, end systolic diameter; ESV, end systolic volume; IVRTc, isovolumic 
relaxation time corrected for heart rate; LVET, left ventricular ejection time; LVETc, left 
ventricular ejection time corrected for heart rate; LVH, left ventricular hypertrophy; LVM, left 
ventricular mass; MAP, mean arterial pressure; PW, posterior wall; RWT, relative wall 
thickness.
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Introduction 
The hypertensive heart undergoes several structural and functional alterations, 
including increased left ventricular mass, abnormal left ventricular texture, function, and 
geometry, and impaired coronary reserve. Left ventricular hypertrophy (LVH), present in all 
patients with severe hypertension, is linked to unfavorable prognosis. A variety of deleterious 
consequences of cardiovascular diseases, with conditions, such as coronary heart disease, 
stroke, congestive heart failure and sudden death, are aggravated by LVH. It is not surprising 
therefore that numerous therapeutic approaches have been pursued with the aim of regressing 
or preventing LVH and, hence, reducing cardiovascular risk (Pierdomenico et al., 2008).  
Many genetic, hemodynamic, neurohormonal, and growth factors, including 
sympathetic factors, play an important role in left ventricular remodelling (Grassi et al., 2009).
 
In human hypertension, LVH correlates with increased cardiac noradrenaline spillover 
(Schlaich et al., 2003). Exposure to high concentrations of noradrenaline causes 
cardiomyocyte hypertrophy and loss as well as expansion of the interstitial fibroblast 
compartment and enhanced collagen deposition. Noradrenaline stimulates the -adrenergic 
receptor pathway that includes activation of oxidative stress
 
and the pro-inflammatory 
cytokines, TNF- , IL-1  (Communal et al., 1998;   Fu et al., 2004; Neri et al., 2007) and IL-6 
(Leicht et al., 2003). 
Moxonidine is a centrally acting antihypertensive imidazoline compound that reduces 
excessive sympathetic tone and peripheral vascular resistance, accompanied by reduced 
plasma noradrenaline concentration (Wenzel et al., 1998). Moxonidine treatment in patients 
and rats results in regression of cardiac hypertrophy (Haczynski et al., 2001; Paquette et al.,  
2008; Mukaddam-Daher et al., 2009), restoring the myocardial structure, and improving the 
coronary flow reserve (Mitrovic et al., 2001). We have reported that the anti-hypertrophic 
effect of moxonidine in hearts from spontaneously hypertensive rats (SHR), results from a 
sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation and 
apoptotic proteins Bax and caspase3, occurring after 1 week but subsiding by 4 weeks of 
treatment. Cardiomyocyte apoptosis plays a causal role in the development of heart failure 
through progressive left ventricular wall thinning (Liao et al., 2004). Inhibition of cardiomyocyte 
apoptosis attenuates contractile dysfunction in heart failure (Foo et al., 2005). Accordingly, if 
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moxonidine-stimulated apoptosis occurred in cardiomyocytes, cardiac dysfunction would 
ensue. In addition, a sub-hypotensive dose of moxonidine tended to offset some of the 
favorable effects of the angiotensin receptor blocker, eprosartan, on cardiac function in stroke-
prone SHR (Mukaddam-Daher et al., 2009), suggesting that higher doses may be detrimental. 
These studies, therefore investigated, in SHR, the time- and dose-dependent effects of chronic 
moxonidine treatment on cardiac structure and function as well as on the inflammatory 
process and signaling proteins involved in cardiac cell survival/death. In this respect, studies 
revealed pressure-dependent and –independent improvement of cardiac function and 
regression of LVH and fibrosis by moxonidine. Together with our previous finding that 
imidazoline I1-receptors, which selectively mediate the actions of moxonidine in brainstem 
medulla, are also expressed in the heart (El-Ayoubi et al., 2002), these results led us to suggest 
that, in addition to central actions, the control of LVH by moxonidine may, at least in part, 
include direct effects on the heart. However, the participation of cardiac I1-receptors in LVH 
regression in whole animal studies may be masked by the antihypertensive and sympatholytic 
effects of the drug. Therefore; the direct effect of moxonidine on cardiac cell growth and death 
and the implicated signalling proteins were investigated in vitro, on cardiomyocytes and 
fibroblasts in culture, in the absence of confounding mechanisms..  
Methods 
For further details of the Methods please see Appendix S1. 
Animals 
All animal care and experimental procedures for this study were approved by the 
Institutional Committee for Animal Protection, according to the Canadian Guidelines. SHR 
and normotensive Wistar-Kyoto (WKY) rats, purchased from Charles River (St. Constant, 
Quebec, Canada), were investigated at 12–13 weeks of age, when hypertension and LVH are 
established. The animals were housed at 22°C, maintained on a 12 h light-dark cycle, fed 
Purina Rat Chow (Ralston Purina) and had free access to tap water. They were allowed at least 
3 days before experimentation. 
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Experimental protocols 
Cardiac structure and function were analyzed by transthoracic echocardiography, as 
previously described (Mukaddam-Daher et al., 2009). Then, the rats  were randomly assigned 
to treatment with moxonidine (0, 100, or 400 μg.kg-1.h-1), for 1 and 4 weeks, via Alzet osmotic 
minipumps (model 2ML1 and 2ML4, Alzet Corporation Cupertino, CA, USA), implanted 
subcutaneously at the neck area,  under isoflurane anesthesia, as previously described 
(Paquette et al., 2008; Mukaddam-Daher et al., 2009). The low and high concentrations of 
moxonidine (sub-hypotensive and antihypertensive respectively) were chosen from previous 
studies showing regression of LVH in hypertensive rats (Paquette et al., 2008; Mukaddam-
Daher et al., 2009). 
Rats were weighed and inspected twice per week.  Food and water intake and 2 x 24 h 
urine output (metabolic cages) were measured after 4 weeks of treatment. Echocardiographic 
examination was repeated after 4 weeks of treatment. At the end of the experiment (after 1 and 
4 weeks), intra-carotid blood pressure was recorded under 2% isoflurane anaesthesia. Then, 
blood and hearts were collected for later measurements of cytokines, molecular determinations 
and histopathological examination, as previously described (Paquette et al., 2008; Mukaddam-
Daher et al., 2009). 
Histopathological examination  
Cross-sections of heart ventricles were stored in neutral buffered 4% formalin. After 
ethanol dehydration and embedding in paraffin, 5 m sections were obtained and stained with 
hematoxylin-phloxine-saffron for cell surface measurements, or with Masson’s Trichrome for 
measurement of collagen deposition. Microscopic visualization and photographs were 
obtained and measurements performed by a blinded investigator, using computer software 
(Micro ImageJ 1.38x, NIH, USA). 
Plasma and Cardiac Cytokines 
Plasma inflammatory cytokines (IL-1β, IL-6, and TNF-α) and anti-inflammatory 
cytokine (IL-10) were measured by Bio-Plex 200 System (Bio-Rad Laboratories, ON, 
Canada). IL-1β (Pierce/Thermo scientific, Rockford, IL) and TNF-α (Invitrogen, Camarillo, 
CA, USA) were also measured in left ventricles, by ELISA. 
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Cardiac cell culture, flow cytometry 
Cardiomyocytes and fibroblasts were isolated from neonatal (1–2 days old) rat hearts 
using the Neonatal Cardiomyocyte Isolation System (Worthington Biochemical Corp, 
Lakewood, NJ, USA), following the manufacturer’s instructions. Cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum, then serum 
deprived (DMEM + 0.1% fetal bovine serum) for 24 h to induce quiescence, before incubation 
with DMEM alone or with increasing concentrations of noradrenaline (10
-7
 to 10
-4
 mol·L
-1
) 
without and with moxonidine at 10
-7
 and 10
-5
 mol·L
-1
 concentrations. Cell death was measured 
after 24 and 48 h, by flow cytometry after the addition of propidium iodide. In addition, cells 
were incubated with the above treatments for 15 min, then collected for measurement of Akt 
and MAPK phosphorylation, by Western blot. The participation of imidazoline I1-receptors 
(nomenclature follows Alexander et al., 2009) was identified using the I1-receptor antagonist, 
AGN192403 (10
-5
 mol·L
-1
), added 15 min before addition of treatment products. 
Western blot analysis 
Cardiac proteins were measured by Western blotting using antibodies recognizing the 
following antigens: total and phospho-specific Akt at Ser473 (1:1000), total and phospho-
specific ERK1/2 at Thr202/Tyr204 (1:1000), total and phospho-specific p38 MAPK at 
Thr180/Tyr182 (1:1000), total and phospho-specific c-Jun N-terminal kinase (JNK) at 
Thr183-Tyr185  (1:1000), (Cell signalling Technology, Inc,  MA, USA), α-smooth muscle 
actin (α-SMA, 1:1000) and anti-GAPDH (1:10000) (Sigma-Aldrich, ON, Canada). 
Imidazoline I1-receptor protein expression was identified in cardiomyocytes and fibroblasts 
using antibody raised against the murine form, nischarin (1:1000, BD Biosciences, ON, 
Canada). Densitometric measurements of bands was performed using ImageQuant 5.1. 
Statistical analysis 
All data obtained from SHR were compared with corresponding normotensive WKY 
rats and moxonidine-treated SHR. Data obtained from cultured cells were compared with 
corresponding DMEM-, noradrenaline- or noradrenaline + moxonidine-treated cells, as 
required. Comparisons were performed by one-way ANOVA (and non-parametric) test 
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followed by Neuman–Keuls multiple comparison test, using the computer program PRISM 
4.0. Statistical significance was taken as P < 0.05. Data are reported as mean ± SEM. 
Materials 
The sources of the compounds used were as follows: noradrenaline (L-(-)-
norepinephrine (+)-bitartrate salt monohydrate) from Sigma-Aldrich Canada Ltd., Oakville, 
Ontario, Canada; AGN192403 (2-endo-amino-3-exoisopropylbicyclo[2.2.1]heptane) from 
Cedarlane Laboratories, Burlington, Ontario, Canada; isoflurane, from Abbott Laboratories, 
Saint-Laurent, Quebec, Canada. 
Results 
Physical and hemodynamic parameters 
The effect of moxonidine on biomechanical stress in the hypertensive heart was 
investigated in SHR and compared with normotensive WKY rats. The SHR had higher blood 
pressure, LVH (left ventricular mass normalized to tibia length) and hypertrophied 
cardiomyocytes (Table 1), as well as higher interstitial and perivascular collagen volume 
(Figure 1). Moxonidine (100 mg) lowered blood pressure and heart rate after 1 week, and by 4 
weeks it lowered heart rate, LVH and collagen deposition, without significant changes in 
blood pressure. Moxonidine at 400 mg reduced blood pressure, heart rate and LVH, at 1 and 4 
weeks and collagen deposition after 4 weeks of treatment (Table 1, Figure 1). Moxonidine did 
not alter 24 h volume and electrolyte excretion in these rats (data not shown). 
The structure and function of the left ventricle, evaluated by echocardiography (Table 
2), showed that there was no significant difference in systolic functions, ejection fraction and 
fractional shortening among the WKY and SHR groups. Anterior wall and left ventricular 
posterior wall tended to increase, but relative wall thickness and left ventricular end systolic 
diameter were significantly higher in SHR, indicating LVH. There was no significant 
difference among the WKY and the three SHR groups in the ejection fraction and fractional 
shortening of the left ventricle, indicating maintained systolic function (Table 2). The diastolic 
and global functions of the heart were compromised in SHR, evidenced by delayed isovolumic 
relaxation time (IVRT) and higher left ventricular myocardial performance index (LVMPI) 
(Table 2). All systolic and diastolic function parameters were not altered within the study 
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duration in vehicle-treated rats. However, the two concentrations of moxonidine increased left 
ventricular ejection time and E wave deceleration time, and reduced E wave deceleration rate, 
in comparison to corresponding vehicle-treated SHR (Figure 2) or pretreatment values (not 
shown). In addition, 400 mg moxonidine lowered IVRT (Figure 2), and reduced relative wall 
thickness as well as LVMPI (Table 2), denoting decreased hypertrophy and improved global 
cardiac performance. 
Cytokines  
Inflammatory and anti-inflammatory cytokines were measured in plasma and hearts of 
SHR with and without moxonidine treatment and compared to WKY rats. Fig 3 shows that, 
compared to WKY, circulating TNF-α and IL-6 levels were reduced by treatment, but IL-1β 
levels were elevated in SHR and were further stimulated by moxonidine after 1 week, then 
tended to decrease after 4 weeks of treatment. Plasma IL-10 was not altered by hypertension 
or treatment. In contrast, left ventricular IL-1β (28 ± 1 pg.mg-1 protein) which was not altered 
by hypertension, was significantly decreased (14 ± 1 and 17 ± 2 pg.mg
-1
 protein; P<0.01) after 
4 weeks of treatment with both moxonidine concentrations, respectively. Left ventricular 
TNF-α (25 ± 5 pg.mg-1 protein) was not altered by hypertension or treatment (Figure S1). 
Cardiac Proteins 
To further elucidate the underlying molecular mechanism involved in signal 
transduction responsible for cardioprotection by moxonidine, we investigated activation of 
Akt and the MAPK pathway in SHR and WKY rat hearts. Figure 4 and Figure S2 show that 
the protein expression of P-Akt/Akt, P-ERK/ERK, and P-p38/p38 were enhanced in SHR left 
ventricles. Akt and p38 (Fig 4), but not ERK phosphorylation (Figure S2) were reduced by the 
two concentrations of moxonidine after 1 and 4 weeks of treatment. Neither hypertension nor 
treatment had an effect on total or phosphorylated JNK (Figure S2). Figure 4 also shows that 
moxonidine reduced the protein expression of α-SMA, a marker of fibroblast differentiation 
into contractile and hyper-secretory myofibroblasts (Petrov et al., 2002). 
Cardiomyocyte and fibroblast mortality and the underlying mechanisms    
Western blot analysis revealed that neonatal rat cardiomyocytes and fibroblasts express 
imidazoline receptors (Figure S3). Cardiomyocytes and fibroblasts also express α- and β-
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adrenoceptors whose activation by noradrenaline stimulates cell growth and death. 
Cardiomyocytes and fibroblasts were exposed to increasing concentrations of noradrenaline, 
for 24 and 48 h. Analysis by flow cytometry showed that noradrenaline at 10
-7
 to 10
-4
 mol·L
-1
 
increased cardiomyocyte mortality in a concentration- and time-dependent manner (data not 
shown) and that these effects were prevented in cells co-incubated with moxonidine at 10
-7
 
and 10
-5
 mol·L
-1
, indicating a protective action of moxonidine in cardiomyocytes (Figure 5). 
Moxonidine abolished noradrenaline-induced p38 MAPK phosphorylation, while maintaining 
noradrenaline-induced Akt phosphorylation (Figure 6). In contrast, incubation of fibroblasts 
with increasing concentrations of noradrenaline resulted in less cell death (reflecting 
proliferation), an effect prevented upon co-incubation with moxonidine (Figure 7). 
Moxonidine also abolished noradrenaline-induced p38 MAPK and Akt phosphorylation 
(Figure 8). The effects of moxonidine on cell death/protection and downstream signalling 
were opposed by the antagonist, AGN192403, demonstrating imidazoline I1-receptormediated 
actions. 
Discussion 
Studies were performed in SHR, a genetic model of hypertension that shares many 
common features of human essential hypertension, including increased activity of the 
sympathetic nervous system and cardiac noradrenaline spillover and myocardial inflammation 
(Kai et al., 2005; Nonaka-Sarukawa et al., 2008; Kumar et al., 2009). These studies reveal that 
1 month treatment with moxonidine improves diastolic function and global cardiac 
performance in hypertensive rat hearts. The effects were associated with regression of cardiac 
hypertrophy and fibrosis, attenuation of cardiac IL-1β and circulating TNF-α and IL-6 as well 
as inhibition of Akt and p38 MAPK phosphorylation. In vitro studies point to a possible 
contribution of cardiac imidazoline I1-receptors in the structural improvement, protecting 
against cardiomyocyte death while selectively stimulating loss of fibroblasts. 
Echocardiographic/Doppler measurements revealed that systolic function was 
preserved in SHR but diastolic function was reduced, as shown by reduced left ventricle 
deceleration and ejection time and delayed relaxation time. Diastolic dysfunction, an early 
manifestation of cardiac dysfunction in hypertensive patients, correlates with fibrosis and 
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energetic functional changes in myocytes (Verma and Solomon, 2009) and independently 
correlates with cardiovascular risk and total mortality (Schillaci et al., 2002). 
Moxonidine, at both doses, did not affect systolic function but improved diastolic 
function parameters, even after correction to heart rate changes. The higher dose attenuated 
the delayed relaxation (IVRT corrected for heart rate) and reduced LVMPI, a calculated index, 
which includes systolic and diastolic cardiac effects independently from heart rate influence. 
The improved cardiac performance, which includes reduced stiffness and improved relaxation, 
may be due to the decrease in blood pressure and inhibition of sympathetic nerve activity and 
subsequent noradrenaline release by the higher dose of moxonidine (Van Kerckhoven et al., 
2000). However, the sub-hypotensive dose, which is lower than the concentration that did not 
reduce plasma noradrenaline levels in a rat model of myocardial infarction-induced heart 
failure (Van Kerckhoven et al., 2000), also improved cardiac parameters. The effects were 
associated with attenuated LVH and collagen accumulation and substantial reduction in left 
ventricular IL-1β and circulating TNF-α and IL-6. The cytokines, IL-1β, IL-6 and TNF-α are 
implicated in the pathogenesis of cardiac hypertrophy and cardiomyocyte apoptosis, in vivo 
and in vitro (Bozkurt et al., 1998; Dhingra et al., 2007) and in stimulation of cardiac fibroblast 
proliferation and differentiation into activated myofibroblasts, which produce large amounts of 
collagens (Petrov et al., 2002; Melendez et al., 2010).  
Hypertension-associated neurohormones, growth factors and cytokines activate MAPK 
signalling cascade and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. MAPKs, 
including ERK, p38 and JNK have distinct functions: ERK1/2 activation results in cell 
proliferation and survival responses, whereas JNKs and p38 are implicated in inflammation 
and cell growth, differentiation, migration and apoptosis (Wang et al., 1998). Akt (or PKB), a 
serine/threonine kinase with potent anti-apoptotic action in vitro and in vivo, is a downstream 
target of PI3K and is linked to hyperplasia and hypertrophy of cardiomyocytes and increased 
proliferation and collagen synthesis in fibroblasts (Colombo et al., 2003; Oudit et al., 2004; 
Heineke and Molkentin, 2006). MAPK and Akt activation were evaluated in WKY and SHR 
hearts with and without moxonidine treatment. Our results showed no change in total or 
phosphorylated JNK but higher levels of phosphorylated ERK, p38 and Akt in SHR than 
WKY hearts. Previous studies have shown LVH and cardiac fibrosis, in association with 
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elevated p38 and Akt phosphorylation in several models of experimental and genetic 
hypertension (Behr et al., 2001; Liang et al., 2006; Bao et al., 2007; Bartha et al., 2009; 
Soesanto et al., 2009; Esposito et al., 2010). Activation of p38 in cardiomyocytes leads to a 
rapid onset of lethal cardiomyopathy associated with cardiomyocyte hypertrophy, interstitial 
fibrosis and contractile dysfunction (Liao et al., 2004; Streicher et al., 2010). p38 is activated 
by cytokines and, in turn, it is involved in the release of pro-inflammatory cytokines 
(Fotheringham et al., 2004; Li et al., 2005), a mechanism by which p38 contributes to 
myocyte cell death (Dhingra et al., 2007). On the other hand, ERK and Akt activation reduces 
cardiomyocyte death and protects against ischaemia-reperfusion injury (Fujio et al., 2000; Liu 
et al., 2004), but sustained activation of Akt signalling results in progression from adaptive to 
maladaptive hypertrophy and fibrosis (Taniyama et al., 2005). 
Our results showed that moxonidine treatment reduced the hypertension-associated 
activation of Akt and proapoptotic p38, without affecting anti-apoptotic ERK. Such changes 
could contribute to attenuation of hypertension-induced myocardial hypertrophy and fibrosis 
as well as improved cardiac performance. These results are in agreement with studies showing 
a protective effect of p38-specific inhibitor SB203580, regressing LVH (Behr et al., 2001; Bao 
et al., 2007) and others reporting improved cardiac performance by treatments that reduced 
p38 levels (Liang et al., 2006; Bartha et al., 2009) as well as studies showing in SHR hearts 
that attenuation of high Akt phosphorylation, by blocking mammalian target of rapamycin 
(mTOR) downstream of Akt, reduces LVH (Soesanto et al., 2009). 
The reduction in p38 MAPK and Akt may be indirect effects mediated by central 
inhibition of noradrenaline and subsequent cytokine release (Communal et al., 1998; Leicht et 
al., 2003; Fu et al., 2004; Neri et al., 2007), direct effects on cytokine signalling, or even 
downstream effects of moxonidine opposing the actions of noradrenaline, by activating 
cardiac imidazoline I1-receptors (El-Ayoubi et al., 2002). While further studies are required to 
evaluate these mechanisms, in vitro studies on cultured cardiac myocytes and fibroblasts show 
that moxonidine may act directly on cardiac cells, exerting opposite effects on noradrenaline-
induced p38 MAPK and Akt activation in cardiomyocytes and fibroblasts, and consequently 
reducing cardiomyocyte mortality but stimulating fibroblast mortality. Together, these effects 
may, at least in part, contribute to LVH control and consequently, improved cardiac function. 
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In conclusion, these studies show that the benefits of moxonidine extend beyond blood 
pressure reduction. The previously observed early transient apoptotic effect of moxonidine 
(Paquette et al., 2008), does not lead to deterioration of cardiac function. On the contrary, it 
may be therapeutic apoptosis that targets a subpopulation of susceptible cells (deBlois et al., 
2005) very likely macrophages and myofibroblasts; thus, reducing cytokine secretion and 
collagen accumulation. This anti-inflammatory effect, in addition to moxonidine-induced 
attenuated DNA and protein synthesis (Paquette et al., 2008), may attenuate cardiac 
hypertrophy and fibrosis and improve cardiac function. Importantly, imidazoline I1-receptors 
in the heart can control cardiac cell death/survival in the absence of central and haemodynamic 
contributions. Future new drugs or procedures, specifically targeting heart I1-receptors, may 
prevent the development of cardiac remodelling and heart failure. While the antihypertensive 
action of centrally acting imidazoline compounds is appreciated, new cardiac-selective 
imidazoline receptor agonists with pathway-selective properties may confer additional benefit. 
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Figure Legends: 
Figure 1 
Representative photomicrographs of Masson’s Trichrome stained heart sections of 
spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats with and without 
moxonidine treatment. (A) Interstitial, (B) perivascular collagen deposition (in blue) and (C) 
percentage of interstitial and perivascular collagen deposition in total area. n = 4–6 rats per 
group; †P < 0.01 versus WKY; ‡P < 0.05 versus vehicle; §P < 0.01 versus vehicle. 
Magnification 200x. 
Figure 2 
(A) Representative echo-Doppler images of diastolic function parameters in WKY and SHR. 
(B) Bargraphs represent data obtained after 4 weeks of study. n=10-11 rats per group. † 
P<0.01 versus WKY; ‡ P<0.05 , §P<0.01 vs. vehicle. IVRTc, isovolumic relaxation time 
corrected for heart rate; LVET, left ventricular ejection time. 
Figure 3 
Effect of moxonidine treatment on plasma cytokines. n = 9–16 rats per group. *P < 0.05, †P < 
0.01 versus WKY rats; ‡P < 0.05; §P < 0.01 versus vehicle.  
Figure 4 
Western blot analysis of the effect of treatments on left ventricular Akt and p38 
phosphorylation at 1 and 4 weeks of treatment. Column graphs depict the ratios of phospho-
Akt to total Akt, phospho-p38 to total p38, and a-smooth muscle actin (a-SMA), compared to 
GAPDH (loading control) and presented as per cent of the corresponding WKY values 
(100%). n = 6–10 rats per group. *P < 0.05, †P < 0.01 versus WKY; §P < 0.01 versus vehicle. 
 Figure 5 
(A) Representative flow cytometry and propidium iodide staining depicting total mortality of 
neonatal rat cardiomyocytes in culture. Cells on the right (arrow) represent the percentage of 
cell death out of total number of cells measured. (B) Bargraph represents cardiomyocyte 
mortality after 48 h incubation in Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% fetal bovine serum (FBS), and in conditions of starvation (DMEM + 0.1% FBS) alone or 
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in addition to noradrenaline (NA) without and with co-incubation with moxonidine at 10-7 
and 10-5 mol·L-1, without and with and I1-receptor antagonist, AGN 192403 (AGN) at 10-5 
mol·L-1. Data presented as per cent FBS 10%. n = 8–12 wells per treatment, from five 
independent cultures. †P < 0.01 versus 10% FBS; *P < 0.05 versus 0.1% FBS; §P < 0.01 
versus NA; &P < 0.05 versus corresponding NA + moxonidine. 
Figure 6 
(A) Representative bands of total and phosphorylated Akt and p38 MAPK detection by 
Western blot in cultured neonatal rat ventricular cardiomyocytes incubated with noradrenaline 
(NA) alone, or upon co-incubation with moxonidine at 10-7 and 10-5 mol·L-1, without and 
with I1-receptor antagonist, AGN 192403 (AGN) at 10-5 mol·L-1. (B) Bargraph represents 
ratios of phospho-Akt to total Akt and phospho-p38 to total p38, compared with GAPDH 
(loading control) and presented as per cent corresponding untreated cells. n = 10–12 wells per 
treatment from three independent cultures. †P < 0.01 versus Dulbecco’s modified Eagle’s 
medium (DMEM) + fetal bovine serum (FBS), 0.1%; ‡P < 0.05 versus NA; &P < 0.05 versus 
corresponding NA + moxonidine. 
Figure 7 
(A) Representative flow cytometry and propidium iodide staining depicting total mortality of 
neonatal rat cardiac fibroblasts in culture. Cells on the right represent the percentage of cell 
death out of total number of cells measured. (B) Bargraph represents fibroblast mortality after 
48 h incubation in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal 
bovine serum (FBS), and in conditions of starvation (DMEM + 0.1% FBS), noradrenaline 
(NA) alone, or upon co-incubation with moxonidine at 10-7 and 10-5 mol·L-1, without and 
with I1-receptor antagonist, AGN 192403 (AGN) at 10-5 mol·L-1. Data presented as per cent 
FBS 10%. n = 8–12 wells per treatment, from five independent cultures. †P < 0.01 versus 10% 
FBS; *P < 0.05 versus 0.1% FBS; §P < 0.01 versus NA; &P < 0.05, +P < 0.01 versus 
corresponding NA + moxonidine. 
Figure 8 
(A) Representative bands of total and phosphorylated Akt and p38 MAPK detection by 
Western blot in cultured neonatal rat ventricular fibroblasts incubated with noradrenaline (NA) 
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alone, or upon co-incubation with moxonidine at 10-7 and 10-5 mol·L-1, without and with I1-
receptor antagonist, AGN 192403 (AGN) at 10-5 mol·L-1. (B) Bargraph represents ratios of 
phospho-Akt to total Akt and phospho-p38 to total p38, compared with GAPDH (loading 
control) and presented as per cent corresponding untreated cells. n = 10–12 wells per treatment 
from three independent cultures.*P < 0.05, †P < 0.01 versus Dulbecco’s modified Eagle’s 
medium (DMEM); §P < 0.01 versus NA; &P < 0.05, +P < 0.01 versus corresponding NA + 
moxonidine. FBS, fetal bovine serum. 
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Table 1: Physical and Hemodynamic parameters at 1 and 4 weeks of treatment. 
Hemodynamic and  
Physical Parameters 
WKY SHR  
+ Moxonidine (µg/kg/h) 
  1 Week 
SHR 
 + Moxonidine (µg/kg/h) 
   4 Weeks 
  0 100 400 0 100 400 
 
MAP (mm Hg) 
 
94±3 
 
167±1* 
 
147±4‡ 
 
128±5‡ 
 
160±3* 
 
152±5 
 
130±7‡ 
 
Heart Rate (bpm) 
 
337±7 
 
335±8 
 
313±8 
 
277±14† 
 
338±10 
 
282±11† 
 
265±8‡ 
 
LVM (mg) 
 
455±13 
 
551±4* 
 
527±25 
 
488±8‡ 
 
595±6* 
 
571±9† 
 
535±10‡ 
 
LVH (mg/mm) 
 
10.1± 0.3 
 
12.3±0.1* 
 
11.8 ±0.6 
 
11.0±0.2‡ 
 
13.1±0.1* 
 
12.6±0.2† 
 
11.9±0.2‡ 
 
CSA (μm) 
 
407±4 
 
479±2 
 
444±6‡ 
 
435±5† 
 
565±2 
 
522±5‡ 
 
488±3‡ 
MAP: mean arterial pressure; LVM: Left ventricular mass; LVH: left ventricular hypertrophy; CSA: cross-sectional area; SHR: Spontaneously hypertensive 
rats; WKY: Wistar-Kyoto. *P<0.01 versus WKY; †P<0.05; ‡ P<0.01 versus corresponding vehicle.  
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Table 2: Echocardiographic measurements after 4 weeks of treatment. 
Echocardiographic Parameters WKY SHR + Moxonidine (µg.kg
-1
.h
-1
) 
 
0 
 
0 
 
100 
 
400 
 
ESD (mm) 2.3±0.0 2.7±0.1 2.8±0.2 2.9±0.1 
EDD (mm) 5.8±0.1 5.6±0.1 6.0±0.0 5.8±0.0 
AW (mm) 1.7±0.1 1.8±0.1 1.7±0.0 1.7±0..1 
PW (mm) 2.1±0.1 2.3±0.0 2.2±0.1 2.1±0.1 
RWT 0.72±0.04 0.83±0.03* 0.68±0.06† 0.68±0.07† 
ESV (ml) 0.04±0.00 0.06±0.00* 0.07±0.01 0.08±0.01 
EDV (ml) 0.69±0.04 0.63±0.02 0.76±0.04‡ 0.70±0.03 
Fractional Shortening (%) 60.4±0.9 52.8±0.7‡ 54.1±1.4 50.7±1.8 
Ejection Fraction (%) 92.4±0.4 91.3±0.4 91.0±0.7 88.5±1.2 
Stroke Index (ml.100g-
1
) 0.39±0.02 0.29±0.01* 0.36±0.02‡ 0.35±0.02‡ 
Cardiac Index (ml.min
-1
.100g
-1
) 124±8 98±6* 98±8 87±5 
LVMPI 0.17±0.02 0.32±0.02* 0.31 ± 0.02 0.26 ±0.02† 
 
*P<0.05 versus WKY; † P<0.05, ‡ P<0.01 versus corresponding vehicle. 
AW, Anterior wall; EDD, end diastolic diameter; EDV, end diastolic volume; ESD, end systolic diameter; ESV, end systolic volume; LVMPI, left ventricular 
myocardial performance index; PW, posterior wall; RWT, relative wall thickness; SHR, spontaneously hypertensive rats; WKY, Wistar-kyoto rats.  
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Figure S1. Effect of moxonidine treatment during 4 weeks on left ventricular (LV) cytokines, 
interleukin 1-beta and tumor necrosis factor-alpha. n=7-9 each; §P<0.01 vs. vehicle.  
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Figure S2 : Western blot analysis of the effect of treatments on left ventricular ERK1/2 
and JNK phosphorylation at 1 and 4 week treatment. Column graph depicts the ratio of 
phospho-ERK to ERK, and p-JNK to JNK, normalized to GAPDH (loading control) 
and presented as percent WKY (100%). *P<0.05 vs. WKY. n=6-10 rats/group. 
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Figure S3 : Western blot analysis of imidazoline receptor (nischarin) in left ventricular 
neonatal cardiomyocytes and fibroblasts (2
nd
 passage) and GAPDH (loading control). 20 µg 
protein were loaded. 
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Detailed Methods 
 
Cardiac Function. Transthoracic echocardiographic assessment of ventricular anatomy and 
function was performed under 2% isofluorane anesthesia, as described (Mukaddam-Daher et 
al. 2009; Salemi et al, 2004), using a Sonos 5500 ultrasound system (Philips, Andover, 
Massachusetts) with a 12 MHz transducer, placed gently on the shaved left hemithorax. The 
echocardiography probe was positioned to obtain short and long axis views and four and five 
chambers apical cardiac views.  
From the cardiac short and long axis views, an M-mode tracing of the left ventricular cavity 
allowed measurements of interventricular septal thickness (IVS or anterior wall, AW) and 
posterior wall thickness as well as left ventricular end-diastolic diameter (EDD) and left 
ventricular end-systolic diameter (ESD). Relative wall thickness (RWT) was calculated as: 
(PW thickness + interventricular septal thickness)/LV interior dimension. Fractional 
shortening (FS) was calculated as FS = (EDD –ESD) / EDD x 100. End diastolic volume 
(EDV) and end systolic volume (ESV) were calculated according to Teichholz method: 
[7/(2.4+ESD)] x ESD
3
 and [7/(2.4+EDD)] x EDD
3
. Ejection fraction (EF) was calculated as: 
EF= Stroke volume/EDV.  Mitral peak flow velocity in early diastole (E-wave) and during 
atrial contraction (A-wave) flow were recorded at the tip of mitral valve from an apical view 
by pulsed Doppler. Left ventricular ejection time (LVET) was measured from the beginning to 
the end of the aortic flow wave and the deceleration time of E wave (DT) was measured as the 
interval between the peak of E wave velocity and the point where the steepest deceleration 
slope was extrapolated to the baseline. Isovolumic relaxation time (IVRT) was recorded from 
the aortic outflow tract in the five chamber apical view as the interval between aortic closure 
and the start of mitral flow.  IVRT was corrected by each R-wave and R-wave (R-R) interval 
time to compensate for changes in heart rate. The R-R interval was also used to calculate heart 
rate. Left ventricular myocardial performance index (LVMPI) is the ratio of total time spent in 
isovolumic activity (isovolumic contraction time and isovolumic relaxation time) to the 
ejection time (LVET).  
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All measures were acquired following the American society of Echocardiography 
recommendations (Cheitlin et al, 2003), by the same experienced blinded observer. Three to 5 
representative cardiac cycles were analyzed and averaged for each measurement.   
 
Blood Pressure Measurement. Under 2% isoflurane anesthesia, a polyethylene catheter (PE 
50) filled with heparin sodium was inserted into the rat left carotid artery and pushed into the 
aorta to continuously monitor arterial blood pressure. The catheter was connected to a pressure 
transducer (Baxter Corp., ON, Canada) and signal was fed into Hewlett-Packard 783538 blood 
pressure monitor (Hewlett-Packard, ON, Canada). After 15 min stabilization, blood pressure 
values obtained over 5 minutes were averaged. 
 
Measurement of cytokines  
Frozen left ventricular tissue powder was homogenized in 10 mmol/L HEPES buffer (pH 7.9) 
containing 10 mmol/L KCl, and 0.1 mmol/L EGTA, and 0.5 mmol/L PMSF, and subsequently 
centrifuged at 3,000 g for 15 minutes at 4°C. Protein concentration was determined 
spectrophotometrically, using bovine serum albumin as a standard. Then, equal amounts of 
protein were used for cytokine measurements of left ventricular IL-1β and TNF-α by a 
quantitative sandwich enzyme immunoassay (ELISA), using microplates pre-coated with rat-
specific monoclonal antibodies of either IL-1 β or TNF- α, respectively (Biosource, Montreal, 
QC, Canada). Results were expressed as picograms per milligram of protein. Plasma cytokines 
were measured with the Rat cytokines 4-Plex Kit (Bio-Rad Mississauga, ON, Canada), results 
were reported as pg/ml. 
 
Western blot analysis  
Pulverized left ventricular tissue was homogenized in NP40 buffer (150 mM sodium chloride, 
1% NP-40, 50 mM Tris, pH 8.0, containing protease inhibitors)as previously described.  
Protein content was measured spectrophotometrically, using BSA as standard, according to the 
method of Bradford. Equal amounts of proteins (30 µg) separated
 
on 10% SDS-polyacrylamide 
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gel were transferred to Hybond-C extra
 
membrane (GE Healthcare Bio-Sciences, Montreal, 
QC, Canada). The membrane was blocked in 5%
 
nonfat milk, 4h, at 4°C. After washing, the 
membrane was probed overnight at 4°C with antibodies recognizing the following antigens: 
rabbit polyclonal total and phospho-specific Akt-1 at Ser473 (1:1000), total and phospho-
specific extracellular signal-regulated kinase (ERK1/2) (Thr202/Tyr204 1:1000), total and 
phosphorylated P38 mitogen-activated protein kinase (p38 MAPK) (Thr180/Tyr182 1:1000), 
total and phospho-specific c-Jun N-terminal kinase (JNK) (Thr183-Tyr1851:1000), (Cell 
signalling Technology, Inc,  MA, USA), alpha smooth muscle actin (α-SMA, 1:1000). 
Imidazoline receptor protein expression was identified in cardiac cells, using antibody raised 
against the murine form, nischarin (1:1000, BD Biosciences, ON, Canada). Loading was 
assessed by GAPDH (anti-GAPDH, 1:10000, (Sigma-Aldrich, ON, Canada). Bound 
antibodies were detected by a peroxidase-conjugated anti-rabbit IgG antiserum (1:5000) or 
goat anti-mouse (1:5000) 1h at room temperature, and visualized by ECL-Plus 
chemiluminescence detection (Amersham ECL Hyperfilm). The density of the bands was 
quantified and compared to WKY and vehicle-treated controls. 
 
Histologic determination of collagen deposit 
Cross-sections of heart ventricles were stored in neutral buffered 4% formalin for 5 days. 
After ethanol dehydration and embedding in paraffin, 5 m slices were obtained using a 
microtome. Sections were stained with Masson’s Trichrome. Microscopic visualization and 
photographs were obtained and collagen deposit measurements were performed by a blinded 
investigator using computer software (Micro ImageJ1.38x, NIH, USA).  
 
Cardiomyocyte and fibroblast Culture 
For cell culture, 18 to 21 day pregnant Sprague Dawley rats were purchased form Charles-
River. The animals were maintained at the animal facility until delivery and the pups were 
sacrificed by decapitation at 1 to 2 days of age.  The heart was excised and cardiomyocytes 
and fibroblasts were isolated using the Neonatal Cardiomyocyte Isolation System 
(Worthington Biochemical Corp, Lakewood, NJ) following manufacturer instructions. 
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Cardiomyocytes were counted and plated in 12 well plates  in Dulbecco's Modified Eagle 
Medium (DMEM) low glucose, 4mM L-Glutamine, 1 mM Sodium Pyruvate (Invitrogen, 
Burlington, ON) supplemented with 10% fetal bovine serum (FBS) (HyClone Characterized 
Fetal Bovine Serum, Thermo Fisher Scientific Inc, Brookfield, WI) and  100 U/ml penicillin, 
100 μg/ml streptomycin (P/S) (Invitrogen, Burlington, ON).  At day 3, cells were starved 
(DMEM low glucose 0.1% FBS, P/S) for 24 h to induce quiescence, then incubated with 10
-7
 
to 10
-4
 mol/L norepinephrine (L-(-)Norepinephrine (+)-bitartrate salt, Sigma-Aldrich St. Louis, 
MO), 10
-7
 to 10
-4
 mol/L moxonidine (Solvay Pharmaceuticals, Hannover, Germany) or NE at 
10
-7
 and 10
-4
 mol/L, each in combination with 10
-7
 and 10
-5
 mol/L moxonidine, in the presence 
and absence of I1-receptor antagonist (AGN192403).  
Fibroblasts at the second passing, were plated in 12 well plates (0.5ml/well) in DMEM/F12, 
2.5 mM L-Glutamine, 0.0015 mM Pyridoxine hydrochloride (Invitrogen, Burlington, ON) 
10% FBS, P/S. At 70% confluence cells were starved (DMEM/F12, 0.1% FBS, P/S) for 24 h, 
then incubated for 48h with DMEM+0.1%FBS, norepinephrine (NE), moxonidine (M) or both 
(NE+M), in the presence and absence of I1-receptor antagonist (AGN192403). 
Cardiomyocytes and fibroblasts were recovered after 24 and 48 h, for analysis by flow 
cytometry (FACS).  In each culture, measurement of the influence of starvation alone on cell 
death was performed on non-starved cells, i.e. incubated in DMEM+10%FBS. Ascorbic acid 
(0.001%) was added to the medium to prevent norepinephrine oxidation.  
Similarly treated cells were incubated for 15 min for measurement of Akt and MAPKs (total 
and phosphorylated) by Western blotting.  
 
Evaluation of cell death by Flow Cytometry (FACS): 
Cells were washed with PBS 1X, then  0.5 ml of trypsin 0.25%, 0.38 g/L, EDTA 4Na 
(Invitrogen, Burlington, ON) was added, and incubated for 1 min at 37ºC before cell collection 
and cetrifugation for 10 min. The supernatant was discarded, then, 100 μl PBS and 0.25 μg 
propidium iodide (Invitrogen, Burlington, ON) were added to each sample. After 15 min 
incubation in the dark, samples were analyzed using a BD LSRII with the software FACS 
DIVA version 5.0.2 (BD, Mississauga, ON).      
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Biochemical determinations 
Sodium and potassium concentrations were measured in urine with a flame photometer 
(Instrumentation Laboratory, Lexington, MA). 
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Abstract 
Aims: Heart failure is a progressive deterioration in heart function associated with overactivity 
of the sympathetic nervous system. The benefit of inhibition of sympathetic activity by 
moxonidine, a centrally acting imidazoline receptor agonist, was questioned based on the 
outcome of a failing clinical trial. The following studies measured cardiac structure and 
hemodynamics and mechanisms underlying moxonidine-induced changes, in cardiomyopathic 
hamsters, where the stage of the disease, dose, and compliance were controlled.   
Main methods: Male BIO 14.6 hamsters (6 and 10 months old, with moderate and advanced 
heart failure, respectively) received moxonidine at 2 concentrations: low (2.4 mg/kg/day) and 
high (9.6 mg/kg/day), or vehicle, subcutaneously, for 1 month. Cardiac function was measured 
by echocardiography, plasma and hearts were collected for histological determination of 
fibrosis and apoptosis, as well as for measurement cytokines by Elisa and cardiac proteins by 
Western blotting.  
Key findings: Compared to age-matched vehicle-treated BIO 14.6, moxonidine did not reduce 
blood pressure but significantly reduced heart rate and improved cardiac performance. 
Moxonidine exerted anti-apoptotic effect with differential inflammatory/anti-inflammatory 
responses that culminate in attenuated cardiac apoptosis and fibrosis and altered protein 
expression of collagen types. Some effects were observed regardless of treatment onset, 
although the changes were more significant in the younger group. Interestingly, moxonidine 
resulted in upregulation of cardiac imidazoline receptors.  
Significance: These studies imply that in addition to centrally mediated sympathetic 
inhibition, the effects of moxonidine may, at least in part, be mediated by direct actions on the 
heart. Further investigation of imidazolines/imidazoline receptors in cardiovascular diseases is 
warranted. 
 
Key words: Moxonidine, hamster, cardiomyopathy, apoptosis, fibrosis, 
echocardiography  
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Introduction 
Chronic heart failure, a progressive deterioration in heart function, is characterized by 
an enhanced sympathetic tone, with increased circulating concentrations of catecholamines 
(Kaye et al. 1995) that initially tend to improve cardiac output and maintain tissue perfusion. 
However, long-term exposure to norepinephrine causes cardiomyocyte apoptosis, fibroblast 
proliferation, and cardiac fibrosis (Colucci et al. 2000). Ultimately, progressive cardiac myocyte 
loss, via apoptotic cell death, and the development of interstitial fibrosis contribute to progressive 
cardiac remodeling, arrhythmias, impaired cardiac function and development of heart failure 
(Foo et al. 2005; Kaye et al. 1995). Genetically engineered mice that are unable to synthesize 
norepinephrine exhibit less cardiac hypertrophy and preserved ventricular function after aortic 
banding, demonstrating the deleterious effects of sustained catecholamine excess (Esposito et 
al. 2002). The remodeling process is also associated with stimulated inflammatory cytokines 
(Fedak et al. 2005).  Plasma levels of IL-1β, IL-6, and TNF-α are elevated in heart failure 
patients and have been linked to disease severity and poor prognosis (Aukrust et al. 1999; 
Rauchhaus et al. 2000). These cytokines may stimulate both anti- and pro-apoptotic pathways 
in the myocardium and exert negative inotropic effects, thus aggravating already impaired left 
ventricular function (Kubota et al. 2001; Yokoyama et al. 1993). Antagonism of excess 
exposure to norepinephrine within the failing heart by beta blockers (β-blocker) reduces 
elevated serum cytokine levels and improves cardiac function in patients with dilated 
cardiomyopathy (Kurum et al. 2007; Mayer et al. 2005). These findings form the cornerstone 
of the rationale for β-adrenoceptor antagonist (β-blocker) therapy of heart failure. However, 
treatment with a centrally acting sympatholytic imidazoline compound, moxonidine, did not 
show favorable results in a clinical trial on patients with advanced heart failure (Cohn et al 
2003; Swedberg et al.  2002), despite its established benefits in hypertensive patients (Ollivier 
and Christen 1994) and experimental animals (Amann et al. 1992; Paquette et al. 2008).  This 
reflects incomplete understanding of the mechanisms of action of these drugs. Better 
understanding of the cellular and molecular mechanisms underpinning imidazoline 
compounds would improve treatment of heart failure. Therefore, the aim of these studies was 
to evaluate cardiac structure and performance in relation to altered molecular processes 
induced by moxonidine, with a focus on cardiac imidazoline receptors (El-Ayoubi et al. 2002) 
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as well as cytokines and downstream mechanisms involved in myocardial remodeling. 
Because treatment benefit/adverse effects can be influenced by disease etiology, stage of heart 
failure, treatment dose, and/or compliance, moxonidine was given at 2 concentrations to 
cardiomyopathic BIO 14.6 hamsters, at 2 stages of heart failure: the hypertrophic (6 months 
old) and the overt heart failure (10 months old) stages.  
 
Materials and methods 
Experimental animals and drug treatment 
Male BIO 14.6 hamsters were purchased from Bio Breeders (Fitchburg, MA, USA) at 
6 and 10 months of age (n=32, each). Age-matched F1B hamsters (n=10, each) served as 
normal controls.  Hamsters were housed in a pathogen free environment in a temperature and 
light controlled room, with food and water ad libitum and were allowed 1 week to acclimatize 
before experimentation. Procedures were performed following the approval of the Institutional 
Bioethics Committee, according to the Canadian Guidelines and the Guide for the Care and 
Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of 
Health. 
Cardiac structure and function were analyzed by transthoracic echocardiography 
(Reffelmann and Kloner 2003). Then, cardiomyopathic hamsters were randomly assigned to 
treatment with moxonidine at 2 concentrations: low (2.4 mg/kg/day) and high (9.6 
mg/kg/day), or normal saline vehicle, for 4 weeks, via Alzet osmotic minipumps (model 
2ML4, Alzet Corporation), implanted subcutaneously under isoflurane anesthesia, as 
previously described (Paquette et al. 2008; Mukaddam-Daher et al. 2009). After 4 weeks of 
treatment, echo-Doppler measurements were repeated; then, intra-carotid blood pressure and 
heart rate were recorded. The hamsters were euthanized under isoflurane anesthesia. Blood 
was collected; hearts and lungs were excised, blotted dry, and weighed. To avoid circadian 
variability, all hemodynamic measurements and animal sacrifice were performed in the 
morning, between 8:00 and 12:00 a.m. Also, hamsters representing each group were 
investigated simultaneously.  
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The low and high concentrations of moxonidine (sub-hypotensive and 
antihypertensive, respectively) were chosen from previous studies showing regression of left 
ventricular hypertrophy in hypertensive rats (Paquette et al. 2008, Mukaddam-Daher et al. 
2009).  
Cardiac function 
 Echocardiography was performed under 2% isofluorane anesthesia, as previously 
described (Reffelmann and Kloner 2003; Mukaddam-Daher et al. 2009), using a Sonos 5500 
(Philips, Andover, Massachusetts), with 12 MHz transducer, placed gently on the shaved left 
hemithorax. The echocardiography probe was positioned to obtain short and long axis views 
and four and five chambers apical cardiac views.  
From the cardiac short and long axis views, an M-mode tracing of the left ventricular 
cavity allowed measurements of left ventricular end-diastolic diameter (EDD) and left 
ventricular end-systolic diameter (ESD). Percent fractional shortening (FS) was calculated as: 
%FS = (EDD –ESD) / EDD x 100. EDV and ESV were calculated according to Teichholz 
method: [7/(2.4+ESD)] x ESD
3
 and [7/(2.4+EDD)] x EDD
3
. Percent ejection fraction (EF) 
was calculated as: %EF= (Stroke volume/EDV) x 100.  Mitral peak flow velocity in early 
diastole (E-wave) and during atrial contraction (A-wave) flow was recorded at the tip of mitral 
valve from an apical view by pulsed Doppler. The A-wave was not reported in this study 
because it was merged with the E wave in most of the animals. Left ventricular ejection time 
(LVET) was measured from the beginning to the end of the aortic flow wave and the 
deceleration time of E wave (DT) was measured as the interval between the peak of E wave 
velocity and the point where the steepest deceleration slope was extrapolated to the baseline. 
Isovolumetric relaxation time (IVRT) was recorded from the aortic outflow tract in the five 
chamber apical view as the interval between aortic closure and the start of mitral flow. IVRT 
was corrected by each R-wave and R-wave (R-R) interval time to compensate for changes in 
heart rate. The R-R interval was also used to calculate heart rate. 
All measures were acquired following the American society of Echocardiography 
recommendations (Cheitlin et al. 2003), by the same experienced blinded observer. Three to 5 
representative cardiac cycles were analyzed and averaged for each measurement.   
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Blood pressure measurement 
Under 2% isoflurane anesthesia, a polyethylene catheter (PE 50) filled with heparin 
sodium was inserted into the hamster left carotid artery and pushed into the aorta to 
continuously monitor arterial blood pressure. The catheter was connected to a pressure 
transducer (Baxter Corp., ON, Canada) and signal was fed into Hewlett-Packard 783538 blood 
pressure monitor (Hewlett-Packard, ON, Canada). After 15 min stabilization, blood pressure 
values obtained over 5 minutes were averaged. 
Histopathologic measurements 
Hearts were prepared for histologic determinations as previously described (Paquette et 
al. 2008, Mukaddam-Daher et al. 2009). Sections were stained with hematoxylin, phloxine, 
saffron (HPS) for microscopic cell surface measurements, using computer software (Micro 
Dimension Version 1.01, 1993). Cell surface was measured in 10 different areas of the 
sections. Only cardiac myocytes with nuclei centrally located were included in the analysis.  
Other heart sections were stained with Masson’s Trichrome for collagen measurement. The 
degree of fibrosis was calculated as percentage of the fibrotic area (blue) in relation to the total 
heart area by computer-aided image analysis of tissue sections (Mukaddam-Daher et al. 2009). 
At least 10 fields at 200-fold magnification were captured and assessed in all the samples. To 
detect apoptotic cells, heart sections were subjected to terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling (TUNEL) using ApopTag® Plus Peroxidase In Situ 
Apoptosis Detection Kit (CHEMICON International, Cedarlane Laboratories, ON, Canada). 
Cardiac imidazoline I1-receptors were detected in heart sections using anti-nischarin (murine 
imidazoline I1-receptor) antibody (1:5000). NIH Image J 1.43 was used to calculate the 
integrated density, which takes into account the number of receptors as well as the intensity of 
the signal (Zhang and Abdel-Rahman 2008).  
Cytokine measurement in plasma and hearts 
Plasma inflammatory cytokines (IL-1β, IL-6, and TNF-α) and anti-inflammatory 
cytokines (IL-10) were measured by Bio-Plex 200 System (Bio-Rad Laboratories, ON, 
Canada). IL-1β (Pierce/Thermo scientific, Rockford, IL) and TNF-α (Invitrogen, Camarillo, 
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CA) were also measured in left ventricles, by enzyme-linked immunosorbent assay (ELISA) 
kits following the recommendations of the manufacturers.  
Western Blotting 
Left ventricles were homogenized in NP-40 buffer (150 mM sodium chloride, 1% NP-
40, 50 mM Tris Buffer, pH 8.0) supplemented with protease and phosphatase inhibitors, as 
previously described (Paquette et al. 2008, Mukaddam-Daher et al. 2009). The samples were 
then centrifuged and protein content in the supernatant was determined using the Bradford 
assay.  
To avoid inter-assay variation, equal amount of protein from samples representing all 
groups were simultaneously subjected to SDS-PAGE on a 10-12.5% polyacrylamide gel, and 
proteins were electroblotted on a Pure Nitrocellulose Membrane (Bio-Rad Laboratories, ON, 
Canada). After blocking, the membranes were incubated with antibodies against Bax (1:1000, 
Cell Signaling, Pickering, Ontario, Canada) or Bcl-2 (1:1000, BD Transduction, ON, Canada), 
collagen I and III (1:1000), and alpha smooth muscle actin (α-SMA, 1:5000), with GAPDH 
(1:10,000), as loading control, followed by horseradish peroxidase-conjugated anti-mouse IgG 
or anti-rabbit IgG (Amersham Biosciences, Quebec, Canada). Signals were visualized by ECL 
Plus Western blotting Detection System (Amersham).  
Statistical analysis 
Results are expressed as means ± SEM. Comparisons between groups were performed 
by one way ANOVA followed by Neuman-Keuls Multiple Comparison Test, using the 
computer program PRISM 4.0. Values with p<0.05 were considered statistically significant. 
 
Results  
Hemodynamic and physical parameters  
The hemodynamic and physical parameters of 6- and 10-month-old normal and 
cardiomyopathic (BIO 14.6) hamsters are presented in Tables 1 and 2, respectively. Compared 
to corresponding age-matched normal controls, BIO 14.6 hamsters had lower body weight and 
higher left ventricular hypertrophy (LVH), presented as left ventricular weight normalized to 
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body weight or to tibia length. BIO 14.6 hamsters also showed significantly lower mean blood 
pressure, but similar heart rate (Tables 3 and 4). In addition to LVH, 10-month-old BIO 14.6 
hamsters had hypertrophied right ventricles and right and left atria. All these parameters 
remained unaffected by moxonidine treatment, in both age groups (Tables 1 and 2), except 
heart rate, which was significantly decreased by the high moxonidine (9.6 mg/kg/day) dose 
(Tables 3 and 4). 
Cardiac performance 
To evaluate the impact of moxonidine on cardiac performance, echocardiography was 
performed on all hamsters before and after 1 month of treatment. Fig. 1 shows representative 
M-mode recordings of diastolic and systolic left ventricular (LV) diameters. Measurements 
taken from these views revealed age-dependent deterioration in systolic function. The BIO 
14.6 hamsters showed age-dependent cardiac chambers dilatation, wall thinning, and reduced 
myocardial function represented by fractional shortening (%FS) and ejection fraction (%EF) 
(Fig. 1). The LV fractional shortening and ejection fraction of untreated BIO 14.6 hamsters 
further decreased over 4 weeks, thereby indicating that contractile dysfunction was 
progressing. This deterioration was prevented by the high dose of moxonidine in 6-month-old 
hamsters and by both, low and high doses, in 10-month-old hamsters (Fig. 1).  End diastolic 
volume (EDV) and end systolic volume (ESV) decreased by the high dose only in young 
hamsters (Tables 3 and 4).  
Doppler measurements (Tables 3 and 4) revealed that the low dose moxonidine had no 
effect on diastolic function, but the higher dose prevented the progressive changes in 
ventricular deceleration time (DT), deceleration rate, and ejection time (LVET). Isovolumetric 
relaxation time corrected for heart rate (IVRTc) was not significantly altered by heart failure 
or treatment. Noteworthy, the improvement in diastolic function remained significant after 
correction for heart rate changes, but only in the young group.  
Myocardial fibrosis and myocyte apoptosis 
Histological analysis revealed that ventricular cardiomyocyte cross-sectional area was 
bigger in cardiomyopathic hamsters than corresponding normal controls, and was reduced by 
moxonidine, in both age groups (Tables 1 and 2). TUNEL analysis (Fig. 2) revealed very low 
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level of apoptotic cardiomyocytes in normal hamster hearts, but apoptotic cells were 7.4±0.5% 
and 8.3±0.2% of total cardiomyocyte number measured in young and old cardiomyopathic 
hamsters, respectively. Apoptotic cell number was significantly attenuated by high dose 
moxonidine, in both age groups (Fig. 2). Moxonidine did not alter the high expression of the 
pro-apoptotic protein Bax, but increased the expression of the anti-apoptotic protein, Bcl-2, in 
both groups. These changes resulted in significantly higher Bax to Bcl-2 ratio in 
cardiomyopathic hamsters and in significant lowering by treatment, consistent with anti-
apoptotic action (Fig. 3).  
The percentage of collagen deposition in 6- and 10-month-old BIO 14.6 hamsters was 
2 and 3 fold higher than that in normal controls. Treatment with high dose moxonidine 
attenuated myocardial collagen deposition only in the older group (Fig. 4). Western blot 
analysis of collagen forms showed that both collagen I, and more so, collagen III were higher 
in heart failure hamsters than normal controls (Fig. 5). High dose moxonidine reduced 
collagen III in the young hamsters, resulting in higher collagen I to collagen III ratio, but 
treatment did not alter this balance in the old hamsters. Moxonidine reduced elevated α-SMA, 
a marker of fibroblast differentiation into myofibroblasts, in the young, but not the old group 
(Fig. 6).  
Plasma and LV cytokines and cardiac proteins 
Fig. 7 shows that serum pro-inflammatory cytokine IL-1β increased upon treatment, in 
both age groups, with highest levels detected in high dose moxonidine-treated BIO 14.6 
hamsters. In contrast, left ventricular IL-1β was inhibited by high dose moxonidine in both age 
groups. Low levels of serum TNF-α were detected in normal and cardiomyopathic hamsters 
but were below detectable levels in moxonidine-treated BIO 14.6 hamsters. Left ventricular 
TNF-α was not affected by low, but significantly inhibited by high moxonidine, in both 
groups. Serum IL-6 was elevated in BIO 14.6 and significantly reduced by treatment, in both 
groups. On the other hand, anti-inflammatory IL-10 levels, which were lower in BIO 14.6 than 
normal 10-month old hamsters, tended to increase by high moxonidine, but values did not 
reach statistical significance. Downstream, p65 NF-κB activation (p-NF-κB to NF-κB ratio) 
and iNOS, high in cardiomyopathic hamster hearts, were reduced by treatment (Fig. 8). These 
changes were associated with upregulation of imidazoline I1-receptors in the heart and the up-
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regulation was dose-dependent in the 6-month-old hamsters (Fig. 9), suggesting increased 
responsiveness to treatment.  
 
Discussion  
These studies are the first to dissect the influence of chronic moxonidine/imidazoline 
receptor activation on cardiac proteins and cytokines in heart failure. The results provide 
evidence that moxonidine improves cardiac performance and exerts anti-apoptotic effect with 
differential inflammatory/anti-inflammatory responses that culminate in reduced cardiac 
apoptosis and fibrosis and altered protein expression of collagen types. Some effects are 
observed regardless of treatment onset, although the changes are more significant in the 
younger group. Interestingly, moxonidine results in upregulation of cardiac imidazoline 
receptors, implying that in addition to centrally mediated sympathetic inhibition, the effects 
may, at least in part, be mediated by direct actions on the heart.  
The BIO14.6 cardiomyopathic hamster with a delta-sarcoglycan gene mutation is a 
representative model of hypertrophic dilated cardiomyopathy well characterized and 
extensively used experimentally to study heart failure. This strain presents a defined 
progression to heart failure with age, with hypertrophy starting around 4-5 months, cardiac 
decompensation beginning around 6 months, and as early as 10 months, the hamsters develop 
heart failure (Bajusz 1969; Kawada et al. 1999). These hamsters also demonstrate 
characteristic autonomic imbalance, as observed in human cardiomyopathy (Giudice et al. 
2000; Sakamoto et al. 1997). Thus, the BIO14.6 cardiomyopathic hamster offers a convenient 
and reproducible model that allows evaluation of cardiac function and the effect of treatment, 
at the onset of LV dysfunction as well as in overt heart failure, especially when studies involve 
the autonomic nervous system.  
Moxonidine is an antihypertensive imidazoline compound, highly effective in 
reversing cardiac hypertrophy and protecting myocardial structure in hypertensive patients
 
and 
rats (Amann et al. 1992; Paquette et al. 2008). Moxonidine reduces sympathetic outflow and 
circulating levels of catecholamines by selective binding to imidazoline I1-receptors, primarily 
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located in the brainstem medulla (Haxhiu et al. 1994; Mobini et al. 2006; Motz et al. 1998; 
Van Kerckhoven et al. 2000).   
The BIO 14.6 hamsters presented low blood pressure and age-dependent impaired 
systolic and diastolic functions, evidenced by reduced fractional shortening and ejection 
fraction, as well as reduced E wave deceleration time and faster deceleration rate. One month 
treatment with moxonidine did not significantly affect blood pressure. These findings fully 
agree with the reported inability of moxonidine and other centrally acting drugs to produce 
hypotension, particularly in presence of low or normal blood pressure (Motz et al. 1998; 
Mukaddam-Daher and Gutkowska 2000). It is imperative to note that, even in the absence of 
hypotension, centrally acting drugs cause significant suppression in cardiac sympathetic 
activity (Mobini et al. 2006; Van Kerckhoven et al. 2000).  This latter effect might contribute, 
at least partly, to the favorable cardiac effects by reducing heart rate and improvement of 
myocardial compliance. Lower heart rate in moxonidine-treated animals in the present study 
would be beneficial to the failing heart, because it may lead to longer diastolic filling phase. A 
10% decrease in heart rate was associated with a 20% increase in stroke volume in heart 
failure patients treated with oral moxonidine for 3 months
 
(Motz et al. 1998).  Importantly, 
after correction for heart rate in the present study, the deceleration rate of E wave tended to be 
maintained in the old hamsters, and was significantly improved in the young hamsters. This 
finding reflects improved ventricular compliance, independently from heart rate, most likely 
due to the observed structural modification of the heart (Stilli et al. 2006).  
The high dose of moxonidine prevented the deterioration in ejection fraction observed 
in untreated young hamsters; and both, low and high doses prevented the deterioration in 
ejection fraction in old hamsters. Although the magnitude of these changes appears small, 
representing 13% and 8% in young and old hamsters, respectively; it may be physiologically 
significant. Treatment that resulted in an absolute increase of 5% in EF was associated with 
improved walking distance and respiratory stability and reduced nocturnal respiratory events, 
in patients with advanced heart failure (Oldenburg et al. 2010). Even a smaller increase in EF 
was associated with significantly improved exercise capacity and VO2max in patients with 
dilated cardiomyopathy (Doesch et al. 2010). 
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Moxonidine treatment did not affect cardiac hypertrophy in the BIO 14.6 hamsters. 
However, it reduced cardiomyocyte size, resulted in lower number of TUNEL-detected 
apoptotic cardiomyocytes and reduced the significantly elevated Bax to Bcl-2 ratio. An 
increased expression of pro-apoptotic Bax to anti-apoptotic Bcl-2, an index of apoptosis, has 
been reported in several animal models of heart failure (Dent et al. 2007; Leri et al. 1998; 
Moorjani et al. 2007). In the present study, the expression of Bax was not significantly 
affected by moxonidine treatment in both age groups. However, the expression of Bcl-2 was 
increased by moxonidine; and interestingly, the effect was more evident in response to low 
dose moxonidine in the younger group. These findings demonstrate enhanced beneficial 
effects on left ventricular cell apoptosis when moxonidine is given earlier in heart failure 
development. There is increasing evidence that interrupting or reducing apoptosis can 
attenuate or prevent heart failure, regardless of the mechanisms involved (Bristow 1998; Foo 
et al. 2005; Kawai et al. 2004).  
Moxonidine also attenuated collagen deposition and altered collagen types. Although 
the proportion of type I and III collagens determines stiffening/resistance and elasticity, 
respectively, collagen I to collagen III ratio was higher in the young hamster hearts after 
moxonidine treatment. There are conflicting reports about the significance of altered collagen 
types in heart failure (Pauschinger et al. 1999; Timonen et al. 2008). But the fact that the 
young hamsters had improved pumping capacity after treatment leads to the suggestion that 
preferential activation of collagen I and inhibition of collagen III is beneficial, most likely by 
decreasing or preventing further dilatation of the dilated failing heart.   
The anti-apoptotic and anti-fibrotic effects of moxonidine may be due to its effect on 
cytokines. Circulating proinflammatory cytokine (IL-1β, IL-6 and TNF-α) levels increase with 
progression of heart failure (Aukrust et al. 1999; Timonen et al. 2008).  Cytokines and other 
cytokine-related inflammatory factors contribute to cardiac remodelling by initiating or 
stimulating the cytokine cascade, inducing apoptosis/anti-apoptosis, as well as by regulating 
collagen turnover (Siwik et al. 2000).  Cytokines induce the differentiation of fibroblasts into 
myofibroblasts, which have a higher activity for collagen production than fibroblasts (Petrov 
et al. 2002).  In the present study, untreated heart failure hamsters had elevated IL-6 and TNF-
α and more collagen deposition and protein expression of α-SMA, indicating enhanced 
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differentiation of cardiac fibroblasts into myofibroblasts, which secrete collagens. These 
parameters were reduced by moxonidine, which also attenuated left ventricular TNF-α, IL-1β, 
NF-κB p65 activation, and iNOS expression, demonstrating anti-inflammatory, anti-oxidative, 
and antifibrotic actions. On the other hand, moxonidine increased IL-1β circulating levels. The 
functional consequences of elevated IL-1β on the failing hamster heart warrant further 
investigation; however it was recently shown that a sub-inflammatory low level of IL-1β 
maintains adaptable compensation hypertrophy and inhibits interstitial fibrosis (Honsho et al. 
2009).  
The beneficial effects of moxonidine may be secondary to inhibition of SNS activity. 
The maintenance of ejection fraction after chronic moxonidine treatment may be consequent 
to decreased left ventricular end diastolic volume, and which was shown in patients to 
correlate with the decrease in plasma norepinephrine (Cohn et al. 2003). In addition, 
antagonism of excess exposure to norepinephrine within the failing heart by beta blockers 
reduces elevated serum cytokine levels and improves cardiac function in patients with dilated 
cardiomyopathy (Kurum et al. 2007; Mayer et al. 2005). The mechanisms may include direct 
actions on adrenergic receptors in immune cells and T and B lymphocytes, the primary source 
of cytokines (reviewed by Nance and Sanders 2007) as well as on adrenergic receptors in 
cardiomyocytes and fibroblasts, which can  produce cytokines. However, most of the effects 
were also observed when moxonidine was given at a non-sympatholytic concentration (Van 
Kerckhoven et al. 2000), implying contribution of mechanisms other than centrally-mediated 
sympatholysis. In this regard, moxonidine may have exerted direct actions on up-regulated 
cardiac imidazoline I1-receptors and may have contributed to the anti-apoptotic and anti-
inflammatory effects as well as the inotropic effect, essential to support the failing heart. It 
remains to be mentioned that I1-receptor up-regulation is unlikely influenced by inhibition of 
SNS activity, because a similar treatment in SHR normalized up-regulated receptors (El-
Ayoubi et al. 2003). The mechanisms that lead to imidazoline I1-receptor up-regulation and 
the influence and long term consequences of imidazoline I1-receptor regulation, especially on 
myocardial metabolism (Mobini et al. 2006) and natriuretic peptides (El-Ayoubi et al. 2003)  
remain to be investigated. 
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Some limitations of the study have to be acknowledged. In the present study, 
norepinephrine levels were not measured. However, moxonidine was administered to heart 
failure hamsters at a low concentration (2.4 mg/kg/day) which is within the range that did not 
reduce plasma norepinephrine levels, and a high concentration (9.6 mg/kg/day), which is 
much higher than the 6 mg/kg/day that significantly reduced plasma norepinephrine levels in a 
rat model of MI-induced heart failure (Van Kerckhoven et al. 2000). Accordingly, at least in 
the high dose-treated group, plasma norepinephrine levels are expected to be reduced. Also, 
although low blood pressure in cardiomyopathic hamsters may be secondary to heart failure-
reduced cardiac output, isoflurane anesthesia may have also contributed to it. Taking that in 
consideration, both, cardiomyopathic and normal hamsters were investigated similarly and in 
parallel.  Finally, because several cardiac function parameters are load-dependent, acquiring 
invasive pressure-volume loop measurements would be helpful. Importantly, improved cardiac 
performance, including reduced heart rate, reveal treatment efficacy. A study with longer 
treatment duration and measurement of animal survival would have offered important 
findings, although 1 month treatment is relatively long compared to the hamster lifespan. 
 
Conclusion  
We obtained evidence that moxonidine is effective, preserving and/or improving 
cardiac performance, by slowing/preventing the degenerative disease process in severe but, 
more so, in compensatory heart failure. However, despite the favorable outcome of 
moxonidine when given in early stages of heart failure to a homogenous and well controlled 
animal model, extrapolation to patients should be taken with caution. Furthermore, these 
studies do not aim at improving the chances for moxonidine in heart failure treatment, but at 
gaining insight on the cellular and molecular mechanisms of imidazoline receptor agonists, 
especially that the effects of moxonidine appear to be more complex than those ascribed to its 
sympatholytic effects. Taking into consideration receptor tissue distribution, future studies 
should investigate the consequences of cardiac imidazoline I1-receptor regulation, and 
accordingly, new drugs that specifically target heart imidazoline I1-receptors would be a good 
addition to treatment regimens.  
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Legends to Figure and Tables 
Fig. 1: A. Representative M-Mode Short axis views showing consecutive cycles of ventricular 
dimensions, in 6- and 10-month-old hamsters.  B. Percent FS (Fractional Shortening) and EF 
(Ejection Fraction) calculated from short axis views.  n=6-12 per group. *P<0.01 vs. normal 
F1B; †P< 0.01 vs. pre-treatment; §p<0.02 vs. vehicle-treated BIO 14.6 cardiomyopathic 
hamsters. Moxonidine Low (2.4 mg/kg/day); Moxonidine High (9.6 mg/kg/day). 
Fig. 2: A. Photomicrographs of heart cross sections (400x magnification) from BIO 14.6 
cardiomyopathic hamsters after 1 month treatment with moxonidine or vehicle.  Apoptotic 
cells are shown as brown nuclei with condensed chromatin. B. Bargraphs represent number of 
apoptotic cells in each group, in comparison to age-matched normal F1B hamsters. n=4 per 
group. #P<0.01 vs. vehicle-treated BIO 14.6 cardiomyopathic hamsters.  
Fig. 3:  Western blot analysis of the effect of treatments on left ventricular Bax and Bcl2. 
Bargraphs depict the densitometric measurement of Bax/Bcl2 ratio (normalized to GAPDH, 
loading control), presented as percent of corresponding normal control (100%). n=6-8 per 
group. *P<0.01 vs. F1B; ‡P<0.05, #P<0.01 vs. vehicle-treated BIO 14.6 hamsters.   
Fig. 4: A. Photomicrographs of Masson’s Trichrome-stained heart sections (collagen 
deposition appears in blue) from BIO 14.6 cardiomyopathic hamsters after 1 month treatment 
with moxonidine, as compared to age-matched normal F1B hamsters.  B.  Bargraphs represent 
collagen deposition from 5 hamsters, each. *P<0.01 vs. F1B; ‡P<0.05 vs. vehicle-treated BIO 
14.6 hamsters.   (200x magnification) 
Fig. 5: Western blot analysis of the effect of treatments on left ventricular collagen I and III.  
Bargraphs depict the densitometric measurement of collagen I and collagen III and the ratio of 
collagen I to III, presented as percent of corresponding control (100%). n=6-8 per group. 
*P<0.01 vs. F1B; #P<0.01 vs. vehicle-treated BIO 14.6 hamsters.   
Fig. 6: Western blot analysis of the effect of treatments on left ventricular alpha smooth 
muscle actin (α-SMA). Bargraphs depict the densitometric measurement of α-SMA 
(normalized to GAPDH, loading control), presented as percent of corresponding normal 
control (100%). n=6-8 per group. †P<0.05 vs. F1B; §p<0.02 vs. vehicle-treated BIO 14.6 
hamsters. 
 131 
Fig. 7: A. Effect of treatments on plasma cytokines, IL-1β, TNF-α, IL-6 and IL-10.  B. Effect 
of treatments on left ventricular IL-1β and TNF-α. n=6-8 per group. §p<0.02, ‡P<0.05 vs. 
vehicle-treated BIO 14.6 hamsters. 
Fig. 8: Western blot analysis of the effect of treatments on left ventricular iNOS, p-NF-κB and 
total NF-κB.  Bargraphs depict the densitometric measurement of the ratio of p-NF-κB to total 
NF-κB (normalized to GAPDH, loading control), presented as percent of corresponding 
normal control (100%). n=6-8 per group. §p<0.02 vs. vehicle-treated BIO 14.6 hamsters.  
 Fig. 9:  A. Representative photomicrographs of the immunohistochemical images (400x 
magnification) depicting nischarin (imidazoline receptor)-immunoreactive cells in the heart 
from BIO 14.6 cardiomyopathic hamsters after 1-month treatment with moxonidine, as 
compared to age-matched normal F1B hamsters.  B.  Bargraphs showing immunoreactivity 
data obtained from different treatment and control groups. n=5 per group. *P<0.05 vs. F1B; 
‡P<0.05 vs. vehicle-treated BIO 14.6 hamsters; $P<0.05 vs. low moxonidine dose.        
Table 1. Hemodynamic and physical parameters in normal (F1B) hamsters and in 6-month-
old cardiomyopathic (BIO 14.6) hamsters after 4 weeks of treatment with vehicle or 
moxonidine at low (2.4 mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
Table 2. Hemodynamic and physical parameters in normal (F1B) hamsters and in 10-month-
old cardiomyopathic (BIO 14.6) hamsters after 4 weeks of treatment with vehicle or 
moxonidine at low (2.4 mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
Table 3. Parameters derived from echocardiographic and Doppler assessment of LV function 
measured in 6-month-old normal F1B hamsters and in cardiomyopathic BIO 14.6 hamsters 
before (pre-treatment) and 4 weeks after treatment with vehicle or moxonidine at low (2.4 
mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
Table 4. Parameters derived from echocardiographic and Doppler assessment of LV function 
measured in 10-month-old normal F1B hamsters and in cardiomyopathic BIO 14.6 hamsters 
before (pre-treatment) and 4 weeks after treatment with vehicle or moxonidine at low (2.4 
mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
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Table 1. Hemodynamic and physical parameters in normal (F1B) hamsters and in 6-month-old cardiomyopathic (BIO 14.6) hamsters after 4 
weeks of treatment with vehicle or moxonidine at low (2.4 mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
 F1B BIO 14.6 
Hemodynamic and Physical Parameters n=10 
Vehicle 
n=12 
Moxonidine Low 
n=12 
Moxonidine High 
n=8 
BW, g 127±3 113±3* 113±4* 109±3* 
MAP, mm Hg 108±3 78±4† 75±4† 68±4* 
Lung /BW, mg/g 0.45±0.01 0.42±0.01 0.41±0.01 0.41±0.01 
RA/BW, mg/g 0.09±0.01 0.10±0.01 0.10±0.01 0.11±0.00 
LA/BW, mg/g 0.17±0.00 0.12±0.02 0.09±0.01 0.10±0.01 
RV/BW, mg/g 0.65±0.03 0.75±0.03† 0.73±0.03† 0.83±0.06† 
LVM, mg 300±22 359±8* 355±12* 369±16* 
LVM/tibia length, mg/mm 8.9±0.7 10.7±0.3 10.7±0.3 11.2±0.5 
LVM/BW, mg/g 2.4±0.1 3.1±0.1* 3.1±0.1* 3.1±0.2* 
LV-CSA, μm2 450±17 662±28* 557±45†‡ 517±12‡ 
BW, body weight; MAP, mean arterial pressure; RA, right atria; LA, left atria; LVM, left ventricular mass;  *P<0.01;  †P<0.05  vs. normal F1B; ‡P<0.05 vs. 
vehicle-treated hamsters.  
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Table 2. Hemodynamic and physical parameters in normal (F1B) hamsters and in 10-month-old cardiomyopathic (BIO 14.6) hamsters after 4 
weeks of treatment with vehicle or moxonidine at low (2.4 mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
 F1B BIO 14.6 
Hemodynamic and Physical Parameters n=6 
Vehicle 
n=12 
Moxonidine Low 
n=12 
Moxonidine High 
n=6 
BW, g 140±2 110±3* 115±3* 117±3* 
MAP, mm Hg 97±4 57±4* 56±4* 51±4* 
Lung /BW, mg/g 0.48±0.02 0.49±0.03 0.48±0.02 0.44±0.02 
RA/BW, mg/g 0.06±0.00 0.21±0.05 0.21±0.03 0.16±0.02 
LA/BW, mg/g 0.07±0.00 0.17±0.03† 0.2±0.03† 0.14±0.03 
RV/BW, mg/g 0.67±0.04 1.02±0.05* 0.89±0.06* 1.06±0.04* 
LVM, mg 358±1 390±20 391±20 410±10 
LVM/tibia length, mg/mm 10.4±0.1 11.8±0.4* 11.7±0.4* 12.4±0.3* 
LVM/BW, mg/g 2.6±0.1 3.6±0.2* 3.4±0.1* 3.5±0.1* 
LV-CSA, μm2 463±3 733±56* 588±22‡ 587±21‡ 
BW, body weight; MAP, mean arterial pressure; RA, right atria; LA, left atria; LVM, left ventricular mass;  *P<0.01, †P<0.05 vs. normal F1B;  ‡P<0.05 vs. 
vehicle-treated hamsters.  
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Table 3. Parameters derived from echocardiographic and Doppler assessment of LV function measured in 6-month-old normal F1B hamsters 
and in cardiomyopathic BIO 14.6 hamsters before (pre-treatment) and 4 weeks after treatment with vehicle or moxonidine at low (2.4 
mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
  F1B BIO 14.6 
Parameter n= 8 
Pre-Treatment Vehicle Moxonidine Low Moxonidine High 
n= 32 n= 12 n= 12 n= 8 
Heart Rate, bpm 336±9 336±7 356±13 349±11 301±23‡ 
EDD, cm 0.38±0.01 0.49±0.02* 0.57±0.03* 0.60±0.02* 0.53±0.02* 
ESD, cm 0.21±0.01 0.33±0.02* 0.45±0.03* 0.46±0.02* 0.38±0.03* 
EDV, µl 184±13 439±47* 792±116* 796±91* 472±62*‡ 
ESV, µl 29±5 144±23* 413±78* 354±50* 203±43*‡ 
E cm/sec 70.7±5.3 72.6±1.1 71.5±1.1 71.5±1.1 73.8±1.7 
DT cm/sec 51±2 51±1 48±2 50±5 54±2 # 
Dec rate cm/sec2 1338±49 1393±37 1505±36 1571±96 1303±57‡ 
LVET, msec 86±2 84±2 75±3* 79±3 84±5‡ 
LVETc 6.1±0.2 6.1±0.1 5.5±0.2† 5.7±0.1 5.8±0.1 
IVRTc 1.7±0.1 1.9±0.1 2.0±0.1 1.9±0.1 2.0±0.1 
EDD, end diastolic diameter; ESD, end systolic diameter; EDV, end diastolic volume; ESV, end systolic volume, E: peak E-wave velocity;  DT, E wave 
deceleration time; Dec rate, E wave deceleration rate;  LVET, left ventricular ejection time; LVETc, left ventricular ejection time corrected for heart rate; 
IVRTc, isovolumetric relaxation time corrected for heart rate. *P<0.01 vs. normal F1B; †P<0.02 vs. pre-treatment; ‡P<0.05, #P<0.01 vs. vehicle-treated 
hamsters.  
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Table 4. Parameters derived from echocardiographic and Doppler assessment of LV function measured in 10-month-old normal F1B hamsters 
and in cardiomyopathic BIO 14.6 hamsters before (pre-treatment) and 4 weeks after treatment with vehicle or moxonidine at low (2.4 
mg/kg/day) or high (9.6 mg/kg/day) concentrations. 
 
F1B BIO 14.6 
Parameter 
 
Pre-Treatment Vehicle Moxonidine Low Moxonidine High 
 
n= 8 n= 30 n= 12 n= 12 n= 6 
Heart rate, bpm 360±11 316± 8 304±10 310±15 257±22‡ 
EDD, cm 0.38±0.02 0.67±0.02* 0.71±0.02* 0.72±0.03* 0.69±0.03* 
ESD, cm 0.23±0.02 0.56±0.02* 0.62±0.02* 0.61±0.03* 0.58±0.03* 
EDV, µl 191±29 1118±86* 1329±111* 1448±152* 1252±135* 
ESV, µl 45±10 648±63* 861±85* 858±116* 717±101* 
E cm/sec 70.7±3.2 75.3±1.1 70.7±3.7 74.6±.4 79.0±0.2 
DT cm/sec 47±1 45±1 44±3 40±2 56±5# 
Dec rate cm/sec2 1391±34 1593±53 1763±133 1810±101 1289±135‡ 
LVET, msec 79±2 76±1 72±4 73±3 87±5‡ 
LVETc 5.4±0.3 5.7±0.1 5.1±0.2* 5.2±0.2 5.6±0.1 
IVRTc 1.6±0.1 2.3±0.0 2.6±0.1 2.4±0.1 2.3±0.3 
EDD, end diastolic diameter; ESD, end systolic diameter; EDV, end diastolic volume; ESV, end systolic volume, E: peak E-wave velocity;  DT, E wave 
deceleration time; Dec rate, E wave deceleration rate;  LVET, left ventricular ejection time; LVETc, left ventricular ejection time corrected for heart rate; 
IVRTc, isovolumetric relaxation time corrected for heart rate. *P<0.01 vs. F1B; #P<0.01, ‡P<0.05 vs. vehicle-treated hamsters.
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Nischarin Over-Expression Opposes Cell-Death Induced By Oxidative 
Stress 
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Abstract  
Nischarin (murine imidazoline I1-receptor) has been implicated in central regulation of blood 
pressure and cardiovascular control. Previous studies have also shown that nischarin associates 
with α5 integrin and that nischarin over-expression in a fibroblastic cell line inhibits cell 
motility through inhibition of integrin α5-Rac1 signalling.  Rac1 is a small G protein whose 
activation is linked to increased generation of reactive oxygen species (ROS) and subsequent 
cell hypertrophy, proliferation and apoptosis. The association of nischarin to Rac1 prompted 
us to investigate in human embryonic kidney (HEK293) cells, the role of nischarin in cell 
survival in response to oxidative stress and the signalling proteins, MAPKs and Akt (PKB), 
implicated in cell death and survival. HEK293 cells were transiently transfected with full 
length GFP-tagged nischarin cDNA or empty vector (control), using lipofectamine 2000 
reagent. 48 h post-transfection, cells were plated in 96-or 6-well plates for 24 h and were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum 
(FBS). After inducing quiescence in DMEM+0.1%FBS for 12 h, cells were incubated with 
treatments associated with oxidative stress (cytokines, LPS, H2O2).  I1-receptor mediated 
effects were evaluated by co-incubation with a selective I1-receptor agonist, moxonidine (10
-7 
and
 
10
-5 
M) with and without imidazoline I1-receptor antagonist, AGN192403 (10
-5
 M). Cell 
viability was measured after 48 h incubation, by MTT reduction assay. Total and 
phosphorylated intracellular proteins and nischarin expression were measured by Western 
blot. Data are presented as mean±SEM of n=9-12, from 2-3 independent cultures. The results 
show that compared with control cells (100%), nischarin over-expression (5-fold increase) did 
not modify basal cell viability but increased cell viability in response to (10
-7
 M) moxonidine 
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(117±2%; P<0.01), effect reversed by co-incubation with AGN192403. Western blot analysis 
revealed that nischarin transfected cells incubated in DMEM alone had higher ERK1/2 
(151%±13, p<0.01) and JNK (121%±6, p<0.01) phosphorylation and that 15 min incubation 
with moxonidine abolished this increase. Incubation with TNF+IL1β, LPS, or H2O2 resulted 
in significant (P<0.01) reduction in cell survival, where H2O2 effects were associated with 
reduced Akt phosphorylation and TNF+IL1β with enhanced MAPKs activities, all in control 
cells; effects prevented in nischarin-transfected cells. These results show that nischarin over-
expression potentiates cell viability in response to moxonidine and opposes cell-death induced 
by oxidative stress by differential actions on Akt and MAPKs. These studies point to over-
expression of nischarin in the heart as a therapeutic tool opposing oxidative stress and 
promoting cardiac cell survival, a function especially important in heart failure.   
Keywords: nischarin, imidazoline receptors, moxonidine, Akt, MAPK, oxidative stress, cell 
viability, HEK293 cells  
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Introduction  
The hypotensive action of imidazoline compounds, such as clonidine and moxonidine, 
is selectively mediated by imidazoline I1-receptors (also known as nischarin), non-adrenergic 
neurotransmitter receptors primarily present in brainstem medulla and involves activation of 
ERK, nitric oxide, and cardiac natriuretic peptides, ANP and BNP ([reviewed in [1]). 
Molecular characterization revealed that I1-receptor/nischarin is not a classical transmembrane 
receptor; it is rather a protein localized to the cytosol, anchored on the inner layer of plasma 
membranes. In addition to imidazoline binding, I1-receptor/nischarin associates with α5 
integrin and insulin receptor substrate IRS-4 [2], [3], [4], which allows regulation of different 
biological functions, beyond blood pressure control. Studies by Alahari and colleagues [2], 
[3], revealed that nischarin over-expression in a fibroblastic cell line inhibits cell motility 
through inhibition of integrin α5-Rac1 signalling, mediated by PAK-dependent and PAK-
independent mechanisms [2], [3]. Rac1 is a small GTPase whose activation is linked to 
increased generation of reactive oxygen species (ROS) and subsequent cell hypertrophy, 
proliferation, and apoptosis, through activation of  JNK and p38 MAPK [5]. The association 
of nischarin with Rac1 prompted us to investigate the role of nischarin in cell survival in 
response to oxidative stress. The signalling proteins, MAPKs and Akt (PKB), implicated in 
cell death and survival as well as in I1-receptor/nischarin signalling were also investigated.  
 
Methodology 
Microscopy 
HeLa cells were seeded on polylysine-coated coverslips that were placed in six-well 
plates and transfected with full length GFP-tagged nischarin cDNA or GFP-tagged empty 
vector (control) [2],[3], using Lipofectamine 2000 (Invitrogen) following the manufacturer’s 
protocol. 48 h post-transfection, cells were fixed, permeabilized, then labeled with either 
mouse anti-GFP antibody and AlexaFluor 488 anti-mouse antibody, or rabbit anti-nischarin 
antibody. Nuclei were stained with Hoechst. Slides were observed using a Zeiss Axioplan 2 
Imaging microscope. 
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PCR 
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco Modified 
Eagle's Minimal Essential Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), and 5 mg/ml penicillin-streptomycin in a humidified atmosphere of 95% air and 5% 
CO2 at 37° C. HEK293 cells, transfected as above, were grown in DMEM+10%FBS for 2 
days, then harvested for detection of nischarin mRNA by PCR.  
Measurement of Cell Death and Viability by FACS and MTT  
HEK293 transfected cells were incubated in DMEM supplemented with either 0.1% 
FBS (serum-deplete) or 10% FBS (serum-replete). In both conditions, cells were incubated 
without or with I1-receptor/nischarin agonist, moxonidine (10
-7
 &10
-5
 M) and I1-receptor 
antagonist, AGN192403 (AGN, 10
-5
 M), or mixed I1-receptor/ 2-adrenoceptor antagonist, 
efaroxan (10
-5
 M). After 24 h, cells were stained with propidium iodide (PI). PI positive cells, 
reflecting cell death, were counted on 10,000 cells, using a LSR II flow cytometer.  In 
addition, cells plated in 96-well plates were incubated without and with 10
-7
 &10
-5
 M 
moxonidine and 10
-5
 M AGN. Other cells were subjected to oxidative stress by incubation 
either with 10 ng/ml TNF- , 5 ng/ml IL-1 , TNF+IL1 , 100 ng/ml lipopolysccharide (LPS), 
or 10
-4
 M hydrogen peroxide (H2O2).  Viable cells were detected after 48 h, by incubation for 
4 h at 37°C with tetrazolium salt (MTT). Metabolically oxidized formazan product, reflecting 
mitochondrial activity/viability, was read from an absorbance plate reader at 570 nm.  
Western Blot 
Signaling proteins involved in cell growth and death were evaluated by western blot, in 
cells exposed to different treatments for 15 min, or 1 or 24 h. The antibodies used were 
(1:1000) rabbit polyclonal phospho-specific Akt-1 (Ser473), extracellular signal-regulated 
kinase (P-ERK1/2, Thr202/Tyr204), p38 mitogen-activated protein kinase (P-p38 MAPK, 
Thr180/Tyr182), and c-Jun N-terminal kinase (P-JNK, Thr183-Tyr185), and antibodies 
against inducible nitric oxide synthase (iNOS) and nischarin. Loading was assessed by anti-
GAPDH or anti-β-actin. 
Statistical Analysis 
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Data were compared to corresponding DMEM-incubated cells (considered as 100%) 
and presented as mean±S.E.M. Statistical significance was evaluated using unpaired Student's 
t-test. p<0.05 was considered significant. 
 
Results 
Detection of Nischarin Expression 
Nischarin transfection in HeLa cells detected by fluorescent microscopy reveals that 
nischarin (which was undetectable in native cells) is diffused in cell cytosol, but not in nuclei 
(Fig.1).  In addition, PCR and Western blotting reveal that nischarin is expressed at very low 
levels in HEK293 cells but transfection results in significantly increased nischarin mRNA as 
well as 5 fold increased nischarin protein (not shown). 
Effect of Nischarin Expression on Cell Death and Viability/Proliferation  
Cell death and viability/proliferation were measured by flow cytometry and MTT 
assays, respectively, in serum-starved and serum-replete conditions. In serum-starved 
conditions, only efaroxan and efaroxan+moxonidine caused an increase in cell death (PI+ve) 
in control cells, whereas AGN had no effect. In nischarin-cells, incubation with AGN or 
moxonidine, significantly increased cell death, but in combination, cell death was significantly 
reduced. Also, incubation of nischarin-cells with efaroxan alone had no effect, but efaroxan 
tended to attenuate moxonidine-induced cell death (Fig.2).  There were no significant changes 
by all treatments in serum-replete conditions (data not shown). 
Cell viability/proliferation measured by MTT in serum-starved cells was not affected 
by moxonidine and AGN or efaroxan (data not shown). However, in serum-replete conditions 
(Fig. 3, left), cell viability was modestly improved (117±2%, P<0.01) in nischarin-transfected 
cells by incubation with 10
-7
 M moxonidine, in comparison to their corresponding DMEM-
incubated control cells and to moxonidine-incubated empty vector-transfected cells. The effect 
was prevented by co-incubation with AGN, indicating an I1-receptor-mediated survival effect 
of moxonidine.  
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Fig. 3 (right) shows that exposure of control cells to combined cytokines, LPS, or 
H2O2 significantly reduced the number of viable cells compared to DMEM control. However, 
exposure of nischarin-transfected cells to these oxidants resulted in modest but significant 
increases in cell viability in comparison to corresponding DMEM and empty vector controls. 
In addition, (data not shown) co-incubation of nischarin-transfected cells with 10
-7
 M 
moxonidine potentiated interleukin-improved cell viability but opposed TNF-improved cell 
viability, without altering the effects of combined TNF+IL1β, LPS, or H2O2. These results are 
consistent with an inherent action of nischarin against oxidative stress-reduced cell viability 
and reveal a stimulus-specific effect of moxonidine.   
Signalling Proteins 
Western blot analysis revealed that control HEK cells contained P-Akt as well as low 
levels of P-ERK, P-JNK, and P-p38 MAPK.  Nischarin expression did not affect basal Akt and 
p38 phosphorylation but increased ERK (151%±13, p<0.01) and JNK (121%±6, p<0.01) 
phosphorylation. To rule out the influence of altered basal values and selectively investigate 
the effect of moxonidine on Akt and MAPKs, results were compared to corresponding 
DMEM-incubated cells. Fig. 4 shows that incubation with moxonidine increases p38 and JNK 
phosphorylation in control cells but not in nischarin-cells. Also, 10
-7
 M moxonidine inhibits 
ERK phosphorylation in nischarin-cells and 10
-5
 M moxonidine inhibits ERK phosphorylation 
in both, nischarin- and control cells (Fig. 4). These results are consistent with anti-apoptotic 
and anti-inflammatory actions of moxonidine in nischarin-expressing cells. 
The effect of nischarin expression on signaling proteins was also evaluated in response 
to H2O2 and TNF+IL1β, stimuli associated with ROS generation and oxidative stress (Fig. 5). 
The results show that H2O2 reduces Akt phosphorylation in control cells, but not in nischarin-
cells, where Akt phosphorylation is rather significantly increased. On the other hand, H2O2 
increases ERK and JNK and reduces p38 phosphorylation in both nischarin- and control cells. 
Co-incubation with moxonidine does not significantly affect these changes. Incubation with 
combined TNF+IL1β does not affect Akt phosphorylation but increases ERK, p38, and JNK 
phosphorylation in control cells. Increased MAPKs are significantly attenuated or prevented in 
nischarin-cells and not affected by moxonidine (Fig. 5). These results reflect a stimulus-
dependent signaling of nischarin. 
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Inducible NOS can be expressed in many cell types in response to oxidative agents, 
such as LPS, cytokines, or H2O2, and involves the MAPK cascades [6]. Therefore, we 
investigated the influence of nischarin transfection and moxonidine on iNOS expression in 
HEK cells exposed to oxidative stress. Basal iNOS expression was not altered by nischarin 
transfection. Moxonidine tended to increase iNOS in control cells but significantly inhibited it 
in nischarin-cells. The effect of 10
-5
 M moxonidine was significantly reversed by co-
incubation with AGN. Incubation with H2O2 resulted in increased iNOS expression, an effect 
prevented by moxonidine, only in control cells. In nischarin-cells H2O2-induced iNOS was 
significantly lower than control and not affected by moxonidine (Fig. 6). Thus, together with 
low expression of nischarin in control cells, the anti-inflammatory effect of moxonidine does 
not appear to be totally mediated by I1-receptor/nischarin. 
 
Conclusions 
This study shows that nischarin overexpression results in increased cell 
viability/proliferation in response to moxonidine, which outweighs increased percent cell 
death. The overall survival response is associated with moxonidine’s inhibition of ERK, JNK, 
and p38 MAPK, but not Akt activation. Nischarin also opposes the reduced cell viability in 
response to oxidative stimuli, with differential responses to moxonidine.  
Previous studies have shown that I1-receptor/nischarin activation by I1-receptor ligands 
and/or over-expression increases neuronal PC12 cell survival [7], [8].  Also, activation of I1-
receptor/nischarin by moxonidine protects against norepinephrine-induced cardiomyocyte 
mortality and fibroblast proliferation [9]. The present studies extend to show that nischarin 
opposes H2O2-induced cell-death and reduced Akt activation.  Also, nischarin opposes 
TNF+IL1β-induced cell death and ERK, JNK, and p38 MAPK activation. This suggests that 
the control of cell fate by nischarin is stimulus-specific and may be due to the balance between 
signaling proteins involved in cell proliferation and those involved cell death. The preferential 
interaction between nischarin and the Akt signaling pathway downstream of H2O2 and the 
MAPK pathways downstream of cytokines, is consistent with studies showing that Akt 
provides resistance against H2O2-induced oxidative stress and apoptosis [10] and cytokine-
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induced oxidative stress and apoptosis are mediated through downstream signalling of p38 
MAPK and JNK [11].  However, the differential signaling between H2O2 and TNF+IL1β may 
have been influenced by different incubation times (1 h vs. 15 min) and the kinetics of 
MAPKs and Akt phosphorylation. ERK activation is rapid, peaking at 15 to 30 min and 
decreases thereafter, while Akt activation remains up to 2 hours.  [12]. Alternatively, 
signalling may differ in response to exogenously applied H2O2 and subsequent ROS 
generation in comparison to that endogenously produced by cytokines, in terms of 
concentration and mode of action.   
Previous studies in PC12 have shown that I1-receptor agonists cause concentration-
dependent increased phosphorylation of ERK1/2, JNK, and Akt [13], [14].  In contrast, the 
present studies show that incubation of nischarin-expressing HEK293 cells with moxonidine 
does not affect Akt, but inhibits ERK, JNK, and p38 MAPK activation, albeit at different 
concentrations. Furthermore, the effect of moxonidine was more pronounced in control 
HEK293 cells, which express physiologically irrelevant nischarin level. Thus, the effects of 
moxonidine appear to depend on the cell-type and cellular context, including the level of 
nischarin expression and resulting imidazoline binding sites as well as proteins that associate 
with nischarin and downstream signaling pathways. Different cellular context may include 
measurable basal ERK activity in PC12 [12] but very low in HEK293 cells [4]; overexpression 
of hIRAS (human nischarin) results in imidazoline binding sites in PC12 but not in HEK293 
cells; and hIRAS expression in HEK293 cells has no effect on basal Akt and ERK activation 
or insulin activation of Akt, but enhances insulin activation of ERK1/2 through association 
with IRS-4, abundant in HEK cells [4]. We have shown high nischarin mRNA and protein 
expression in nischarin transfected cells, but must also evaluate resulting imidazoline binding 
sites. Further studies are also required to explain the differential effects of moxonidine as well 
as the influence of oxidative stress on proteins that associate with nischarin, such as integrin 
5 and IRSs, and others not yet identified. However, the present studies reveal that nischarin 
over-expression opposes cell-death induced by oxidative stress and point to nischarin 
overexpression in the heart as a therapeutic target, especially in heart failure, where 
cardiomyocyte survival is of ultimate importance. 
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Abstract  
Regression of left ventricular hypertrophy and improved cardiac function in SHR by 
the centrally acting imidazoline I1-receptor agonist, moxonidine, are associated with 
differential actions on circulating and cardiac cytokines. Herein, we investigated cell-type 
specific I1-receptor (also known as nischarin) signalling and the mechanisms through which 
moxonidine may interfere with cytokines to affect cardiac cell viability.  Studies were 
performed on neonatal rat cardiomyocytes and fibroblasts incubated with interleukin (IL)-1β 
(5 ng/ml), tumor necrosis factor (TNF)-α (10 ng/ml), and  moxonidine (10-7 and 10-5 M), 
separately and in combination, for 15 min, and 24 and 48 h for the measurement of MAPKs 
(ERK1/2, JNK, and p38) and Akt activation and inducible NOS (iNOS) expression, by 
Western blotting, and  cardiac cell viability/proliferation and apoptosis by flow cytometry, 
MTT assay, and Live/Dead assay. Participation of imidazoline I1-receptors and the signalling 
proteins in the detected effects was identified using imidazoline I1-receptor antagonist and 
signalling protein inhibitors. The results show that IL-1β, and to a lower extent, TNF-α, causes 
cell death and that moxonidine protects against starvation- as well as IL-1β –induced 
mortality, mainly by maintaining membrane integrity, and in part, by improving mitochondrial 
activity. The protection involves activation of Akt, ERK1/2, p38, JNK, and iNOS.  In contrast, 
moxonidine stimulates basal and IL-1β-induced fibroblast mortality by mechanisms that 
include inhibition of JNK and iNOS.  Thus, apart from their actions on the central nervous 
system, imidazoline I1-receptors are directly involved in cardiac cell growth and death, and 
may play an important role in cardiovascular diseases associated with inflammation.  
 
Keywords: Cardiomyocytes; fibroblasts; moxonidine; imidazoline I1- receptors; cytokines; 
apoptosis. 
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Chemical compounds used in this article 
Moxonidine (PubChem CID: 4810)   
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Abbreviations 
AGN192403 (2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane)  
ANP, atrial natriuretic peptide 
DMEM, Dulbecco's Modified Eagle Medium  
ERK1/2, extracellular signal-regulated protein kinase  
FBS, Fetal Bovine Serum  
IL-1β, Interleukin 1 beta 
Imidazoline I1-receptors, Imidazoline receptors type 1  
iNOS, inducible nitric oxide synthase 
JNK, c-Jun NH2-terminal protein kinase  
LVH, left ventricular hypertrophy  
MAPK, mitogen activated protein kinase 
NO, nitric oxide 
PI3K, phosphatidylinositol 3-kinase  
RVLM, rostral ventrolateral medulla 
S1P, sphingosine 1 phosphate 
TNF-α, tumor necrosis factor alpha  
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1. Introduction  
Left ventricular hypertrophy (LVH) and remodelling in hypertension and heart failure 
have been associated with increased circulating and cardiac expression of pro-inflammatory 
cytokines, tumor necrosis alpha (TNF-α) and interleukin (IL)-1β  (Duerrschmid et al., 2013; 
Gullestad et al., 2012). These cytokines lead to cardiomyocyte hypertrophy and apoptosis in 
vivo and in vitro (Haudek et al., 2007; Hiraoka et al., 2001; Hu et al., 2009), and stimulation 
of cardiac fibroblast proliferation and differentiation into activated myofibroblasts, which 
produce large amounts of collagens. The ensuing structural changes, LVH and fibrosis, 
impede cardiac contractility and compromise cardiac performance. The intracellular signalling 
pathways include generation of reactive oxygen species (Khurana et al., 2014; Kohler et al., 
2014),  activation of phosphatidylinositol 3-kinase (PI3K)/Akt (also known as protein kinase 
B, PKB) (Chu et al., 2012; Tullio et al., 2013) and mitogen activated protein kinases 
(MAPKs): extracellular signal-regulated protein kinase (ERK), p38, and c-Jun NH2-terminal 
protein kinase (JNK)  (Chae et al., 2006; Haudek et al., 2007; Hiraoka et al., 2001; Sugden and 
Clerk, 1998; Yndestad et al., 2010).   
Moxonidine is a centrally-acting sympatholytic imidazoline compound that shows 
higher affinity to non-adrenergic imidazoline I1-receptors than α2-adrenergic receptors. 
Moxonidine is used in hypertension treatment, including hypertension complicated with LVH 
(reviewed in (Mukaddam-Daher, 2012).  Our studies have shown that treatment of spontaneously 
hypertensive rats (SHR) with moxonidine improves cardiac performance, attenuates LVH and 
collagen accumulation, in association with a transient apoptotic effect in SHR ventricles. The 
effects also include a substantial reduction in left ventricular IL-1  and circulating TNF-  and 
IL-6 levels, as well as attenuated ventricular Akt and p38 phosphorylation and inducible nitric 
oxide synthase (iNOS) expression (Aceros et al., 2011; Mukaddam-Daher et al., 2009; 
Paquette et al., 2008). On the other hand, moxonidine improves cardiac performance in 
cardiomyopathic hamsters in association with differential inflammatory/anti-inflammatory 
responses that culminate in reduced cardiac apoptosis (Stabile et al., 2011). The 
cardioprotective effects of in vivo moxonidine may be secondary to inhibition of sympathetic 
nerve activity, reduced noradrenaline release and cytokine levels, and subsequently, their 
downstream actions. Moxonidine may also directly act on cardiac cells to modulate the actions 
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of cytokines. This hypothesis is supported by data showing that cardiac cells express cytokine 
receptors and imidazoline I1-receptors (also known as nischarin), and in vitro moxonidine 
attenuates noradrenaline-induced cardiomyocyte apoptosis and fibroblast proliferation (Aceros 
et al., 2011).  Accordingly, we sought to examine in primary cultures of neonatal rat 
cardiomyocytes and fibroblasts: i) the direct effect of moxonidine on cardiac cell viability and 
mechanisms involved, including the expression of imidazoline I1-receptor/nischarin; and ii) to 
identify at what level moxonidine may regulate cytokine-induced cellular effects, focussing on 
their common signalling pathways, MAPKs, iNOS, and Akt (Aceros et al., 2011; Akira and 
Takeda, 2004; Edwards et al., 2001; Peng et al., 2009; Tesfai et al., 2011).  The results 
demonstrate for the first time, the direct effect of moxonidine on cardiac cell viability. The 
mechanisms involve I1-receptor activation and subsequent ERK and Akt activation in 
cardiomyocytes and ERK, p38, JNK, and Akt in fibroblasts. Furthermore, moxonidine 
modulates cytokine-induced effects on cardiomyocyte and fibroblast viability, through 
differential effects on cytokine-induced p38, JNK and iNOS. 
 
2. Materials and methods  
2.1. Cell Cultures  
Ventricular cardiomyocytes and fibroblasts were isolated, enzymatically digested, and 
purified from 1 to 2 day old Sprague Dawley rat pups, using the Neonatal Cardiomyocyte 
Isolation System (Worthington Biochemical Corp, Lakewood, NJ, USA) following 
manufacturer instructions, as we previously described (Aceros et al., 2011). Recovered cells 
were pre-plated on plastic flasks twice, for 30 min each, to reduce non-myocyte cell numbers. 
The adherent cells are mostly fibroblasts while cardiomyocytes are in the suspension. 
Isolated Cardiomyocytes seeded at a density of 2.5 x 10
5 
per ml were cultured in 
Dulbecco's Modified Eagle Medium (DMEM), low glucose, 4 mM L-Glutamine, 1 mM 
Sodium Pyruvate (Invitrogen, Burlington, ON), supplemented with 10% FBS (Fetal Bovine 
Serum, Qualified, Canada Origin, Invitrogen, Burlington, ON, Canada), 100 U/ml penicillin 
and 100 μg/ml streptomycin (P/S) (Invitrogen, Burlington, ON, Canada).  The medium was 
changed every 2 days.  
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Cytosine arabinoside (cyt Ara, 10 µM) was added throughout the cardiomyocyte 
culture period to inhibit non-cardiomyocyte outgrowth (Condorelli et al., 2002). Because of its 
possible toxicity (Gonzalez-Juanatey et al., 2004), and to rule out possible influence on 
cytokine-induced cell death, cyt Ara was omitted in some cultures.  However, cytotoxicity 
assays, performed simultaneously did not show differences between the cells cultured with or 
without cyt Ara, at the concentration used, so results were pooled. Furthermore, microscopic 
evaluation of α-sarcomeric actin (mouse, Sigma-Aldrich A2172, Oakville, ON, Canada) 
confirmed purity (>95%) of cardiomyocyte cultures.  
Fibroblasts reaching 70% confluence after 3 days of culture were sub-cultured to reduce 
the possible contamination by cardiomyocytes and endothelial cells, then seeded at a density 
of 1.25 x 10
5
 per ml in six-well plates, in triplicate. 
The cultured cardiomyocytes and fibroblasts were a pooled cell population from 11-15 
neonatal rat ventricles in each experiment. Four to five independent experiments done in 
triplicate were performed for each condition. All experimental procedures were approved by 
the Ethical Committee of CRCHUM following the Canadian Guidelines. 
2.2. PCR Analysis 
Nischarin mRNA (accession number NM_022656.2) was detected in cardiomyocytes 
collected after 3 days of isolation and in fibroblasts on first and second passages. Normal 
C57BL/6 mouse (Charles-river, St-Constant, QC) brain and heart were used as positive control 
for nischarin mRNA.   
Cardiomyocytes, seeded at a density of 2.5 x 10
5 
per ml and fibroblasts at a density of 
1.25 x 10
5
 per ml in six-well plates, in triplicate, as well as tissues were collected and snap 
frozen in liquid nitrogen. Total RNA was extracted using TRIzol reagent; equal amounts of 
RNA were reverse transcribed to cDNA using Maloney murine leukemia virus reverse 
transcriptase (M-MLV reverse transcriptase), then amplified with Taq polymerase (all from 
Invitrogen, Burlington, ON, Canada). cDNA was then amplified by PCR using the following 
primers for nischarin:  
Fw: AGAGGCTCCAGCTCCAAAC; Rv: TTCTTGTCCCCAAATTCTGA, with an 
expected product of 706 bp. After 40 cycles with an annealing temperature of 60 °C, the 
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product was migrated using a 1% agarose gel with SYBR safe DNA gel stain (Invitrogen, 
Burlington, ON, Canada). S18 amplification was used as loading control. Images were taken 
with Typhoon trio imager (GE Healthcare Life Sciences, Baie d’Urfe, QC, Canada). 
2.3. Cell treatment 
Cardiomyocytes on day 3 after isolation and fibroblasts at the second passage were 
treated and harvested simultaneously under identical experimental conditions, using the same 
concentrations and duration of treatments. All cells were grown in DMEM containing 10% 
FBS, then rendered quiescent by incubation overnight in DMEM supplemented with 0.1% 
FBS.  All procedures were performed using DMEM+0.1%FBS, hereafter termed DMEM, as 
control vehicle, unless otherwise specified. 
Synchronized quiescent cells were then incubated for different time points, either in 
freshly prepared DMEM alone or containing 10
-7
 or 10
-5
 M moxonidine (Solvay 
Pharmaceuticals, Hannover, Germany), TNF-  (10 ng/ml; Recombinant rat, catalog number 
CLR08, Cedarlane Canada, Burlington, ON, Canada), or IL-1  (5 ng/ml; Recombinant rat, 
catalog number EN-RR202420, Thermo Scientific, Rockford, IL, USA), each alone or in 
combination with moxonidine. The concentrations of TNF-α and IL-1  and incubation times 
were chosen following published reports showing increased reactive oxygen species 
production and iNOS expression in neonatal rat cardiomyocytes, respectively (Higuchi et al., 
2002), (LaPointe and Sitkins, 1996). Incubation in DMEM supplemented with 10%FBS 
(DMEM+10%FBS, replete condition) or H2O2 (10
-4
 M), which induces neonatal 
cardiomyocyte apoptosis (Long et al., 2004), were used as positive and negative controls. 
Incubation with lipopolysaccharides from Escherichia coli 0111:B4 (LPS, 100 ng/ml) (Sigma-
Aldrich, Oakville, ON, Canada) was used as positive control for iNOS expression (Li et al., 
2009b). The participation of imidazoline I1-receptor/nischarin was confirmed by incubating 
the cells in the presence of AGN192403 (2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane, 
10 µM, Tocris Bioscience, Ellisville, MO, USA), an imidazoline I1-receptor antagonist 
(Aceros et al., 2011).  
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2.4. Western blot analysis 
To investigate the signalling pathways activated by moxonidine and interaction with 
cytokines, cardiomyocytes and fibroblasts were treated for 15 min or 24h and 48h, with 
indicated products freshly prepared in DMEM. The cells were harvested, rinsed then lysed 
with a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 10 mM EDTA 
(Ethylenediamine tetraacetic acid) and a protease inhibitor cocktail. 
Equal amounts of proteins (20 µg for MAPKs and Akt, 50 µg for iNOS and nischarin) 
separated
 
on 10% SDS-polyacrylamide gel were transferred to nitrocellulose membrane, then 
blocked in 5%
 
non-fat milk, for 6 h, at 4°C. After washing, the membrane was probed 
overnight at 4°C with antibodies recognizing the following antigens: Rabbit polyclonal Bax 
antibody (20 kDa, 1:1000); rabbit polyclonal phospho Akt-1 at Ser473 (60 kDa, 1:1000), 
mouse monoclonal phospho-p44/42 mitogen-activated protein kinase extracellular signal-
regulated kinase (ERK1/2) (Thr202/Tyr204, 44 and 42 kDa, 1:1000), rabbit polyclonal 
phospho p38 mitogen-activated protein kinase (p38 MAPK) (Thr180/Tyr182, 38 kDa, 
1:1000), rabbit polyclonal phospho c-Jun N-terminal kinase (JNK) (Thr183-Tyr185, 54 and 46 
kDa, 1:1000) (all from cell signalling, Danvers, MA, USA), purified mouse anti Bcl2 (26 kDa, 
1:1000) (BD transduction Laboratories, Mississauga, ON, Canada) and rabbit polyclonal 
NOS2 inducible nitric oxide synthase (iNOS, 130 kDa, 1:1000; Santa Cruz, Dallas, TX, USA). 
Imidazoline I1-receptor protein expression was identified using a monoclonal mouse antibody 
raised against the murine form, nischarin (250 kDa, 1:1000; BD Pharmigen, Mississauga, ON, 
Canada). Antibodies against total non-phosphorylated proteins performed in preliminary 
experiments were found not to be altered by 15 min incubation, therefore omitted in further 
Westerns. Loading was assessed by GAPDH (rabbit anti-GAPDH, 36 kDa 1:10,000; Sigma-
Aldrich, Oakville, ON, Canada) or β-actin (mouse Anti-actin, 42 kDa, 1:10,000; Chemicon, 
Billerica, MA, USA). Appropriate peroxidase-conjugated secondary antibodies were used for 
detection, and visualized by ECL-Plus or ECL-Advanced chemiluminescence detection (GE 
Amersham, Baie d’Urfe, QC, Canada). The density of the bands was quantified and 
normalized to corresponding DMEM-incubated control cells (considered as 100%).  
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2.5. Analysis of Cell Viability  
Cell viability was examined in 3 methods that detect different parameters of cellular 
toxicity/viability. Flow cytometry with fluorescein isothiocyanate-(FITC)-conjugated annexin 
V and propidium iodide stains detect the rate of apoptosis and necrosis, 
respectively.  Colorimetric MTT assay detects cell membrane integrity and enzyme activity in 
mitochondria, reflecting the degree of change in mitochondrial function, which also correlates 
with cell division/proliferation. The Live/Dead assay discriminates live cells from dead ones 
on the basis of membrane integrity, using calcein acetoxymethyl ester (Calcein AM) stain to 
detect intracellular esterase activity, and ethidium homodimer-1 (EthD-1) stain to detect cell 
membrane integrity.  
Cells were incubated for 48 h in DMEM vehicle, moxonidine, and cytokines, each 
alone or in combination. In order to determine which of the signaling pathways was important 
for cell growth and death, the Live/Dead assay also included pre-treatment for 1h with 
antagonists/inhibitors. AGN192403 (10 µM, Tocris Bioscience, Ellisville, MO, USA); 
PD98059 (2-(2’-Amino-3’-methoxy)-flavone) (10  µM), a selective inhibitor of MEK1/MEK2, 
the upstream activator of ERK1/ERK2; SB203580 (4-(4'-fluorophenyl)-2-
(4'methylsulfinylphenyl))-5-(4'-pyridyl)imidazole)  (10 µM), an inhibitor of p38-MAPK; 
SP600125 (Anthra(1,9-cd)pyrazol-6(2H)-one) (10 µM), a JNK inhibitor; wortmannin (0.5 
µM), a PI3K inhibitor,  all from Cell signalling (Danvers, MA, USA), and S-
Methylisothiourea Sulfate (SMT, 1 µM, Calbiochem, Darmstadt, Germany), an iNOS 
inhibitor. The concentrations of the products used in this study are consistent with the range 
previously used on cardiac myocytes in vitro (Engelbrecht et al., 2004).   
2.5.1 Flow cytometry  
The rate of apoptosis was quantitatively evaluated by flow cytometry using the FITC 
AnnexinV Apoptosis Detection Kit I (BD Biosciences, Mississauga, ON, Canada), following 
manufacturer instructions, as we previously described (Aceros et al., 2011). After 48 h of 
incubation with the products, cells were washed with PBS, trypsinized then centrifuged. The 
pellet was incubated with 5 μl propidium iodide (PI, 50 µg/ml) and 5 μl annexin V, in 100 μl 
Annexin binding buffer, for 15 min in the dark. Cells were next analyzed for 
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annexin/propidium iodide binding by flow cytometry using a BD LSRII with the software 
FACS DIVA version 5.0.2 (BD, Mississauga, ON). Annexin binding represents plasma 
membrane phosphatidylserine externalization to the outer leaflet of the plasma membrane, an 
early step in the apoptotic process, whereas propidium iodide, a fluorescent nucleic acid 
binding dye, excluded from live cells, stains cells in the late stages of apoptosis and necrosis 
(DeBiasi et al., 2004). Cells in each category were expressed as percentages of the total 
number of stained cells. The values were then expressed as percentages of DMEM-incubated 
control. 
2.5.2 MTT assay  
After 48 h treatment, viable cells were detected by incubation with 10 µl tetrazolium 
salt (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT), in phenol red-free 
culture medium, for 4h, at 37°C (MTT Cell Proliferation Assay, ATCC, Manassas, VA, USA).  
Metabolically oxidized purple-colored formazan crystal, which forms only in the presence of 
intact cell membranes and functional mitochondria, were solubilized in 100 µl of 10% 
SDS/0.01 M HCl and read from an absorbance plate reader (Biotek Synergy HT with the 
software Gen5 data analysis, Winooski, VT, USA) at a wavelength of 570 nm, within 24h.   
2.5.3 LIVE/DEAD assay  
After 48h incubation, 0.5 mM calcein acetoxymethyl ester (Calcein AM) and 4 mM 
and ethidium homodimer-1 (EthD-1) (LIVE/DEAD Viability/Cytotoxicity Kit for mammalian 
cells, Invitrogen, Burlington, ON, Canada) were added to the culture dishes for 30 min, and 
incubated at 37°C, then the cells were immediately viewed with a fluorescent inverted 
microscope, Olympus IX 71 (Center Valley, PA, USA).  The non-fluorescent calcein-AM is 
converted into green fluorescent polyanionic calcein by intracellular esterase, indicating active 
cell metabolism. Ethidium homodimer is excluded by viable cells but permeates damaged cell 
membranes, binds to nucleic acids, and results in red fluorescence. The number of green and 
red colored cells was counted in three wells per treatment and 4 fields per well, at 100-fold 
magnification. 
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2.6. Statistical analysis 
All results are presented as mean±S.E.M.  Statistical comparisons among multiple 
groups were performed using analysis of variance (ANOVA) followed by Newman–Keuls test 
for multiple comparisons. The criterion of statistical significance was P<0.05. All analyses 
were carried out using Prism 4.0 (GraphPad Software, San Diego, CA, USA). 
 
3. Results 
3.1. Expression of nischarin in neonatal cardiomyocytes and fibroblasts  
Nischarin mRNA expression was detected in mouse brain and heart at 706 bp, 
confirming previous results (Alahari et al., 2000). Nischarin mRNA was also detected in 
neonatal rat cardiomyocytes and second passage fibroblasts.  Nischarin mRNA was reduced 
after 24 h incubation with moxonidine in cardiomyocytes, but not altered in fibroblasts (Fig. 
1).  Imidazoline I1-receptor/nischarin expression and regulation was further explored by 
Western blot. Fig. 2A shows that nischarin protein expression is reduced in cardiomyocytes 
and increased in fibroblasts after 24 h incubation with moxonidine.  
Furthermore, cardiomyocyte incubation with noradrenaline (10
-5
 M) induced nischarin 
protein over-expression (134±9%, P<0.01 vs. DMEM) and the effect was reversed by 10
-5
 M 
moxonidine (58±15%, P<0.01 vs. noradrenaline).  However, TNF-α and IL-1β, each alone or 
in combination with moxonidine did not modify nischarin expression in cardiomyocytes. On 
the other hand, nischarin expression in fibroblasts was not affected by noradrenaline but 
significantly reduced by combined noradrenaline and moxonidine (31±7%; P<0.01 vs. both, 
DMEM and noradrenaline). Nischarin expression was reduced by TNF-α, an effect reversed 
by moxonidine. However, nischarin expression in fibroblasts was not affected by IL-1β alone 
or in combination with moxonidine (Fig. 2B). These results demonstrate differential regulation 
of nischarin by hypertension- and heart failure-associated stimuli. 
3.2. Effects of moxonidine on signalling proteins in cardiomyocytes and fibroblasts 
MAPK and the PI3K/Akt pathways play a critical role in the regulation of cell growth 
and differentiation and in the control of cellular responses to cytokines and various stresses in 
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cardiomyocytes and fibroblasts (Clerk et al., 1999; Thaik et al., 1995).  ERK1/2 and JNK as 
well as Akt are implicated in imidazoline I1-receptor signalling in neuronal 
pheochromocytoma PC12 cell line (Edwards et al., 2001; Tesfai et al., 2011). But imidazoline 
I1-receptor signalling in different cells may lead to the activation of distinct downstream 
targets resulting in different physiological effects and the relative contribution of each 
pathway may vary in different cell types. Therefore, we investigated whether similar 
imidazoline I1-receptor signalling pathways occur in cardiomyocytes and fibroblasts  
Western blot analysis revealed that 15 min incubation of cardiomyocytes with 10
-5 
but 
not 10
-7
 M moxonidine causes an increase in Akt and ERK1/2 but not JNK or p38 
phosphorylation. ERK1/2 activation is inhibited by imidazoline I1-receptor antagonist, 
implicating imidazoline I1-receptors in this effect (Fig. 3). Because moxonidine at 10
-5
 but not 
10
-7
 M concentration activated cellular pathways in cardiomyocytes, this concentration was 
used in further experiments.  
Akt and ERK1/2 are important regulators of cell viability.  Akt provides resistance 
against oxidative stress as well as apoptosis in neonatal rat cardiomyocytes, by modifying the 
balance of apoptotic/anti-apoptotic mitochondrial enzymes Bax and Bcl2.  Therefore, we 
measured the protein expression of these enzymes. Western blot analysis revealed that 10
-5
 M 
moxonidine, for 24 h, inhibits apoptotic protein Bax (62±6%; n=6-9; P<0.01) and increases 
anti-apoptotic Bcl2 (150±15%; n=6-9; P<0.03), thus reducing Bax to Bcl2 ratio, consistent 
with an anti-apoptotic effect of moxonidine in cardiomyocytes (Fig. 4).  
Incubation of fibroblasts with 10
-5
 M moxonidine for 15 min results in ~ 2 fold 
increase in ERK1/2, p38, JNK, and Akt phosphorylation.  In contrast to cardiomyocytes, 24h 
incubation of fibroblasts with moxonidine alone increases Bax (189±12%, n=9; P<0.01) and 
attenuates Bcl2 (86±4%; n=9), resulting in a higher Bax to Bcl2 ratio.  These results are 
consistent with apoptotic effects of moxonidine in fibroblasts (Fig. 4). 
3.3. Effects of moxonidine and cytokines on signalling proteins in cardiomyocytes and 
fibroblasts 
The interaction of moxonidine and cytokines was investigated in cardiomyocytes and 
fibroblasts.  Fig. 5 shows that 15 min cardiomyocyte incubation with IL-1 , but not TNF-α, 
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causes an increase in phosphorylated Akt and MAPKs.  Incubation with moxonidine 
potentiates IL-1β-induced activation of p38 and JNK while it activates Akt and ERK1/2 in the 
presence of TNF-α. These differential effects indicate stimulus-dependent imidazoline I1-
receptor signalling in cardiomyocytes. 
Fibroblast incubation with IL-1β activates MAPKs and Akt, but TNF activates 
MAPKs.  Moxonidine opposes IL-1β-induced Akt and JNK and TNF-α-induced ERK1/2 and 
JNK, but potentiates TNF-α-induced Akt and p38 phosphorylation (Fig. 6). 
3.4. Effects of moxonidine and cytokines on iNOS expression  
MAPKs may activate the constitutive NOS isoforms, eNOS and nNOS (Kan et al., 
2008). However, cytokine-induced MAPK and Akt activation in cardiomyocytes and 
fibroblasts enhances iNOS production (Gustafsson and Brunton, 2000; Kan et al., 1999; 
Lizano et al., 2013; Shindo et al., 1995). Accordingly, we investigated whether 
moxonidine/imidazoline I1-receptor activation modulates the cytokine-iNOS pathway. The 
iNOS protein expression was measured in cells incubated with moxonidine alone or in 
combination with IL-1  or TNF-α, for 24 and 48 h. Cells incubated in 100 mg/ml LPS were 
used as a positive control. Western blot revealed that iNOS protein expression was detected in 
DMEM-incubated cardiomyocytes and significantly increased by LPS (~750%).  The iNOS 
expression in cardiomyocytes was not affected by 24h incubation with 10
-7
 and 10
-5
 M 
moxonidine, however it was increased by 10
-5
 M moxonidine by 48h (247±50%, P<0.02) (Fig. 
7). 
Incubation with IL-1  and TNF-α for 24 h significantly increased iNOS expression in 
cardiomyocytes.  IL-1β- but not TNF-α-induced iNOS was potentiated by 10-5 M moxonidine 
(Fig. 7).   
Compared to DMEM-incubated fibroblasts (considered as 100%), moxonidine reduced 
iNOS expression to 75±5% and 9±3% (P<0.01) by 24 and 48h, respectively.  Incubation with 
cytokines for 24 h increased iNOS to much higher levels than those measured in 
cardiomyocytes. Co-incubation with moxonidine did not affect TNF-α-induced iNOS, but, 
inhibited IL-1β-induced iNOS (Fig. 7). 
 177 
The differential effects of moxonidine alone and on IL-1β- and TNF-α-induced 
signalling proteins in fibroblasts, in a manner different from those observed in cardiomyocytes 
indicate that moxonidine/imidazoline I1-receptor signalling is stimulus-specific as well as cell-
type specific.  
3.5. Effect of moxonidine and cytokines on cardiomyocyte viability  
The signalling proteins altered by moxonidine and cytokines are implicated in cell 
growth and death. Accordingly, we measured the influence of moxonidine on cell viability and 
interaction with cytokines. Incubation in DMEM+10%FBS (serum-replete) indicated normal 
growth and 10
-4
 M H2O2 in starvation conditions (DMEM) indicated cell death. 
Compared to 48 h serum-starved cardiomyocytes, incubation in serum-replete 
conditions resulted in 23±2% lower annexin positive/PI negative cells (early apoptosis) and 
45±5% in PI positive binding (necrosis). Cardiomyocyte viability/mitochondrial function was 
mildly, yet significantly higher (12±2%, P<0.01) in serum replete myocytes. The LIVE/DEAD 
assay revealed higher metabolic activity and 50% lower cellular and nuclear membrane 
damage. Similar trends were obtained with fibroblasts. These results show that starvation 
conditions result in cardiomyocyte and fibroblast death by inducing apoptosis and necrosis, 
secondary to membrane damage, and in part, to reduced mitochondrial function and cell 
metabolic activity. These effects are abrogated in the presence of serum, indicating that the 
cells are responsive to growth conditions.  
In serum starvation conditions, 48h incubation of cardiomyocytes with 10
-7
 and 10
-5
 M
 
moxonidine resulted in lower percentage of cells in early apoptosis and mildly higher 
percentage in necrosis, culminating in a mild increase in percent alive cells. Incubation with 
AGN192403 prevented these actions, indicating imidazoline I1-receptor mediated actions (Fig. 
8). As expected, cardiomyocyte incubation with H2O2 increased the rate of early apoptosis and 
to a lower extent cell necrosis. Both actions were prevented by co-incubation with 10
-5
 M 
moxonidine (Fig. 8). Although H2O2 was used as a cell death control, this finding is consistent 
with an anti-oxidant effect of moxonidine in cardiomyocytes. 
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The MTT assay revealed that moxonidine had no effect, but IL-1β and TNF-α mildly 
reduced (~15%) cardiomyocyte viability/mitochondrial activity, effects prevented by co-
incubation with 10
-5
 M moxonidine (Fig. 9). 
Fig. 10A shows fluorescent micrographs of calcein and ethidium homodimer staining 
in cardiomyocytes, reflecting intracellular esterase activity in live cells as well as cell death 
due to compromised membrane integrity, respectively. Calcein staining was not affected by 
either treatment. Percent red stained cell number, was not affected by moxonidine, however it 
was significantly increased upon co-incubation of moxonidine with AGN192403, SP600125, 
and SMT, and opposed the toxic effect of SB203580, indicating that moxonidine protects 
cardiomyocyte membrane integrity through imidazoline I1-receptors and activated p38, JNK, 
and iNOS (Fig. 10B). 
Incubation with IL-1  caused 70% increase in the number of ethidium stained cells, 
reflecting damaged cell membranes (Fig. 11A). IL-1β-induced cardiomyocyte death was 
prevented by SB203580 and SMT, implicating p38 and iNOS in this action, effects consistent 
with previous reports (Arstall et al., 1999; Shindo et al., 1995). Moxonidine attenuated IL-1β-
induced cell death, an effect prevented by wortmannin, PD98059, SB203580, and SMT. 
Therefore, moxonidine protects cardiomyocytes against IL-1β-induced membrane damage 
through Akt, ERK1/2, p38, and iNOS.   
Similarly, TNF-  caused an increase in cell death, but of a smaller magnitude (~20%) 
and the effect was prevented by co-incubation with moxonidine (Fig. 11B). The ERK1/2 
inhibitor, PD98059 opposed moxonidine’s effect, implicating ERK1/2 in the protective effect 
of moxonidine against TNF-α-induced cell death. Noteworthy, among the antagonists used 
SB203580, at the same concentration which did not affect metabolic activity, potentiated 
starvation-induced membrane damage, opposed membrane damage induced by IL-1  as well 
as protection by moxonidine. 
3.6. Effect of moxonidine and cytokines on fibroblast viability 
Incubation with 10
-5 
M moxonidine 48 h in serum replete conditions did not affect 
fibroblast apoptosis determined by annexin staining and flow cytometry, however, necrosis 
was lowered (~20%). In contrast, in starvation conditions, 10
-5
 M moxonidine caused an 
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increase in PI positive cells (145%±7, P<0.02) after 24h and did not change further by 48h 
(data not shown). 
Moxonidine, IL-1 , and TNF- , each alone, mildly, yet significantly, reduced (~15%, 
P<0.01) fibroblast viability/mitochondrial activity/proliferation measured by MTT. Co-
incubation of cytokines with moxonidine did not result in further change (data not shown). 
However, calcein staining (Fig. 12A) revealed that fibroblast cellular activity was induced by 
moxonidine but inhibited by cytokines. Moxonidine did not alter IL-1β-reduced cellular 
activity but opposed that of TNF- .  Fig. 12B shows that ethidium homodimer stained cell 
number was more detected in fibroblasts incubated with moxonidine (143±20%; P<0.05) and 
to a greater extent in fibroblasts incubated with IL-1  and TNF-  than in DMEM control 
(100%).  Moxonidine potentiated the action of IL-1 , but opposed that of TNF- . 
The signalling protein inhibitors, PD98059, SB203580, and wortmannin at 
concentrations which did not affect metabolic activity or membrane integrity in 
cardiomyocytes, were very toxic to fibroblasts, rendering unexplainable results. SP600125 did 
not affect basal and SMT reduced cell death, and both potentiated cell death induced by 
moxonidine alone and in combination with IL-1β and TNF-α. These results suggest that in the 
presence of cytokines, fibroblast death by moxonidine involves inhibition of JNK and iNOS. 
Further studies using lower concentrations of the inhibitors are required to evaluate the 
mechanisms that mediate imidazoline and cytokine actions in fibroblasts. However, these 
results reveal that fibroblasts are more sensitive to these inhibitors than cardiomyocytes. 
 
4. Discussion 
Our results provide evidence that moxonidine protects cultured neonatal 
cardiomyocytes against serum starvation-induced apoptosis as well as IL-1β- and TNF-α-
reduced viability, mainly by maintaining membrane integrity, and in part, by improving 
mitochondrial activity. The protection primarily involves PI3K/Akt, ERK1/2, p38, and iNOS, 
in IL-1β-incubated cells, but activation of ERK1/2 in TNF-α-incubated cells. In contrast, 
moxonidine stimulates fibroblast mortality by mechanisms that include JNK and iNOS, and 
potentiates IL-1β- but opposes TNF-α-induced fibroblast mortality. Because the actions of 
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moxonidine are selectively mediated by imidazoline I1-receptors, these studies point to an 
interaction between cytokines and cardiac imidazoline I1-receptors. 
We have previously identified functional imidazoline I1-receptors in the heart (El-
Ayoubi et al., 2002; Mukaddam-Daher et al., 1997; Mukaddam-Daher et al., 2006) and in 
primary cardiac cells (Aceros et al., 2011). The present study extends to assess cardiac cell 
imidazoline I1-receptor/nischarin expression, regulation, and signalling.  Herein, we detect 
nischarin mRNA expression in the heart, both in cardiomyocytes and fibroblasts and 
regulation by moxonidine. We also show that nischarin protein expression is reduced by 
moxonidine in cardiomyocytes but increased in fibroblasts. Also, nischarin levels in 
cardiomyocytes are increased by noradrenaline but not cytokines, while nischarin levels in 
fibroblasts are reduced by TNF-α and not affected by noradrenaline and IL-1β. These results 
demonstrate that imidazoline I1-receptor/nischarin regulation is cell- and stimulus-specific. 
They are also consistent with in vivo studies revealing imidazoline I1- receptor/nischarin up-
regulation in the heart of genetically hypertensive and heart failure animals and differential 
modification by moxonidine (El-Ayoubi et al., 2002; Stabile et al., 2011).  
Imidazoline I1-receptor/nischarin regulation has been previously investigated in other 
cell types. Piletz et al. (2008) reported that imidazoline I1-receptors are increased in platelets 
and frontal cortex of depressed patients and this up-regulation is normalized after 
antidepressant drug treatments. Altered imidazoline I1-receptor expression reflects mood 
disorders (Piletz et al., 2008). Also, Alahari’s group found repressed nischarin expression in a 
breast cancer cell line (BT-474) that was increased in a dose-dependent manner upon 
inhibition of PI3K/Akt by LY294002 (Jin et al., 2013). Accordingly, we may speculate 
activation of Akt by moxonidine, at least in cardiomyocytes, suppresses nischarin levels. 
However, the exact mechanisms involved in the observed changes in nischarin expression 
remain to be investigated. 
Investigation of moxonidine signalling pathways in cardiomyocytes revealed that 15 
min incubation with moxonidine causes an increase in ERK1/2 and Akt but not JNK or p38 
phosphorylation. On the other hand, moxonidine activates Akt, ERK1/2, JNK, and p38 in 
fibroblasts. Long term incubation with moxonidine also increases iNOS protein expression in 
cardiomyocytes while it decreases it in fibroblasts. Importantly, whereas moxonidine and 
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imidazoline I1-receptor signalling through ERK, JNK, and Akt has been shown in PC12 cell 
line (Edwards et al., 2001; Tesfai et al., 2011), to our knowledge, this is the first study that 
investigates these proteins as well as p38 and iNOS expression and regulation by moxonidine 
in primary cardiac cells.  
Our results show that moxonidine differentially interacts with cytokines and in a cell-
specific manner.  Further studies are necessary to pinpoint the sequence of actions of 
moxonidine and the signalling pathways involved downstream of imidazoline I1-receptor in 
inflammatory conditions. However, the interaction of moxonidine and cytokines may occur at 
any one of the common mediators. Imidazoline I1-receptors as well as IL-1β and TNF-α 
receptors, are coupled to PC-PLC signalling pathways (Cobb et al., 1996; Ernsberger, 1999; 
Zhang et al., 2001); signalling in both involves sphingomyelin-ceramide pathway (Krown et 
al., 1996; Molderings et al., 2007),  and both stimulate the increase in MAPKs and PI3K 
activity and downstream Akt, the transcription factor nuclear factor -κB (NF-κB), and iNOS  
(Edwards et al., 2001; Gustafsson and Brunton, 2000; Kan et al., 1999; Peng et al., 2009; 
Shindo et al., 1995; Tesfai et al., 2011). 
The present studies also investigated the interaction between cytokines and moxonidine 
as well as downstream signalling proteins on cardiac cell viability.  Cytokines have been 
shown to increase, decrease, or not change cardiomyocyte survival (Higuchi et al., 2002; Ing 
et al., 1999; Krown et al., 1996). These heterogeneous results depend on the experimental 
conditions, such as the use of neonatal or adult rat cardiomyocytes, presence or absence of 
serum, cytokine concentration, exposure time, culture plate coating, as well as by the complex 
intracellular mechanisms which mediate cytokine actions. TNF-α and IL-1β primarily bind to 
respective receptors to modulate the activities of common intracellular signalling pathways 
involved in cell apoptosis or anti-apoptosis. These pathways include cytokine activation of 
ERK1/2, which mediates cell growth and survival signals, and p38 and JNK, which are 
generally pro-apoptotic (Bogoyevitch et al., 1996; Dhingra et al., 2007; Sugden and Clerk, 
1998; Yndestad et al., 2010). Cytokines activate the transcription factor NF-κB, which in turn, 
is apoptotic and anti-apoptotic. NF-κB induces iNOS expression and NO production, which 
contributes to cell death or blocks the apoptosis signalling cascade (Haudek et al., 2007; 
Hiraoka et al., 2001; Hu et al., 2009; Lu et al., 2008). In addition, cytokines increase the 
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intracellular production of the second messenger sphingolipid metabolites: ceramide, 
sphingosine, and the phosphorylated derivative of sphingosine, S1P (Krown et al., 1996). 
Ceramide and sphingosine induce growth arrest and apoptosis (Hannun and Obeid, 2008), 
while S1P inhibits apoptosis and promotes proliferation (Spiegel and Milstien, 2003). Thus, a 
dynamic balance between pro-apoptotic and anti-apoptotic pathways determines the fate of the 
cells whether to die or survive.   
In the conditions employed, IL-1β, and to a lower extent, TNF-α, reduced 
cardiomyocyte viability and caused cell death, mainly by causing cell membrane damage. 
Cardiomyocyte mortality induced by IL-1β was opposed by the specific inhibitors SP600125, 
SB203580, and SMT, confirming the prominent participation of JNK, p38, and iNOS in IL-
1β-induced cell death in several cell types, including cardiomyocytes (Ing et al., 1999; Luss et 
al., 1995; Shindo et al., 1995). IL-1β-induced cardiomyocytes death was also opposed by 
moxonidine. However, to our surprise, cell death was higher upon inhibition of JNK, p38, and 
iNOS in cardiomyocytes incubated with moxonidine alone and much more in cells incubated 
with moxonidine in the presence of IL-1β.  Accordingly, moxonidine’s potentiation of IL-1β-
induced JNK, p38, and iNOS in cardiomyocytes observed by Western blot may be 
compensatory cytoprotective mechanisms, since their inhibition potentiates cell death.  
In fact, the implication of p38, JNK, and iNOS in mediating cardiomyocyte survival 
has been previously shown (Jones and Bolli, 2006; Li et al., 2009a; Markou et al., 2011; 
Munoz et al., 2010; Wei et al., 2011). In ischemia/reperfusion conditions, blocking p38 
activity in adult rat cardiomyocytes reverses the protection induced by phosphodiesterase 
inhibition (Markou et al., 2011); and  JNK activity can be both, protective or deleterious, 
depending on the availability of glucose and ATP (Wei et al., 2011). Studies of ischemic 
preconditioning and iNOS gene transfer have clearly shown that iNOS protects against 
myocardial infarction and that the beneficial effect of several agents, including statins and 
phosphodiesterase-5 inhibitors, on the heart are associated with induced iNOS activity, more 
significantly linked to late preconditioning (Jones and Bolli, 2006; Li et al., 2009a). Protection 
by iNOS may include reduction of reactive oxygen species generation or activation of NF-κB-
mediated survival pathway (Li et al., 2009a). Again, the resulting cell survival or death 
depends on the balance between associated pro- and anti-survival proteins.  
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In this respect, based on published data and our present results, we propose that 
moxonidine protects against cytokine-induced cardiomyocyte death, as follows (Fig. 13): IL-
1β alone increases p38, JNK, and iNOS and results in cell death.  Moxonidine causes an 
increase in the anti-apoptotic protein Bcl2 and reduces the apoptotic protein Bax, favoring 
cardiomyocyte survival.  Moxonidine also potentiates IL-1β-induced p38, JNK and iNOS. 
Once iNOS is expressed, it produces large quantities of nitric oxide (NO), which can be both 
pro- and anti-apoptotic, depending on quantities and downstream signalling pathways: NO 
combining with oxidants generates the free radicals, peroxynitrites (ONOO-), inhibits 
mitochondrial enzymes, and induces cell death.  On the other hand, NO can be cytoprotective, 
inducing Bcl2, which normally protects cells from apoptotic triggers. Through activation of 
the pro-survival/anti-apoptotic signals, as well as through its antioxidant effect, moxonidine 
may shift the balance towards the anti-apoptotic effect of NO.  Opposite mechanisms may take 
place in fibroblasts, where moxonidine increases Bax, reduces basal and IL-1β-induced JNK 
and iNOS and does not exert an anti-oxidant effect, thus the balance is shifted towards cell 
death.   Further studies are required to confirm these postulated survival/death pathways which 
may be strongly re-enforced by measurement of the effect of moxonidine and cytokines on 
nitric oxide and reactive oxygen species production as well as Bax, Bcl2 and downstream 
caspase3 activity, the final common death pathway. 
 
5. Conclusion 
Studies on isolated neonatal cardiac cells in culture cannot be extrapolated to whole 
animals, especially in those with cardiac disease, where myriad of diverse mediators are 
activated. However, the finding that moxonidine/imidazoline I1-receptor protects 
cardiomyocytes and favors elimination of myofibroblasts in inflammatory conditions,  is 
consistent with regression of LVH and fibrosis and improved cardiac function in SHR (Aceros 
et al., 2011) and heart failure hamsters (Stabile et al., 2011). Moreover, the current 
observations implicate imidazoline I1-receptors in cardiac cell growth and death independently 
of their role in blood pressure regulation. They also establish the foundation that cardiac 
imidazoline I1-receptors differentially interact with cytokines, and suggest that therapy should 
take into consideration the nature of the inflammatory disorder and the cell type involved. 
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Further studies are required to confirm the beneficial effects of moxonidine in a wide range of 
animal models of inflammation and organ injury.  
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Figure Captions: 
 
Fig. 1. RT-PCR detection of nischarin product in neonatal rat cardiomyocytes (CM) and 
fibroblasts (Fb), at first (P1) and second (P2) passages, and after 48h incubation with 
moxonidine at 10
-7
 and 10
-5
 M concentrations. Normal mouse C57BL/6 brain and heart were 
used as positive controls. S18 run in parallel showed that all samples contained equal amounts 
of cDNA.  
Fig. 2. Representative bands of nischarin detected by Western blot in cultured neonatal rat 
ventricular cardiomyocytes and fibroblasts incubated for 24 h with, A: moxonidine 10
-7
, 10
-6
 , 
and 10
-5
 M, or B: IL-1β and TNF-α, each alone and in combination with 10-5 M moxonidine. 
Bar graphs represent ratios of nischarin protein expression compared to GAPDH (loading 
control) and normalized to corresponding DMEM-incubated cells (100%).  n=3-6. *P<0.05 vs. 
DMEM; &P<0.05 vs. corresponding IL-1β or TNF-α.  
Fig. 3. Representative bands of phosphorylated Akt and MAPKs (ERK1/2, p38, and JNK) 
detected by Western blot in cultured neonatal rat ventricular cardiomyocytes incubated for 15 
min with moxonidine (10
-7
 and 10
-5
 M), without and with the imidazoline I1-receptor 
antagonist, AGN192403 (10
-5
 M). Bar graphs represent ratios of phosphorylated Akt, ERK1/2, 
p38, and JNK, compared to GAPDH (loading control) and normalized to corresponding 
DMEM-incubated cells (100%).  n=12. *P<0.01 vs. DMEM; &P<0.05 vs. corresponding 
moxonidine.  
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Fig. 4. Representative bands of Bax and Bcl2 detected by Western blot in cultured neonatal rat 
ventricular cardiomyocytes and fibroblasts incubated for 24 h with moxonidine (10
-5
 M). Bar 
graphs represent Bax, Bcl2, and Bax to Bcl2 ratio, compared to corresponding β-actin (loading 
control) and normalized to DMEM-incubated control cells (100%).  n=6-9. *P<0.01 vs. 
DMEM. 
Fig. 5. Representative bands of phosphorylated Akt and MAPK (ERK1/2, p38, and JNK) 
detected by Western Blot in cultured neonatal rat ventricular cardiomyocytes incubated for 15 
min with IL-1β (5 ng/ml) or TNF-α (10 ng/ml) alone and in combination with  10-5 M 
moxonidine. Bar graphs represent ratios of phosphorylated Akt, ERK1/2, p38, and JNK, 
compared to GAPDH (loading control) and normalized to corresponding DMEM-incubated 
cells (100%). *P<0.01 vs. DMEM; &P<0.01 vs. corresponding IL-1β or TNF-α, n= 9-12. 
Fig. 6. Representative bands of phosphorylated Akt and MAPK (ERK1/2, p38, and JNK) 
detected by Western Blot in cultured neonatal rat ventricular fibroblasts incubated for 15 min 
with moxonidine (10
-5
 M),  IL-1β (5 ng/ml), TNF-α (10 ng/ml), separately and in combination. 
Bar graphs represent ratios of phosphorylated proteins compared to GAPDH (loading control) 
and normalized to DMEM-incubated control cells (100%).  *P< 0.01 vs. DMEM; &P< 0.01 
vs. corresponding IL-1β or TNF-α; n= 9-12. 
Fig. 7. Representative bands of iNOS protein expression, detected by Western Blot, in 
cultured neonatal rat ventricular cardiomyocytes and fibroblasts incubated for 24h (left) with 
DMEM, moxonidine (10
-5
 M),  IL-1β (5 ng/ml), TNF-α (10 ng/ml), separately and in 
combination. LPS, positive control. Right:  48h incubation with DMEM or moxonidine (10
-5
 
M). Bar graphs represent ratios of iNOS compared to GAPDH (loading control) and 
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normalized to corresponding DMEM-incubated cells (100%).  *P<0.01 vs. DMEM; &P<0.05 
vs. corresponding IL-1β; n=6-9.  
Fig. 8. A: Representative flow cytometry after annexin V (x-axis) and propidium iodide (PI, y-
axis) staining in cardiomyocytes after 48 h incubation in starvation conditions (DMEM) and 
moxonidine (10
-7
 and 10
-5
 M), without and with and imidazoline I1-receptor antagonist, 
AGN192403 (10
-5
 M). DMEM+10%FBS, normal growth control; H2O2 (10
-4
 M) death 
control. B: Bar graphs represent percent cardiomyocytes in early apoptosis (annexin positive, 
PI negative), necrosis (PI positive) and alive (annexin negative, PI negative). Data presented 
as percent corresponding DMEM.  *P<0.01 vs. DMEM; &P<0.05 vs. corresponding 
moxonidine; $P<0.05 vs. H2O2; n= 9-12.  
Fig. 9. MTT assay in cardiomyocytes incubated for 48h in starvation conditions (DMEM) 
without and with moxonidine (10
-5
 M), IL-1β (5 ng/ml), TNF-α (10 ng/ml), H2O2 (10
-4
 M), 
separately and in combination. *P<0.05 vs. DMEM; &P<0.05 vs. corresponding IL-1β, TNF-
α, or H2O2; n=12-15. 
Fig. 10. A: Representative fluorescent micrographs of calcein (Green) and ethidium 
homodimer (Red) staining in cardiomyocytes incubated for 48 h in starvation condition 
(DMEM) without and with moxonidine (10
-5
 M), IL-1β (5 ng/ml), or TNF-α (10 ng/ml), 
separately and in combination; n=3. Scale bar: 200µm. B: Representative fluorescent 
micrographs and corresponding bar graphs of ethidium homodimer staining in cardiomyocyte 
incubated for 48 h in starvation condition (DMEM) without and with moxonidine (10
-5
 M), 
and imidazoline I1-receptor antagonist AGN192403 (10
-5
 M), and protein inhibitors, separately 
and in combination. SB (10 µM), p38 inhibitor; SP (10 µM), JNK inhibitor; SMT (1 µM), 
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iNOS inhibitor. *P<0.05 vs. DMEM; &P<0.05 vs. corresponding inhibitor; n=3; Scale bar: 
200µm. (For interpretation of the references to color in this figure legend, the reader is 
referred to the web version of this article.) 
Fig. 11. A: Representative fluorescent micrographs and corresponding bar graphs of ethidium 
homodimer staining in cardiomyocyte incubated for 48 h in starvation condition (DMEM) 
with IL-1β (5 ng/ml), without and with moxonidine (10-5 M) and signalling protein inhibitors. 
*P<0.05 vs. DMEM; &P<0.05 vs. corresponding IL-1β; #P<0.05 vs. corresponding IL-
1β+moxonidine; $P<0.05 vs. corresponding inhibitor; n=3. B: Representative fluorescent 
micrographs and corresponding bar graphs of ethidium homodimer staining in cardiomyocyte 
incubated for 48 h in starvation condition (DMEM) with TNF-α (10 ng/ml), without and with 
moxonidine (10
-5
 M) and signalling protein inhibitors. *P<0.05 vs. DMEM; &P<0.05 vs. 
corresponding cytokine; #P<0.05 vs. corresponding TNF+moxonidine; $P<0.05 vs. 
corresponding inhibitor; n=3. PD (10 µM), ERK inhibitor; SB (10 µM), p38 inhibitor; SMT (1 
µM), iNOS inhibitor; wortmannin (0.5 µM), PI3K/Akt inhibitor. Scale bar: 200µm. 
Fig. 12. A: Representative fluorescent micrographs of calcein (green) staining and 
corresponding bar graphs of fibroblasts after 48 h incubation with moxonidine (10
-5 
M), IL-1β 
(5ng/ml), or TNF-α (10 ng/ml), separately and in combination in serum starvation conditions 
(DMEM). B: Representative fluorescent micrographs of ethidium homodimer (red) staining 
and corresponding bar graphs of fibroblasts after 48 h incubation with moxonidine (10
-5 
M), 
IL-1β (5ng/ml), or TNF-α (10 ng/ml), separately and in combination in serum starvation 
conditions (DMEM).  *P<0.05 vs. DMEM; &P<0.05 vs. corresponding cytokine; n=3. Scale 
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bar: 200µm. (For interpretation of the references to color in this figure legend, the reader is 
referred to the web version of this article.)  
Fig. 13. Schematic diagram showing hypothetical mechanisms of cardiomyocyte protection by 
moxonidine in the presence of cytokines. IL-1β alone increases p38, JNK, and iNOS and 
results in cell death.  Moxonidine causes an increase in the anti-apoptotic protein Bcl2 and 
reduces the apoptotic protein Bax, favoring cardiomyocyte survival.  Moxonidine also 
potentiates IL-1β-induced p38, JNK and iNOS. Once iNOS is expressed, it produces large 
quantities of nitric oxide (NO), which can be both pro- and anti-apoptotic, depending on 
quantities and downstream signalling pathways: NO combining with oxidants generates the 
free radicals, peroxynitrites (ONOO-), inhibits mitochondrial enzymes, and induces cell death.  
On the other hand, NO can be cytoprotective, inducing Bcl2, which normally protects cells 
from apoptotic triggers. Through activation of the pro-survival/anti-apoptotic signals, as well 
as through its antioxidant effect, moxonidine may shift the balance towards the anti-apoptotic 
effect of NO.  Opposite mechanisms may take place in fibroblasts, where moxonidine 
increases Bax, reduces basal and IL-1β-induced JNK and iNOS and does not exert an anti-
oxidant effect, thus the balance is shifted towards cell death.  SB, p38 inhibitor; SP, JNK 
inhibitor; SMT, iNOS inhibitor. Solid lines, potentiation; Dotted lines, inhibition. 
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3.6 Supplementary data: 
This small section pertains to data obtained in the framework of the studies, but not used in the 
publications. These data do not change the papers’ conclusions, but allow for a more complete 
discussion in this thesis. 
Activation of the imidazoline I1-receptor by moxonidine in neonatal rat cardiomyocytes 
induces the release of atrial natriuretic peptide (ANP). 
 
Figure 14: Time-dependent ANP release to the culture medium (DMEM) from cultured neonatal rat 
cardiomyocytes following incubation with the imidazoline I1-receptor agonist moxonidine (10-5 M), alone or in 
combination with the imidazoline I1-receptor antagonist efaroxan (10-5 M) or the α2-adrenergic receptor 
antagonist yohimbine (10-5 M). * P<0.01 vs. medium; $ P<0.01 vs. moxonidine.  
 
Cardiomyocytes were incubated in 1 ml DMEM or DMEM+moxonidine for 120 minutes. 
Aliquots (50 µl) were collected at indicated times (0, 15, 30, 60 and 120 minutes) for 
measurement of ANP, by radioimmunoassay. Compared to DMEM alone, moxonidine 
significantly stimulated the release of ANP at 60 and 120 min in atrial and ventricular 
cardiomyocytes, respectively. Moxonidine-induced ANP release was inhibited by co-
incubation with efaroxan more than by yohimbine. The greater effect of efaroxan compared to 
 209 
the α2-adrenergic receptor antagonist yohimbine suggests a predominant involvement of 
imidazoline I1-receptors in the action. Most importantly, these studies indicate that cardiac 
imidazoline I1-receptors are functional without CNS contribution. 
 
Activation of the imidazoline I1-receptor by moxonidine induces the release of atrial 
natriuretic peptide (ANP) form hearts isolated from normotensive (Sprague-Dawley) 
and hypertensive (SHR) rats. The effect of moxonidine is potentiated in SHR hearts. 
 
Figure 15 : ANP release following perfusion of isolated rat hearts with the imidazoline I1-receptor agonist 
moxonidine (10
-6
 M) or control Krebs buffer.  
 
After 30 min equilibration, isolated rat hearts were perfused ex vivo with moxonidine (10
-6
 M) 
or Krebs-Henseleit perfusion buffer for 20 minutes. Aliquots were collected every minute for 
the measurement of ANP, by radioimmunoassay. ANP concentration was corrected for the 
flow per minute and reported as ng/min. Compared to buffer perfusion, moxonidine 
significantly stimulated the release of ANP in normotensive hearts; this effect was augmented 
in hypertensive SHR hearts. These studies indicate that cardiac imidazoline I1-receptors are 
functional without CNS contribution and are consistent with the notion that imidazoline I1-
receptors are altered in cardiovascular diseases. 
  
 
Chapter 4. Discussion   
Previous studies from this laboratory have shown that chronic activation of the imidazoline I1-
receptor with the selective agonist moxonidine regresses left ventricular hypertrophy (LVH) in 
hypertensive rats, at both hypotensive and sub-hypotensive doses (Mukaddam-Daher et al., 
2009; Paquette et al., 2008). Regression of LVH is associated with a sustained reduction of 
DNA synthesis and transient stimulation of DNA fragmentation and apoptotic proteins Bax and 
caspase 3, occurring after 1 week but subsiding by 4 weeks of treatment (Paquette et al., 2008). 
Cardiomyocyte apoptosis plays a causal role in the development of heart failure through 
progressive left ventricular wall thinning (Kemp & Conte, 2012; Liao et al., 2004; Ward et al., 
2011) and  inhibition of cardiomyocyte apoptosis attenuates contractile dysfunction in heart 
failure (Foo, Mani, & Kitsis, 2005). Accordingly, if moxonidine-stimulated apoptosis occurred 
in cardiomyocytes, cardiac dysfunction would ensue, despite the transient increase in 
ventricular ANP synthesis that also subsided by 4 weeks of treatment (El-Ayoubi et al., 2003), 
indicating treatment efficacy. Taken in the context of the negative results of the MOXCON 
trial in heart failure patients (Cohn et al., 2003), these studies led us to question the effect of 
moxonidine on cardiac function. Accordingly, studies investigated in hypertensive and heart 
failure animals the dose- and time-dependent effects of moxonidine on cardiac function. In 
addition, studies investigated the effect of moxonidine on hypertension- and heart failure-
associated mechanisms, specifically cytokines.  
The models chosen in these studies, the 12-week old spontaneously hypertensive rat (SHR) 
and the 6 month-old BIO14.6 hamster (Aceros et al., 2011; Stabile et al., 2011), are well 
described models of hypertensive and normotensive hypertrophic cardiomyopathy, 
respectively. They share an increased sympathetic activity, LVH, and a decreased diastolic 
function (Aceros et al., 2011; Cabassi et al., 2007; Gertz, 1972; Okamoto & Aoki, 1963; 
Slama, Ahn, Varagic, Susic, & Frohlich, 2004; Sole, Lo, Laird, Sonnenblick, & Wurtman, 
1975; Stabile et al., 2011). However, the SHR differs from BIO14.6 hamsters in that systolic 
function is preserved in SHR  (Slama et al., 2004), while in the BIO14.6 hamster systolic 
function declines in an age-dependent manner until ventricular dilatation and overt heart 
failure occur at the age of 10 months and above. This age-dependent development of heart 
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failure has been shown in previous studies (Gertz, 1972; Kyoi et al., 2006; Strobeck et al., 
1979), as well as in our present results (Stabile et al., 2011).  
In addition, the SHR presents with a robust cardiac inflammatory response, shown by an 
increase in serum pro-inflammatory markers (Aceros et al., 2011). On the other hand, serum 
pro-inflammatory markers in the young BIO14.6 cardiomyopathic hamsters are not 
significantly different from normal controls, but continuous low grade inflammation is 
observed in the heart, which manifests in the older hamsters (Gertz, 1972; Stabile et al., 2011). 
These characteristics are similar to those observed in humans suffering from chronic 
hypertension and dilated cardiomyopathy, respectively (Dornas & Silva, 2011; Houser et al., 
2012), allowing for evaluation of the imidazoline I1-receptor activation by moxonidine under 
chronic conditions, mimicking the evolution from hypertension, to heart failure, and finally to 
the state of uncompensated dilated heart failure, observed in untreated patients (Nielsen, 1986; 
Strauer, 1984).  
 
4.1 Moxonidine improves cardiac function in hypertensive and 
heart failure models, in association with anti-inflammatory and 
anti-oxidative actions  
Heart rate is regulated by the balance between sympathetic (tachycardic) and parasympathetic 
(bradycardic) actions at the level of the sinoatrial node in response to cardiovascular stress 
(Tobaldini et al., 2013). Increased heart rate (above 90 bpm) has been related to increase in 
cardiovascular and all-cause mortality (Kannel, Kannel, Paffenbarger, & Cupples, 1987; 
Kristal-Boneh, Silber, Harari, & Froom, 2000), and decreasing heart rate has been 
independently related to a decrease in mortality in coronary artery disease (Fox, Ford, Steg, 
Tendera, & Ferrari, 2008) and heart failure (Bohm et al., 2010). Our studies have shown that 
high concentrations of moxonidine reduce heart rate in both SHR and BIO14.6 hamsters 
(Aceros et al., 2011; Stabile et al., 2011), suggesting a possible beneficial effect of long term 
treatment. This decrease might be related to a centrally mediated decrease in sympathetic 
output by moxonidine acting on imidazoline I1-receptors located on the rostro-ventro lateral 
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medulla (Chan et al., 2005; Haxhiu, Dreshaj, Schafer, & Ernsberger, 1994). On the other hand, 
in the SHR, heart rate was decreased by both concentrations, despite that the low 
concentration of moxonidine did not reduce blood pressure (Aceros et al., 2011). The selective 
decrease in heart rate by low moxonidine concentration is consistent with previous studies 
from our laboratory that have shown that moxonidine reduces heart rate in isolated rat hearts 
(ex vivo) by mechanisms that include imidazoline I1-receptors in the heart (Mukaddam-Daher 
et al., 2006). Schafer et al., (2003) have also shown that moxonidine reduces norepinephrine 
release induced by stimulation of epicardial ganglia on isolated rat hearts (Schafer et al., 
2003). Additionally, it has been described that moxonidine has parasympathomimetic actions 
in normotensive animals and humans (Kaya, Barutcu, Esen, Celik, & Onrat, 2010; Turcani, 
2008), an effect that might contribute to the decrease in heart rate independent of changes in 
blood pressure.  Finally, activation of the imidazoline I1-receptor by moxonidine induces ANP 
release in isolated hearts (Mukaddam-Daher et al., 2006), an effect particularly important in 
hypertensive animals (Figure 15). ANP potentiates reflex bradycardia via guanylyl cyclase 
receptors, probably by inducing NO and cGMP at cardiac level (Thomas & Woods, 2003), 
possibly leading to an increase sensitivity to bradycardic stimuli.  Taken together, these 
studies imply that the bradycardia observed in SHR treated with non-hypotensive 
concentration of moxonidine results from a combined action on central and peripheral 
imidazoline I1-receptors.  
Consistent with previous reports (Slama et al., 2004), our echocardiographic measurements 
confirm the presence of diastolic dysfunction and the absence of systolic dysfunction in 
untreated SHR. The measurements also reveal that activation of imidazoline I1-receptors by 
moxonidine regresses LVH and improves diastolic and global cardiac function without 
negatively affecting systolic function (Aceros et al., 2011). Furthermore, moxonidine 
improves diastolic dysfunction and prevents the time-dependent deterioration in systolic 
function in young hamsters with moderate heart failure, as well as older hamsters with 
advanced heart failure. The effect is particularly important in the younger group, where 
treatment reduces end systolic and end diastolic volumes, pointing towards an improvement in 
ventricular geometry following treatment (Stabile et al., 2011). 
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Diastolic and systolic dysfunctions are considered as different evolutionary stages of heart 
failure (Hunt et al., 2009). Diastolic dysfunction is an alteration commonly observed in 
hypertensive patients (Palatini et al., 2001; Slama, Susic, Varagic, & Frohlich, 2002), is 
associated with normal ejection fraction. Patients with symptomatic heart failure usually have 
both diastolic and systolic dysfunction, defined as ejection fraction below 55% (Lang et al., 
2005).  Also, in around 40% of diabetic patients, diastolic dysfunction without other obvious 
causes (like ischemia or hypertension) has been found, configuring the first phases of diabetic 
cardiomyopathy (Pappachan, Varughese, Sriraman, & Arunagirinathan, 2013; Schilling & 
Mann, 2012).  
An increase in mortality has been observed in patients with moderate and severe diastolic 
dysfunction (Halley, Houghtaling, Khalil, Thomas, & Jaber, 2011); and diastolic dysfunction 
increases the risk of symptomatic heart failure by 30% (Lam et al., 2011).  
Diastolic dysfunction can be defined as “the inability of the heart to fill with blood during 
diastole” (Slama et al., 2002). It results from impaired LV relaxation and an increase in LV 
wall stiffness, both of which impede blood flow into the ventricle. Thus, it is related to 
ventricular fibrosis, hypertrophy, and alterations in cardiomyocyte relaxation (Slama et al., 
2002; Wan, Vogel, & Chen, 2014), characteristics also observed in the SHR where left 
ventricular relaxation is impaired and stiffness increased (Slama et al., 2004).  
The quality of diastole is affected by the static properties of the myocardium, the extracellular 
matrix (ECM) and the cardiomyocytes and their interaction via matricellular proteins (Wan et 
al., 2014). The ECM stiffness is determined by the amount of collagen, the abundance of 
collagen I, and collagen cross linking (Bonow et al., 2012; Diez, 2008; Diez et al., 2002). 
Severe diastolic dysfunction with an increased collagen deposition when compared with 
normoglycemic rats is described in 18 week old type II diabetic Goto-Kakizaki rats (D'Souza 
et al., 2014; El-Omar, Yang, Phillips, & Shah, 2004) and treatment with the hypoglycemic 
medication metformin diminishes cardiac fibrosis and ventricular hypertrophy, and improves 
diastolic function (Picatoste et al., 2013). In Dahl salt-sensitive rats, a model of accelerated 
hypertensive diastolic failure, an increase in collagen deposition is also observed. Treatment of 
these rats with sub-hypotensive doses of the calcium channel antagonist nifedipine diminishes 
collagen deposition and ventricular hypertrophy, and improves diastolic function (Yamada et 
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al., 2009). These studies highlight the importance of blood pressure and glucose metabolism in 
the control of cardiac function, but most importantly, suggest that reducing collagen 
deposition and ventricular hypertrophy improves diastolic function and that the effect is 
independent of changes in blood pressure.  
On the other hand, systolic function is influenced by changes in the relative abundance of 
collagen I and collagen III. A reduced  pro-collagen I to pro-collagen III ratio was observed in 
patients with idiopathic dilated cardiomyopathy when compared to normal controls (Timonen 
et al., 2008) and a higher ratio was found in patients successfully treated with a left ventricular 
assist device compared to those  that required heart transplantation (Liang et al., 2004). These 
studies demonstrate that a change in collagen I to collagen III ratio favouring a decrease in 
collagen I may be deleterious in heart failure. 
Consistent with the above studies, our studies reveal that moxonidine treatment reduces both 
cardiomyocyte hypertrophy and ventricular collagen deposition in SHR and cardiomyopathic 
hamsters. Moxonidine administration to young cardiomyopathic hamsters also increased the 
relative content of collagen I and decreased relative content of collagen III, an effect that may 
hinder further ventricular dilatation, improving ventricular geometry (Stabile et al., 2011). The 
decreased cardiomyocyte hypertrophy, combined with a decrease in collagen deposition and a 
relative increase in collagen type I expression could explain, in part, the observed 
improvement in both diastolic (SHR and cardiomyopathic hamsters) and systolic 
(cardiomyopathic hamsters) functions.  
In addition to collagen deposition, intrinsic cardiomyocyte stiffness also contributes to 
diastolic LV dysfunction (Wan et al., 2014). The extent of ventricular hypertrophy is directly 
related to the level of diastolic dysfunction observed in patients with hypertrophic 
cardiomyopathy or hypertension (De Marchi, Allemann, & Seiler, 2000). It has been observed 
that cardiomyocytes from patients with diastolic heart failure have developed hypertrophy and 
increased passive stiffness (van Heerebeek et al., 2006). Elevation of cardiomyocyte stiffness 
has been related to the cytoskeletal protein titin isoform switching, phosphorylation status, as 
well as oxidative stress-induced formation of disulfide bridges within the titin molecule 
(Borbely et al., 2009; Borbely et al., 2005; Borlaug & Paulus, 2011). The mechanisms include 
the activation of protein kinase A, a pathway normally stimulated by the β1 adrenergic 
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receptor at cardiac level (Hidalgo & Granzier, 2013). In addition, in hypertrophied 
cardiomyocytes from rats treated with the β1-adrenergic receptor agonist isoproterenol, an 
increased residual actin-myosin cross bridge formation was observed, an additional factor that 
decreases myocardial relaxation (Sumita Yoshikawa et al., 2013). These results point towards 
a link between cardiomyocyte hypertrophy and diastolic dysfunction, yet, the relative 
importance of ventricular hypertrophy on the development of diastolic dysfunction needs 
further research (Wan et al., 2014).   
Another factor mediating diastolic dysfunction is altered cardiomyocyte relaxation, an active 
process modulated by myocardial and systemic factors (Silverthorn, 2013).
 
Cardiomyocyte 
relaxation is related to alterations in intracellular calcium handling (Slama et al., 2002; Wan et 
al., 2014) and nitric oxide signalling. A decrease in relaxation, related to a slower decrease in 
cytosolic calcium content is observed in cardiomyocytes isolated from renovascular 
hypertensive rats (Yelamarty et al., 1992). Additionally, diastolic dysfunction in SHR is 
associated with an increase in baseline intracellular calcium in isolated cardiomyocytes and a 
decrease in the expression of the Sarco(endo)plasmic Ca
2+
-ATPase isoform 2a (SERCA 2a), 
an enzyme linked to calcium reuptake by the sarcoplasmic reticulum (Dupont et al., 2012; 
Eisner, Bode, Venetucci, & Trafford, 2013).  
Studies in unilaterally nephrectomized, deoxycorticosterone acetate (DOCA)-salt hypertensive 
mice have shown that diastolic dysfunction is induced by oxidative stress mediated by the 
uncoupled activity of neural and endothelial nitric oxide synthases (NOS), increasing the 
production of superoxide (∙O2−), and non-selective blocking of NOS with L-NAME reduces 
superoxide production and reverses diastolic dysfunction (Silberman et al., 2010). The 
mechanisms of this effect include reduction of the activity of phospholamban, a protein related 
to the control of SERCA activity. Thus, coupling of nitric oxide synthase, increasing NO 
production instead of free oxygen radicals, improves relaxation in this model (Silberman et al., 
2010). Noteworthy, NO via its downstream mediator cyclic guanosine monophosphate 
(cGMP) reduces myofilamentary Ca2+ sensitivity and thereby facilitates cross-bridge 
detachment (Layland, Li, & Shah, 2002). 
Alterations in cardiomyocyte calcium handling and subsequent cardiac dysfunction in SHR 
may be influenced by increased cardiac inflammatory mediators. Injection of IL-1β impairs 
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myocardial relaxation in mice (Van Tassell, Toldo, Mezzaroma, & Abbate, 2013). Blocking 
IL-1β with the recombinant IL-1 receptor antagonist Anakinra improves exercise tolerance in 
patients with heart failure with preserved systolic function (Van Tassell et al., 2014), a clinical 
syndrome of exercise intolerance due to impaired myocardial relaxation and/or increased 
stiffness (Borlaug, 2014). These studies suggest an improvement in cardiac function following 
IL-1β inactivation (Van Tassell et al., 2014). Also, in SHR, 16 weeks of moderate treadmill 
exercise improves diastolic function in association with a decrease in myocardial TNF-α and 
IL-1β and attenuated activity of nuclear factor κB (NF-κB) (Agarwal et al., 2009), a 
transcription factor that, among other functions, controls the production of pro-inflammatory 
cytokines as well as enzymes that increase oxidative stress in cardiac cells, including inducible 
nitric oxide synthase (iNOS) (Elks et al., 2009; Sun et al., 2009).   
Accordingly, pro-inflammatory cytokines may activate nitric oxide synthase (NOS) via NF-
κB, which, in turn, increases oxygen free radicals, decreases SERCA activity, increases resting 
intracellular calcium levels, and reduces diastolic function. 
In this respect, our studies in SHR show that 4-week-treatment with moxonidine decreases 
cardiac levels of IL-1β and TNF-α, probably reducing ventricular oxidative stress, and 
improving calcium handling, an effect likely to improve the active phase of diastole. This 
mechanism together with the decrease in collagen deposition, may contribute to the observed 
improvement in diastolic function following activation of imidazoline I1-receptors (Aceros et 
al., 2011).  
The progressive decline in left ventricular function involves apoptotic cardiomyocyte loss. 
Apoptosis can be induced via the extrinsic (for example through the TNF receptor) or, more 
importantly in heart failure, the intrinsic pathway (Konstantinidis, Whelan, & Kitsis, 2012; 
Orogo & Gustafsson, 2013). The intrinsic pathway is regulated by the balance in the activity 
of the mitochondrial pro-apoptotic protein, Bax and the anti-apoptotic protein, Bcl-2, a 
balance that maintains mitochondrial activity (Konstantinidis et al., 2012; Orogo & 
Gustafsson, 2013).  The increase in Bax in cardiomyocytes is induced by inflammatory iNOS, 
and the subsequent production of the NO degradation product peroxynitrite (ONOO-) (Arstall, 
Sawyer, Fukazawa, & Kelly, 1999). On the other hand, ischemia-induced apoptosis is 
inhibited by the phosphodiesterase-5 inhibitor sildenafil, by mechanisms that included an 
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iNOS-dependent increase in Bcl-2 (Das, Xi, & Kukreja, 2005). Together, these studies reveal 
a dual NO effect: a direct NO-Bcl-2-mediated anti-apoptotic and an indirect NO-peroxynitrite-
Bax apoptotic effects. 
Moxonidine results in a transient apoptotic effect in SHR ventricles, increasing it at the onset 
of treatment, but decreasing it by the end of a 4-week-treatment (Paquette et al., 2008). Based 
on the improved cardiac function, the early apoptotic response most likely involves 
susceptible (myo)fibroblasts, while cardiomyocytes remain protected. Similar anti-
inflammatory and protective effects have been shown in cardiomyopathic hamsters, where 4 
week-treatment with moxonidine reduces ventricular cell death, an effect associated with 
increased Bcl-2 expression (Stabile et al., 2011), suggesting a decrease in peroxynitrite 
production and a local anti-oxidative effect.  
Thus, decreased oxidative stress mediated by inhibition of SNS activity, changes in 
inflammatory mediators, and decreased nitric oxide synthase activity, may also explain the 
observed improvement in cardiac function.  
The BIO14.6 cardiomyopathic hamster has been described as a model of necrosis-induced 
heart failure (Gertz, 1972; Kyoi et al., 2006; Strobeck et al., 1979). Our studies in BIO14.6 
hamster hearts revealed elevated number of TUNEL positive cardiomyocytes. The number of 
these cells decreased following moxonidine treatment, in association with a decrease in the 
ventricular Bax/Bcl-2 ratio (Stabile et al., 2011). Noteworthy, TUNEL assay is commonly 
used to identify apoptotic cells in situ. However because this assay detects double-and single-
stranded DNA fragmentation that is also produced by necrotic DNA degradation in different 
cell types, including cardiomyocytes (Ohno et al., 1998; Widlak, Li, Wang, & Garrard, 2000), 
cell death in the myopathic hamster heart may be caused by both necrotic and apoptotic 
mechanisms. On the other hand, the Bax to Bcl-2 ratio has been related to cardiomyocyte 
apoptosis, Bax, being pro-apoptotic and Bcl-2 anti-apoptotic (Elsasser, Suzuki, & Schaper, 
2000; Hofstaetter, Taimor, Inserte, Garcia-Dorado, & Piper, 2002). In addition, our present in 
vitro studies reveal that moxonidine opposes starvation-induced cardiomyocyte apoptosis 
measured by FACS (Aceros, Farah, Noiseux, & Mukaddam-Daher, 2014). Accordingly, 
cardiac cell protection by moxonidine includes, at least in part, an anti-apoptotic mechanism.    
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These studies reveal that moxonidine does not deteriorate, rather, improves myocardial 
function, possibly by imidazoline I1-receptor mediated anti-inflammatory and anti-oxidative 
mechanisms that hinder cardiac hypertrophy, cardiomyocyte death, and fibrosis. The proposed 
mechanisms for moxonidine actions are presented in Figure 16. 
 
Figure 16: Cardioprotective effects of in vivo moxonidine treatment in hypertensive SHR and Bio14.6 hamsters:  
Increased SNS activity and subsequent release of neurotransmitter norepinephrine (NE) is implicated in the 
pathogenesis and maintenance of hypertension in SHR.  SNS overactivity increases the secretion of systemic (IL-
1β and IL-6) and cardiac (IL-1β) proinflammatory cytokines. Neurohormones and cytokines lead to 
morphological changes (LVH and fibrosis, manifested by increased cardiomyocyte surface area (CSA) and 
collagen deposition) and to functional changes (diastolic dysfunction, shown by increased IVRTc, increased E 
deceleration rate and decreased E deceleration time, and decreased general myocardial performance, shown as 
increased LV performance index (LVMPI)), together with preserved systolic function (normal percent ejection 
fraction (%EF)).  Eventually, these changes lead to heart failure (reduced both, diastolic and systolic cardiac 
functions). In vivo moxonidine (in green) improves diastolic function and global LV performance (decreased 
LVMPI) and results in LVH regression (reduced cardiomyocyte CSA and fibrosis). These effects are associated 
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with modulated inflammatory responses (decreased circulating IL-6 and TNFα, as well as decreased cardiac IL-
1β) and reduced high Akt and p38 phosphorylation. 
On the other hand, the Bio14.6 hamster is a genetic model of heart failure. It is characterized by age-dependent 
progressive cardiac hypertrophy followed by dilatation and cardiac dysfunction which result in neurohormonal 
activation and inflammation, causing ventricular cell death and fibrosis, thus leading to further ventricular 
diastolic and systolic functions. Treatment with moxonidine prevents/delays systolic and diastolic cardiac 
dysfunctions and ventricular dilatation (increased collagen I/III ratio and reduced cardiomyocyte apoptosis) and 
modulates inflammatory responses (increased IL-1β and decreased circulating IL-6 and cardiac IL-1β and TNFα 
and inflammatory markers, pNF-kB and iNOS).  
The benefits of in vivo moxonidine may be secondary to inhibition of SNS overactivity, which may improve 
cardiac function and reduce circulating neurohormones and cytokines levels and their downstream death and 
fibrotic actions, in association with blood pressure reduction (high concentrations in SHR) or no effect (low 
concentrations in SHR, low and high concentrations in BIO14.6). In addition, moxonidine, at least in part, may 
act directly on the heart to interfere with the actions of NE and cytokines.  This hypothesis emerges from the 
pressure-independent cardioprotective effects of moxonidine as well as on the presence of adrenergic and 
cytokine receptors and imidazoline I1-receptors on cardiac cells. 
 
Most of moxonidine’s benefits were observed in response to high, hypotensive concentrations, 
typically mediated by central imidazoline I1-receptor activation and subsequent inhibition of 
SNS activity (El-Mas et al., 2009; Zhang & Abdel-Rahman, 2008). However, these benefits 
also occurred in response to low, sub-hypotensive concentrations, pointing to a local action, 
mediated by cardiac imidazoline I1-receptors. The participation of cardiac imidazoline I1-
receptors in LVH regression, and the mechanisms involved in whole animal studies may be 
masked by the antihypertensive and sympatholytic effects of the drug. Therefore, in order to 
selectively investigate cardiac actions, the interaction of moxonidine with oxidative and 
inflammatory markers was investigated in vitro on primary cardiac cells in culture.  
 
 220 
4.2 In vitro imidazoline I1-receptor activation by moxonidine 
protects cardiomyocytes against inflammatory and oxidative 
stressors. Opposite effects occur in fibroblasts 
As regression of LVH by moxonidine may include cardiac cell hypertrophy, proliferation, and 
death, the direct effect of moxonidine on hypertension and heart failure-induced cardiac cell 
growth and death and the implicated signaling proteins were investigated in vitro, on primary 
cardiomyocytes and fibroblasts in culture, in the absence of confounding mechanisms.  
Neonatal but not adult rat cardiac cells have been chosen because they are easier to handle, 
and can be grown and maintained in vitro longer times. More importantly, although the use of 
neonatal cell data may not be translated to normal adult cells, they may be translated to 
pathological situation, such as the hypertrophied heart, in which the fetal gene program is re-
initiated (Ames, Lawson, Mackey, & Holmes, 2013). As for neonatal rat cardiac fibroblasts, 
these cells have been extensively used to identify potential pro-fibrotic factors, and elucidate 
the signalling pathways coupled to growth and ECM protein expression (Peng, Dai, Ji, & Dai, 
2010).  
Using primary cultures of neonatal rat cardiac myocytes and fibroblasts, the present studies 
identify cardiac cell type-specific signalling pathways of imidazoline I1-receptors/nischarin. 
They also demonstrate that moxonidine protects cardiomyocytes and modulates cardiac 
fibroblast survival in the presence of oxidative and inflammatory stimuli, namely 
norepinephrine, TNF-α and IL-1β. These studies reveal that activation of imidazoline I1-
receptors by moxonidine does not only inhibit the production of norepinephrine and cytokines 
but also directly interferes with their actions in cardiac cells (Aceros et al., 2011; Aceros et al., 
2014). 
Norepinephrine induces cardiomyocyte death by increasing oxidative stress and downstream 
activation of p38 MAPK, followed by secretion of TNF-α. Blocking any of these mediators 
reduces norepinephrine-induced cardiomyocyte death (Chen, Jiang, Wan, Bi, & Yuan, 2012; 
Fu et al., 2004; Iwai-Kanai et al., 2001). In addition, IL-1β increases cardiomyocyte mortality 
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by mechanisms that include the activation of p38 MAPK and iNOS (Arstall et al., 1999; 
Shindo et al., 1995).  
The effects of iNOS are mediated by its nitric oxide (NO) production. However, as mentioned 
above, NO exerts both pro- and anti-apoptotic effects in cardiomyocytes, depending on 
quantities and downstream signalling pathways. Low NO concentrations are anti-apoptotic, 
increasing Bcl-2 expression and inhibiting caspase-3 by S-nitrosylation. On the other hand, 
high NO concentrations induce apoptosis by increasing Bax and activating the death receptor 
(reviewed by Ravazi et al., 2005) (Razavi, Hamilton, & Feng, 2005), as well as formation of 
the free radical peroxynitrite (ONOO-). Peroxynitrite, which triggers both apoptosis and 
necrosis (Levrand et al., 2006), is an NO degradation product generated by combination of NO 
with oxidants. Through activation of the pro-survival/anti-apoptotic signals, as well as through 
its antioxidant effect, moxonidine may shift the balance towards the anti-apoptotic effect of 
NO.   
The present studies show that co-incubation with moxonidine reduces norepinephrine- and IL-
1β-induced cardiomyocyte mortality, mainly by decreasing p38 MAPK activation via the 
imidazoline I1-receptor (Aceros et al., 2011), and by shifting the p38 MAPK-iNOS pathway 
from stimulation to inhibition of cell death (Aceros et al., 2014). An anti-oxidative action of 
imidazoline I1-receptor activation by moxonidine may underlie these actions. The anti-
oxidative effect of imidazoline I1-receptor/nischarin has been demonstrated in HEK293 cells, 
where nischarin-transfection improved cell survival (Aceros, Cobos-Puc, Farah, Noiseux, & 
Mukaddam-Daher, 2013), and in cardiomyocytes where moxonidine opposed H2O2-induced 
cell death (Aceros et al., 2014). It is also consistent with the recent in vivo finding that 
moxonidine decreases nitrite/nitrate production and increases the anti-oxidative enzymes, 
superoxide dismutase and catalase, in brains of rats challenged with the mitochondrial 
complex II inhibitor 3-Nitropropionic acid, a model of Huntington’s disease (Gupta & 
Sharma, 2014).  
In addition to an anti-oxidative effect, moxonidine, through imidazoline I1-receptors, may 
activate the p38 MAPK and Akt/mammalian target of rapamycin (mTOR) cardioprotective 
pathway, while inhibiting the p38 MAPK-mediated death pathway. This hypothesis is 
supported by the protective effects of parallel activation of p38 MAPK and Akt, followed by 
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activation of mTOR observed in neonatal rat cardiomyocytes exposed to H2O2 (Hernandez et 
al., 2011), as well as with the finding that the protective mTOR pathway in cardiomyocytes is 
activated by the IRS1/2-Akt pathway (Troncoso et al., 2013). Imidazoline I1-receptor 
signalling pathway includes IRS1-4/Akt (Edwards et al., 2012; Sano et al., 2002). Noteworthy, 
IRS proteins are the main targets for the insulin-activated protein tyrosine kinase. After 
phosphorylation, IRSs associate with the enzyme PI3-kinase, which upon activation, leads to 
translocation of the glucose transporter, Glut-4. Under basal conditions, Glut-4 protein is 
stored in intracellular vesicles, and upon stimulation, is translocated to the plasma membrane, 
increasing the membrane capacity for glucose transport (Chang, Chiang, & Saltiel, 2004). 
Increased glucose uptake reduces hypoxia-induced apoptosis in cultured neonatal rat 
cardiomyocytes (Malhotra & Brosius, 1999). Importantly, the imidazoline I1-receptor 
signalling pathway includes IRS1-4/Akt (Edwards et al., 2012; Sano et al., 2002), supporting 
the possibility that moxonidine could activate the protective mTOR pathway via imidazoline 
I1-receptors. 
In short, imidazoline I1-receptor-mediated anti-oxidative mechanism, with parallel activation 
of the pro-survival IRS/Akt pathway may explain the observed in vitro local moxonidine-
imidazoline I1-receptor-mediated cardiomyocyte protection. 
On the other hand, the observed effects of moxonidine in fibroblasts are mostly opposite to 
those observed in cardiomyocytes. The imidazoline I1-receptor/moxonidine mediated 
protective anti-oxidative mechanism observed in cardiomyocytes is absent in fibroblasts.  
Also, in contrast to cardiomyocytes, moxonidine stimulates basal and IL-1β-induced fibroblast 
mortality by inhibition of JNK and iNOS (Aceros et al., 2011; Aceros et al., 2014). Cell-type 
selective effects have been previously shown in response to endothelin. Endothelin induces 
cardiomyocyte hypertrophy and fibroblast proliferation (Drimal, Mislovicova, Ismail, & 
Moncek, 1999; Gan, Chakrabarti, & Karmazyn, 2003; You et al., 2006), through local 
activation of endothelin A receptor, a G-protein coupled receptor that classically binds to a 
Gαq/11 protein, activating phospholipase C, and increasing inositol phosphate production (Ivey, 
Osman, & Little, 2008).  However, endothelin A receptor activation markedly increases 
inositol phosphate production in cardiomyocytes but not in fibroblasts (Hilal-Dandan, 
Urasawa, & Brunton, 1992; Meszaros et al., 2000). These studies show that the same receptor 
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has cell-selective alternative signalling pathways. Similar observations have been reported for 
the angiotensin 1 receptor and the prostaglandin E2 receptor (Meszaros et al., 2000), a 
situation that may also apply for the imidazoline-I1 receptor. 
The differential actions of moxonidine on cardiomyocytes and fibroblasts, especially on cell 
survival and iNOS induction in the presence of stressors may depend on several factors, 
including a differential effect on ANP secretion. Moxonidine stimulates the release of ANP 
from neonatal cardiomyocytes following imidazoline I1-receptor activation in vitro (Figure 14, 
Supplementary data). Noteworthy, the presence of ANP in the culture medium potentiates IL-
1β-induced iNOS expression in cardiomyocytes (Horio et al., 1998; Yamamoto et al., 1997). 
This mechanism is not observed in fibroblasts, where ANP release is absent or negligible. 
In addition, cardiomyocytes and fibroblasts express different subtypes of sphingosine 1 
phosphate (S1P) receptors: cardiomyocytes mainly express S1P1 and fibroblasts mainly 
express S1P3 receptors (Means & Brown, 2009). Molderings et al. (Molderings et al., 2007) 
have shown that imidazoline I1-receptor agonists, including moxonidine, interact with both 
S1P1 and S1P3. S1P inhibits IL-1β induction of NO production and iNOS expression in rat 
vascular smooth muscle cells (Machida et al., 2008), a proliferative cell type closely related to 
cardiac fibroblasts in culture (myofibroblasts) and, like fibroblasts, expresses S1P3 receptors. 
The effect of S1P is similar to the observed decrease in iNOS following co-incubation of 
fibroblasts with Il-1β and moxonidine. It is not known whether an opposite effect through 
S1P1 receptors occurs in cardiomyocytes, however, S1P protects cardiomyocytes from 
hypoxia-induced cell death (Karliner, Honbo, Summers, Gray, & Goetzl, 2001). 
On the other hand, it has been shown that the imidazoline I1-receptor/nischarin with the α5 
integrin subunit (Alahari et al., 2000). In normal cardiomyocytes α5 integrin expression is 
scarce; while is normally expressed in fibroblasts. The expression of the α5 integrin subunit is 
differentially regulated in ventricular hypertrophy, decreasing in fibroblasts and increasing in 
cardiomyocytes (Burgess et al., 2002; Ross, 2002). The expression of the α5 integrin subunit 
may influence the imidazoline I1-receptor/nischarin sub-cellular localization, possibly by 
anchoring it to the membrane. The imidazoline I1-receptor/nischarin is a cytosolic protein, as 
we have demonstrated by overexpressing it in HEK293 cells (Aceros et al., 2013), and those  
in Cos7, Neuro 2A and 293T cells (Alahari et al., 2000; Jain et al., 2013), as well as a 
 224 
membrane-associated protein in PC12 cells (Zhang & Abdel-Rahman, 2006). Interestingly, 
this difference in localization is related to a functional difference. In HEK293 (Aceros et al., 
2013) and 293T cells expressing nischarin, an anti-proliferative effect was observed when 
compared to non-expressing cells (Jain et al., 2013), suggesting that the sub-cellular 
localization may influence imidazoline I1-receptor/nischarin effects. Accordingly, differential 
α5 integrin subunit expression in cardiomyocytes and fibroblasts might influence nischarin’s 
localization and subsequently, the mechanisms that differentiate cellular responses to 
moxonidine.   
Thus, differential receptor expression and/or subsequent availability of different signalling 
pathways as well as the activation of distinct downstream targets in cardiomyocytes and 
fibroblasts may underlie the observed different cell-type selective physiological effects. 
Finally, an important finding that emerges from our previous and present work is imidazoline 
I1-receptor regulation in response to endogenous and exogenous factors. Ex vivo perfusion of 
isolated normotensive rat hearts with imidazoline compounds stimulates ANP release 
(Mukaddam-Daher et al., 1997; Mukaddam-Daher et al., 2006), with greater effect observed in 
SHR hearts (Figure 15, Supplementary data). These studies demonstrate that cardiac 
imidazoline I1-receptors are functional without the contribution of the central nervous system 
and suggest a possible up-regulation in hypertensive hearts.
  
Binding studies have confirmed 
that
 
heart imidazoline I1-receptors are up-regulated in rat hypertension and hamster and human 
heart failure and have shown that heart imidazoline I1-receptors are normalized in SHR by 
chronic in vivo treatment with moxonidine (El-Ayoubi et al., 2002; El-Ayoubi et al., 2003, 
2004). In contrast, heart imidazoline I1-receptors/nischarin are further up-regulated by in vivo 
moxonidine in hamster heart failure (Stabile et al., 2011). In vitro studies extend to identify 
imidazoline I1-receptor/nischarin mRNA and protein in both cardiac cell types, fibroblasts and 
myocytes, and show that imidazoline I1-receptor/nischarin protein is targeted by treatment, 
thus regulating its expression, in a cell-selective and stimulus-specific manner (Aceros et al., 
2014). 
Recent studies by Alahari’s group show higher expression of nischarin mRNA in normal 
human breast tissue than tumor tissue, associated with decreased α5 integrin expression, FAK 
phosphorylation, and Rac activation (Baranwal et al., 2011). They also show that nischarin 
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suppression leads to faster cell growth, consistent with our results showing anti-proliferative 
action of nischarin in fibroblasts. Therefore, based on the link of nischarin to integrin signaling 
and on its intrinsic antiproliferative action mediated by Rac1 inhibition, together with our 
studies showing up-regulated nischarin in myopathic hearts, it is tempting to speculate that 
nischarin up-regulation is an adaptive response of the myocardium to pressure/volume 
overload and point to cardiac nischarin overexpression as a protective mechanism, 
contributing to LVH control through an anti-oxidative action. Alternatively, cardiac nischarin 
suppression in the presence of LVH may be deleterious.   
 
4.3 Conclusion 
This work on various experimental models mimicking human cardiomyopathies, shows that 
activation of imidazoline I1-receptors protects hypertensive hearts from LVH and slows the 
functional decay in heart failure. Importantly, moxonidine does not deteriorate cardiac 
function; it rather improves it and reduces mortality in heart failure hamsters, suggesting that 
the negative effects observed in clinical trials may not be related to a direct deleterious effect 
of the imidazoline I1-receptor on cardiac function. 
 Furthermore, a unifying protective mechanism is suggested by this work. The in vivo and in 
vitro experiments propound that the presence and/or activation of the imidazoline I1-receptors 
exert anti-inflammatory, and anti-oxidative effects, which appear to be particularly important 
in cardiomyocytes, reducing the formation of peroxynitrite, thus probably switching excess 
NO actions from deleterious to protective. This effect is not observed in cardiac fibroblasts. In 
fact, activation of imidazoline I1-receptors induces fibroblast death in vitro. Since abnormal 
fibroblast proliferation is observed in LVH (Cacciapuoti, 2011), and fibroblasts are the main 
producer of extracellular matrix and collagen in cardiac tissue (Jugdutt & Amy, 1986; 
Kuwahara et al., 2003; Weber et al., 1992), imidazoline I1-receptor mediated fibroblast death 
may mediate the reduced fibrosis in vivo, together with improvement of cardiac structure and 
function following pharmacological treatment (Aceros et al., 2011; Aceros et al., 2014; Stabile 
et al., 2011).  
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These results support the hypothesis that local activity of imidazoline I1-receptors protects 
cardiomyocytes under stress.     
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4.4 Perspectives 
Cell culture studies have revealed that activation of nischarin results in protective effects in 
cardiomyocytes and anti-proliferative actions in fibroblasts (Aceros et al., 2014). In an attempt 
to further explore nischarin’s signalling pathways, specifically those involved in the 
modulation of action of NO, lipid-mediated transfection (Lipofectamine 2000, Invitrogen, 
Burlington, ON) with GFP tagged-nischarin cDNA was performed in both cardiomyocytes 
and fibroblasts, similarly to that performed on HEK293 cells (Aceros et al., 2013). Efficiency 
of this approach was low, with transfections efficiencies of around 10% after optimization. 
This efficiency is similar to the one reported in the literature for this technique (Louch, 
Sheehan, & Wolska, 2011), yet, is too low to allow for clear evaluation of signalling and 
survival differences between GFP-nischarin transfected and GFP-vector transfected 
cardiomyocytes. However, better transduction can be achieved by viral vector, especially in 
cardiac cells and when the protein is as big (~250 kDa). Figure 17 includes preliminary in 
vitro lentiviral-GFP overexpression in rat cardiomyocytes and fibroblasts, demonstrating 
feasibility of the proposed experimental approach. Transfection with lentivirus resulted in 41% 
of cardiomyocytes and 62% of fibroblasts as GFP positive, 24h after viral infection, an 
efficiency that would be sufficient to give meaningful results.  
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Figure 17: Flow cytometry images showing the percentage of GFP positive cardiomyocytes or fibroblasts after 
lentiviral infection (2.5x10
4
 infectious units (IFU) and 2.5x10
5
 IFU).  
 
This method would lead to better evaluation of nischarin signalling and functions in cardiac 
cells. Once viral transfection of cardiomyocytes and fibroblasts with GFP-tagged-nischarin 
cDNA or GFP-empty vector as control is performed, cells will be incubated with NE and IL-
1β, stimuli that have induced differential effects on survival, whether alone or in the presence 
of moxonidine. Cell survival and signalling pathways involved will be investigated by the use 
of specific inhibitors. Also, since the proposed protective mechanism of moxonidine includes 
an antioxidant effect, it would be important to measure the activity levels of antioxidant 
enzymes like superoxide dismutase and catalase (Gupta & Sharma, 2014).  
In view of altered nischarin levels in cardiovascular diseases and in response to treatment, 
studies are required to determine the impact of in vivo cardiac nischarin modulation on cardiac 
Cardiomyocytes Fibroblasts
lenti-GFP (2.5x104 IFU)
62,500 cells/wel125,000 cells/well
lenti-GFP (2.5x105 IFU)
PolyBrene
no viral vector
40.9 % 
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11.9%
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0% 0%
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structural, functional, and metabolic parameters, in basal conditions and in response to a 
chronic hemodynamic stress, such as that induced by aortic banding, or in ischemia-induced 
heart failure, such as that induced by coronary artery ligation  (Houser et al., 2012). The latter 
is based on Grassi’s (Grassi, 2013) proposal that activation of imidazoline I1-receptors might 
not be as effective in this type of heart failure because of the deleterious effects observed in 
ischemic heart failure patients following moxonidine treatment (Cohn et al., 2003).  
Furthermore, based on the improved metabolic profile by moxonidine in patients with 
metabolic syndrome and diabetes, and on our studies revealing improved cardiac function 
independently of blood pressure control, the use of the diabetic cardiomyopathy model is also 
warranted. Diabetic cardiomyopathy depends on hyperglycemia-induced increase in cardiac 
oxidative stress, followed by increase ROS production and inflammation, leading to fibrosis 
and cardiac dysfunction (Boudina & Abel, 2007; Pappachan et al., 2013; Schilling & Mann, 
2012; Varga et al., 2014). In streptozotocin-treated rats (a model of type 1 diabetes), treatment 
with the non-selective α2 adrenergic/imidazoline I1-receptor agonist clonidine in hypotensive 
doses abolished the diabetes-induced decrease in systolic function (Satia, Damani, & Goyal, 
1997), suggesting a beneficial effect of imidazoline I1-receptor activation in cardiac function.   
We expect that nischarin over-expression in vivo will attenuate pressure overload- or 
metabolic-induced hypertrophy and fibrosis, and preserve left ventricular function, together 
with the prevention of enhanced ROS formation. Upregulation of imidazoline I1-
receptor/nischarin in the heart will not only improve diastolic dysfunction (as observed in the 
cardiac sympathetic denervation model (Wang, Wang, Cornish, Rozanski, & Zucker, 2014)), 
but would also prevent or delay some of the long term systolic dysfunction, demonstrating that 
cardiac nischarin levels may account for cardiac protection. Studies will also show that cardiac 
specific nischarin up-regulation potentiates the cardiac response to moxonidine. We speculate 
that nischarin suppression will result in opposite effects. Both ways, they will demonstrate that 
nischarin expression level/distribution could account for many aspects of cardiac remodelling, 
emphasizing its potential importance as an anti-hypertrophic and anti-fibrotic target. 
In this respect we have planned to modulate nischarin levels in mice and to perform, 
simultaneous studies on wild type mice, nischarin knock-out mice (nischarin-/-), and knock-
out mice with cardiac-specific expression of nischarin (c-nischarin). We considered that the 
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nischarin knock-out mouse model (nischarin-/-) would offer new information about the 
importance of nischarin in cardiovascular control. It would also resolve the everlasting debate 
concerning the question whether imidazoline compounds mediate their effects through 
imidazoline receptors (nischarin) or α2-adrenergic receptors. This debate is based on the lack 
of specific agonists and antagonists as well as on studies showing that the antihypertensive 
effect of imidazoline compounds is absent in animals with mutation in the α2-adrenergic 
receptor (Zhu et al., 1999). Also, in addition to cardiovascular research, generating this model 
could be an important achievement for diabetes and cancer research. 
 
We have already started creating nischarin knock-out model. We received from TGIM 
embryonic stem cells with mutations of nischarin. Clones D6 and H7 were injected in mouse 
embryos and successfully gave 2 male and 1 female chimeras (Figure 18).    
 
 
Figure 18: Three different clones of nischarin knockout embryonic stem cells, originated in C57BL/6 mice, were 
laser injected in to CD-1 8-cell to non-compacted morula stage albino mouse embryos to generate Nischarin 
chimeras. The embryos were cultured overnight to the blastocyst stage of embryonic development, and then 
transferred into pseudo-pregnant females that had been mated to vasectomised males.  Pups were born 16-19 days 
after surgery and chimeras were identified by coat color. In the images the change in coat color (arrows) 
characteristic of chimeric animals is observed and contrasted with white-coated littermates.   
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After mating the chimeras with normal C57BL/6 animals, and selection of dark coat offspring, 
polymerase chain reaction (PCR) of genomic DNA extracted from tail snips was performed 
using primers for complete and KO nischarin sequences, giving 2 separate base pairs levels in 
cases of heterozygosis (Figure 19). 
 
Figure 19: PCR gel image of normal and heterozygous nischarin genomic DNA samples derived from tail snips.  
 
Unfortunately, the mating did not result in viable heterozygous animals. The only confirmed 
heterozygous mouse born (offspring of one of the male chimeras, confirmed by the PCR 
showed in figure 19) died shortly after birth, and several cycles of mating over the course of 1 
year did not provide any new heterozygous animals. Sacrifice of pregnant animals, searching 
from embryologic evidence of in utero KO at different gestation times did not show any 
evidence of KO animals being produced, thus suggesting that nischarin KO was lethal pre-
implantation or that the chimeric spermatozoids were less fit (in quantity, quality or both) to 
fertilize ova.  
The failure of this experimental approach does not reduce the interest of observing the cardiac 
results of modulation of the imidazoline I1-receptor, so it would be appropriate to develop a 
local cardiac nischarin expression and KO, an approach that would likely have better survival. 
Tissue specific nischarin KO can be achieved by the creation of a Cre-loxP based cardiac 
specific KO mouse (Moga, Nakamura, & Robbins, 2008), using commercially available 
nischarin-loxP embryonic stem cells, to develop homozygous nischarin-loxP mouse, animals 
that will maintain normal nischarin expression, then mate them with mouse expressing the Cre 
recombinase enzyme, driven by the cardiomyocyte-specific promoter α-myosin heavy chain, 
thus expressing Cre only in adult cardiomyocytes. Since the expression of Cre will delete the 
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nischarin-loxP gene in the tissues were it is expressed (Doetschman & Azhar, 2012; Moga et 
al., 2008), the offspring of these animals will have a KO of nischarin in their cardiomyocytes. 
Nischarin overexpression can be achieved under the control of the α-myosin heavy chain 
promoter (c-nischarin), by creating a plasmid in which full length sequence of nischarin is 
ligated to the cardiac-specific murine alpha-myosin heavy chain promoter, then this plasmid is 
injected in embryonic stem cells, which are later implanted in pseudo-pregnant females. Cross 
breed of the offspring will allow the development of homozygous c-nischarin mice 
(Yarbrough et al., 2014). 
Alternatively, nischarin overexpression in the heart can be achieved by means of a  lentiviral 
vector containing genomic nischarin DNA and enhanced green fluorescent protein (EGFP) 
controlled by cytomegalovirus (Metcalfe et al., 2004).  The vector will be injected in the 
ventricular cavity of 5-day-old neonatal mice (or rats).  At this stage, cardiac cells are still 
dividing and immune system not yet developed. This approach has been frequently used 
(Bonci et al., 2003; Metcalfe et al., 2004; Yoshimitsu et al., 2006). The hearts of neonatal 
mice/rats are visible under the transparent skin and injection into the left ventricular cavity 
would only require a single injection and small volume. Pups recover within minutes after the 
injection, and almost 100% of them survive the process. The use of virus-based vectors for 
gene transfer in the heart has emerged as a powerful approach to over-express and access the 
function of key enzymes and proteins in healthy or diseased hearts. High-efficiency infection 
of the heart in vivo has been achieved in mice and rats (Champion et al., 2003; Donahue, 
Kikkawa, Johns, Marban, & Lawrence, 1997; Hart et al., 2008). The lentiviral vector-mediated 
gene delivery system has several advantages over other viral or non-viral gene delivery 
systems: high efficiency of gene transfer into a wide variety of cells including both dividing 
and non-dividing cells, long-term infection due to gene integration into the chromosome of 
host cells, and no toxicity or immune response (Abbas-Terki, Blanco-Bose, Deglon, Pralong, 
& Aebischer, 2002; Hart et al., 2008).   
Using a similar approach, endogenous nischarin will be inhibited by intra-cardiac injection of 
the same lentiviral vector, but harbouring a 21 base pair siRNA oligonucleotide (ODN) (or 
corresponding mismatched ODN) directed against rat/mouse nischarin. This siRNA has been 
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shown to be effective in PC12 cells and NIH3T3 cells in vitro, and in the brain in vivo (Zhang 
& Abdel-Rahman, 2006, 2008). 
These studies will demonstrate that nischarin expression level/distribution could account for 
many aspects of cardiac remodelling, emphasizing its potential importance as an anti-
hypertrophic and anti-fibrotic target. The results, if positive, will push towards the 
development of specific imidazoline I1-receptor agonists that do not cross the blood-brain 
barrier, and thus are devoid of the central hypotensive effects (Chan et al., 2005; Haxhiu et al., 
1994). While the antihypertensive action of centrally acting imidazoline compounds is 
appreciated, development of new cardiac-selective I1-receptor agonists may confer additional 
benefits with less systemic adverse effects. In addition, specifically-tailored cell/gene-driven 
nischarin treatments could eventually be important for patients with heart disease.  
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